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ABSTRACT OF THE DISSERTATION 
The Chemistry and Biology of Iron-Scavenging Natural Products from 
Pathogenic Acinetobacter baumannii 
by 
Justin A. Shapiro 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis, 2017 
Professor Timothy A. Wencewicz, Chair 
Multidrug resistant (MDR) Gram-negative bacteria represent a global health crisis. Traditional 
antibiotics create selective pressure and breed resistance, making our current drugs less and less 
effective. Targeting of bacterial virulence factors has gained interest as an alternative strategy to 
potentially circumvent this problem. Virulent Acinetobacter baumannii synthesize and secrete 
pre-acinetobactin, a small molecule metal chelator that scavenges life-sustaining iron and is 
critical for establishing infection. The work described herein sheds light on the unusual 
properties of a non-enzymatic isomerization from pre-acinetobactin to acinetobactin and 
proposes a siderophore-swapping mechanism by which A. baumannii expands its pH window for 
virulence. Knowledge from structure-activity studies of the natural siderophores was used to 
design a rigidified pre-acinetobactin analog with antibiotic activity. Oxidation of the phenolate-
oxazoline (pre-acinetobactin) to a phenolate-oxazole (oxidized pre-acinetobactin) confers low-
micromolar MIC90 under iron deficient conditions against a panel of clinical MDR A. baumannii 
isolates. This work helps to lay a foundation for developing antivirulence agents to combat 
disease and resistance.
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Chapter 1: Introduction 
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1.1 Preface 
 
 This chapter was written by Justin A. Shapiro. Section 1.5, titled “Siderophores of 
Acinetobacter baumannii,” was partially adapted from [Shapiro, J. A. & Wencewicz, T. A. ACS 
Infect. Dis. 2, 157–168 (2016)]. Copyright © 2016 American Chemical Society. Both authors 
contributed to writing of the manuscript. JAS performed all experiments. TAW served as 
principal investigator and oversaw experimental design. 
1.2  Multi-Drug Resistant Pathogenic Bacteria 
 
 Former US Surgeon General Dr. William H. Stewart is widely misquoted from 1967 as 
having said, “It’s time to close the books on infectious diseases [and] declare the war against 
pestilence won.” This is meant to underscore our arrogance in thinking that the world of 
microbes had no threats left. Fittingly, this apocryphal quote has been debunked, and in the 
actual speech Dr. Stewart quite prophetically said, “Warning flags are still flying in the 
communicable disease field... While we are engaged in taking on new duties... we cannot and 
must not lose sight of our traditional program responsibilities.”1 As he predicted, today the 
Center for Disease Control lists Multi-Drug Resistant (MDR) bacteria as one of the largest global 
threats. In a 2013 report, it was estimated that there are 2 million annual victims of MDR-
infection and at least 23,000 fatalities in the US. Resistance to antibiotics has developed rapidly 
due in part to overuse and improper use.2 Traditional antibiotics, often called “magic-bullet” 
therapies, inhibit essential life-sustaining processes and wipe out commensal host bacteria, 
creating selective pressure for the survival of bacteria with resistance genes. In addition to 
curbing our use of these drugs to slow the spread of resistance, new drugs must be developed that 
are less susceptible to resistance. An exciting area for exploration is the development of 
therapeutics that target bacterial virulence factors.3 Virulence factors are molecules synthesized 
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by bacteria that are not required for survival in favorable conditions but are essential for 
establishing infection in the hostile host-body environment. An effective anti-virulence drug 
could be used only on immune-healthy patients to cripple the pathogen, allowing the immune 
system to clear the infection. Magic bullet drugs could then, ideally, be reserved for immune-
compromised patients and resistance would be less likely to develop.  
1.3  Iron Acquisition in MDR Pathogenic Bacteria 
 
 Virulence in pathogenic bacteria is mediated by a variety of genetically encoded 
mechanisms which allow otherwise harmless microbes to thrive in the competitive environment 
of the host. These include, but are not limited to: porins that modulate cell permeability and 
facilitate surface adhesion,4 surface capsular polysaccharides and lipopolysaccharides associated 
with antimicrobial resistance and inducement of cell killing host immune responses,5 
phospholipases which degrade host phospholipids and weaken host cell membrane stability,6 
outer membrane vesicles which deliver an array of molecular effectors to host targets without 
direct contact from the invading organism,7 protein secretion systems that aid in 
invasion/damage of host tissue and defense against immune response,8 the formation of biofilms 
as a cooperative interaction to lay dormant until conditions are more favorable for proliferation,9 
and metal acquisition systems to maintain micronutrient homeostasis.10 Bacterial strategies for 
scavenging crucial metals, specifically iron, will be the focus of this dissertation. This 
introduction will bias heavily towards gram-negative pathogens, as the thesis research centers on 
a gram-negative organism, although when a gram-positive organism is referenced it will be 
specifically referred to as such. 
 Iron is required by nearly every known organism for critical life-sustaining cellular 
processes, and this is no less true for bacteria.11 So widespread is the need for iron in enzymes 
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and biological reactions (most famously its role in cytochrome P450 enzymes involved in the 
electron transport chain, made possible by its variable valence between +2 and +3 oxidation 
states) that there is a highly developed hypothesis of life beginning on the surface of iron-sulfide 
minerals, appropriately named the Iron-Sulfur World.12 However, in aerobic environments iron 
mostly exists in its ferric +3 oxidation state, rendering it poorly water-soluble and thus largely 
bio-unavailable. Living organisms, in general, require a 10-5-10-7 M intracellular concentration of 
iron,13 but under aerobic conditions at physiological pH iron is only soluble at ~10-9 M.14 
Furthermore, as a form of innate immunity against bacterial infection, the human body 
sequesters most of its iron inside of proteins (heme-proteins and ferritin intracellularly, 
transferrin/lactoferrin extracellularly), further lowering the concentration of free iron (III) to 10-24 
M.13 This presents a challenge to any bacteria attempting to establish infection. To gain a 
competitive advantage many bacteria have evolved import pathways for scavenging iron (III), 
allowing them to establish infection in the low iron setting of the host body. Bacteria have 
developed systems to acquire host iron through transferrin/lactoferrin, heme, and excretion of 
siderophores (Figure 1.) 
Transferrin/Lactoferrin 
 One such method of iron-acquisition is the use of proteins specifically tailored to bind 
host transferrin and lactoferrin. These two host proteins traffic iron through the body (transferrin 
in serum, lactoferrin in milk) and chelate two iron atoms per protein with high affinity15 (Figure 
2A). Percentage saturation of transferrin is used as a medical assay for anemia and iron-overload 
in humans, with normal levels being between 20-50% saturation depending on gender and other 
factors.16 Homologous TonB-dependent bacterial outer membrane receptors TbpA/TbpB and 
LbpA/LbpB are responsible for binding transferrin and lactoferrin, respectively, and extracting 
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iron for internalization into the cell17 (Figure 2B). TbpA and LbpA consist of a β-barrel domain 
and a plug domain which is opened via a conformational change, triggered by docking of host 
transferrin/lactoferrin to the extracellular binding site. Critically, these proteins contain an L3 
helix finger that is thought to play a role in prying open the iron-binding pocket of 
transferrin/lactoferrin, allowing the iron to be removed and trafficked through the β-barrel 
domain. While the membrane bound lipoproteins TbpB and LbpB have not been crystalized with 
their respective OMRs, they have a strong binding preference for iron-loaded 
transferrin/lactoferrin whereas TbpA and LbpA bind holo- and apo- substrates equally. It is 
proposed that the lipoproteins’ role is to pre-select only iron-bound transferrin/lactoferrin to the 
OMRs to increase iron concentration near the cell surface. They may also have a role in 
protecting against transferrin/lactoferrin derived small antibacterial peptides.18 Movement of iron 
from the extracellular space to the periplasm is facilitated by an iron-binding motif in the barrel. 
Once in the periplasm iron is transported to the inner membrane by Ferric ion binding protein 
FbpA.19 Interestingly, FbpA has structural similarity to transferrin while bearing only 20% 
sequence homology. FbpA then transfers iron to the inner-membrane transporter FbpB/FbpC for 
internalization into the cytoplasm. The fight over transferrin-bound iron at the host-pathogen 
interface is a point of evolutionary conflict, as single amino acid mutations have been identified 
in primate transferrin at residues unimportant for protein function but critical for TbpA 
binding.20 These subtle changes provide an additional form of nutritional immunity and highlight 
the importance of transferrin in the evolutionary battle for iron between pathogen and host. 
Heme 
 Bacterial pathogens have also evolved methods of utilizing heme iron to increase 
intracellular iron concentration. Heme, the porphyrin-type tetrapyrrolic macrocycle, contains an 
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iron in the center and is found in proteins used to traffic oxygen throughout the bloodstream, 
such as hemoglobin.21 While hemoglobin is primarily found intracellularly, low concentrations 
circulate in plasma due to cell death. To combat this, the host protein haptoglobin binds 
hemoglobin and traffics it to the liver for turnover.22 Free heme is sequestered in serum by the 
proteins albumin and hemopexin, but mucus membranes can be host to relatively high 
concentrations of free heme.23 Bacteria have adapted import pathways that specifically target 
heme and heme-associated proteins. Such proteins have been reported in Yersinia,24 Escherichia 
coli,25 and Shigella26 with high sequence identity and the ability to bind free heme as well as 
multiple heme containing host proteins, as in the case of the Y. enterocolitica outer-membrane 
receptor HemR.27 These import pathways bear similarity to transferrin/lactoferrin acquisition 
systems in their use of a TonB-dependent outer membrane spanning β-barrel protein, a 
periplasmic binding protein for trafficking to the inner membrane, and an inner membrane ATP-
binding cassette for transportation into the periplasm. The outer membrane receptors can be 
promiscuous two component systems (HpuA/HpuB from Neisseria meningiditis)28 or specific for 
only heme or a certain heme-protein and single component (HmbR, also from Neisseria 
meningiditis).29 
 Because extracellular heme and heme-protein concentrations are typically low, bacteria 
have evolved virulence associated proteins with cytotoxic and/or proteolytic activity. One such 
example is the E. coli SPATE (serine protease autotransporters of Enterobacteriacae) enzyme 
hemoglobin protease (Hbp).30 Autotransporters are so called because they contain a signal 
peptide regulating transport to the periplasm and a β-barrel domain that associates with the outer 
membrane, allowing a passenger domain to pass through the barrel and be self-cleaved in a type 
V protein excretion pathway. Hbp degrades hemoglobin and increases free heme concentration 
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in the surrounding environment. Hbp and other excreted bacterial proteins are also known to 
bind heme and are therefore termed hemophores, with specific import pathways that bear some 
resemblances to other heme-import proteins. In the case of the heme acquisition system (HAS), 
found in multiple Pseudomonas and Yersinia as well as one Serratia,31 the hemophore (HasA) is 
excreted through a dedicated pathway (HasDEF)32 and associates with heme in a mechanism 
described as a “fish bite”33 (Figure 3). The complex then recognizes a TonB-dependent outer 
membrane transporter that has homology with the other β-barrel outer membrane proteins 
described in this chapter, heme dissociates from the hemophore and is transported into the 
periplasm, where the heme is degraded and iron is assimilated. 
Siderophores 
 Perhaps the most important and individually tailored method of bacterial iron acquisition 
is the production and utilization of siderophores. Siderophores are small-molecule iron (III) 
chelators that are synthesized in the cytoplasm and excreted into the extracellular space where 
they complex previously bio-unavailable iron. These iron-chelate complexes are then imported 
into the cell where the iron is removed from the complex either by enzymatic reduction to iron 
(II) (usually by NADH) or hydrolysis of the siderophore. Nearly 500 siderophores have been 
discovered, of which over half have been fully structurally characterized.34 The biosynthesis of 
siderophores usually occurs on modular assembly line like Non-Ribosomal Peptide Synthetases 
(NRPS) for the incorporation of amino-acid containing moieties, although NRPS-independent 
siderophore (NIS) biosynthetic gene clusters are also known. Common building blocks for 
siderophore biosynthesis are amino-acids (both canonical and non-canonical), chorismate 
derivatives, and citrate. The iron-binding constants of siderophores can vary widely from ~1016-
1049 and possibly higher.35 Factors dictating chelation properties include hard-soft acid-base 
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interactions, ligand:metal stoichiometry, and three-dimensional structure of the ligand backbone. 
Siderophores are covered in greater detail in Section 1.4. 
1.4  Siderophores in Pathogenic Bacteria 
 
Chemistry, Biology, and Biosynthesis of Siderophores 
 Structures referenced in this subsection are shown in Figure 4. 
 Most siderophores derive their high iron affinity from their strongly electron donating 
bidentate (two-tooth) chelating moieties that can occupy two coordination sites of a metal 
center.36 Charged oxygen atoms are ubiquitous, although nitrogen lone-pairs are common as 
well. Common bidentate ligands include catecholates, hydroxamates, hydroxyphenyl-oxazolines 
(or –thiazolines), α-hydroxyimidazoles, α-aminocarboxylates, and α-hydroxycarboxylates (Table 
1). Multiple bi-dentate moieties are often pre-organized on a single scaffold to fit the preferred 
octahedral coordination sphere of iron (III). Some siderophores utilize one type of bidentate 
ligand (ferrichrome, structure 1),37 whereas some combine multiple on the same scaffold 
(mycobactin, structure 2).38 Because of differences in ligand pKa, pH can play a strong role in the 
efficacy of different siderophores.39 Thermodynamic considerations also contribute to the 
affinity of siderophores for iron (III). Increased entropy from displacing coordinated water 
molecules by one hexadentate chelator (MECAM, structure 3) as opposed to three bidentate 
chelators (N,N-2,3-dihydroxybenzamide, structure 4) can result in large (6 log units) increases in 
formation constant, a phenomenon called the chelate effect.40,41 However, such a difference can 
be curtailed by unfavorable enthalpic factors such as molecular strain.35 To wit, stereochemistry 
can pre-dispose a molecule towards stable octahedral coordination by pointing all of the 
chelating ligands in the same direction, increasing formation constant (enterobactin, structure  
5).13 Kinetically, iron-exchange between hexadentate siderophores is extremely slow and likely 
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irrelevant in biological systems,42 but lower (bi-, tri-, and tetra-) dentate siderophores are more 
labile.43 It is possible that these are synthesized at lower biosynthetic cost to solubilize iron (III) 
and hand it off to the stronger hexadentate binders. Additionally, some gram-positive and gram-
negative membrane bound enzymes catalyze the exchange between two high affinity 
siderophores in a shuttle-like import mechanism.44 Octahedral iron (III) centers surrounded by 3 
bidentate ligands can form two enantiomeric complexes, termed lambda (Λ) and delta (Δ), and 
optically active ligands will preferentially form one isomer.45 Most siderophores are redox stable, 
preventing reduction to the less easily bound iron (II) as well as the formation of harmful 
radicals,46 although there are notable exceptions at low pH.47 
 Multiple homologous outer-membrane receptors (OMR) for siderophore intake have been 
characterized by X-ray crystallography and bare some structural resemblance to other receptors 
discussed in this chapter.48–51 They are TonB-dependent active transporters and consist of a 
transmembrane β-barrel domain, a globular cork domain, and an extracellular domain that covers 
the barrel. Binding of the iron complex triggers a conformational change wherein the cork 
domain opens to reveal a periplasmic-side TonB binding site, and the binding of TonB creates a 
transient channel through which the iron complex passes.52 OMRs have strong binding affinity 
for iron-siderophore complexes (1-50 nM), and are often selective for specific complexes 
(pyochelin, structure 6, for FtpA in Pseudomonas aeruginosa) (Figure 5).53 The complexes are 
then shuttled to the inner-membrane by a periplasmic siderophore binding protein54 and 
transported to the cytoplasm by an ABC transporter.55 Siderophore biosynthesis and utilization 
genes are regulated by ferric uptake regulator (Fur) protein, which in its iron bound form blocks 
RNA-polymerase by complexation to a “Fur-box” genetic motif in the gene cluster, preventing 
transcription.56 Thus, biosynthetically expensive siderophore proteins are only produced under 
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low-iron conditions when Fur is in an unbound state (Figure 6). Bacteria sometimes 
biosynthesize the utilization machinery for siderophores that they do not produce, called 
xenosiderophores, thereby placing the burden of siderophore production on competing microbes 
(desferrioxamine-B, structure 7, utilization by Staphylococcus aureus).57,58 Some siderophores 
circumvent the need for dedicated import proteins by conjugation to lipophilic side-chains, 
allowing them to perform a transmembrane flip (acinetoferrin, structure 8).59 These siderophores 
may also have the ability to infiltrate host cells and more effectively gain access to host iron 
stores. Once inside of the cytoplasm, iron (III) can be removed from the siderophore by a 
reductase enzyme to release iron (II),60 or by hydrolysis activity to reduce the affinity of the 
cleaved siderophore scaffold backbone.13 
 In addition to general withholding of iron in proteins, host animal bodies further deny the 
nutrient to bacteria by production of a siderophore-sequestration protein called siderocalin.61 
Siderocalin belongs to a diverse class of metabolite binders called lipocalins, most of which are 
selective for lipophilic molecules. However, siderocalin contains multiple positively charged 
moieties in its binding pocket, giving it high affinity for negatively charged iron-siderophore 
complexes (such as the tri-negative iron (III) complex of enterobactin 5, Figure 7). In addition to 
trapping foreign siderophores from invading bacteria, siderocalin can also use naturally 
occurring urinary metabolites from the commensal microbiome, specifically unsubstituted aryl 
sulfates and catechols, to withhold iron and prevent infection.62 Siderocalin preferentially binds 
catechol siderophores and has been shown to force siderophores into catecholate-type binding 
even under conditions where they would otherwise use a different binding mode. For example, 
vibriobactin (structure 9) has access to catecholate binding at pH=10 but uses hydroxyphenyl-
oxazoline binding at pH=7.4. However, when bound to siderocalin at physiological pH 
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vibriobactin is forced into a catecholate-type binding mode.63 Some bacteria have evolved 
siderophores that evade the binding pocket of siderocalin, termed stealth-siderophores. 
Salmochelins (structure 10) are structural analogs of enterobactin glycosylated on two of the aryl 
moieties, presumably preventing a fit into the siderocalin binding pocket by steric bulk.64 
Petrobactin (structure 11) contains a rare 3,4-catechol, which presumably distorts the typical 
structure of the chelate complex such that it cannot be recognized by siderocalin.65 
 Siderophores comprise a wide range of structurally diverse compounds that often require 
flexibility to achieve high-affinity hexadentate iron chelation. To accomplish this, most 
siderophores are biosynthesized on non-ribosomal peptide synthetase assembly lines, although 
hybrid NRPS-PKS and completely NRPS-independent siderophore (NIS) biosynthetic pathways 
have also been characterized.66–69 NRPS enzymes work by anchoring molecular precursors, often 
amino acids, onto protein domains and condensing them onto each other in a modular fashion, 
passing a growing chain down the assembly line. As the growing chain moves from module to 
module, additional domains catalyze further chemical transformations including epimerization, 
alkylation, cyclization, reduction, and oxidation. Finally, the completed molecule is cleaved from 
the assembly line, either by condensation with water, a final off-enzyme building block, or itself 
to form a cyclic siderophore scaffold.70 Catechol moieties in siderophores come from 2,3-
dihydroxybenzoic acid, which is made by redirecting chorismate away from aromatic amino acid 
synthesis.66 Phenolic moieties come from salicylate, which is produced analogously.71 
Hydroxamates can be derived from multiple pathways but often include acylation of an ornithine 
or lysine and hydroxylation of the amine by a monooxygenase.72 The widely bioavailable citrate 
is used as a pre-formed source of hydroxycarboxylate.73 Five membered heterocycles are formed 
by cyclization of a cysteine (sulfur containing ring), threonine, or serine (oxygen containing 
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ring).74 The saturation of these rings determines flexibility and stereochemistry, directly 
impacting chelation geometry, and thus can be tuned by oxidative/reductive domains within 
individual NRPS modules.66 Just like transport machinery, siderophore biosynthetic machinery is 
regulated by Fur.56 
Sideromycins 
 Structures referenced in this subsection are shown in Figure 8 and Figure 9. 
 To fight back against siderophore theft by competing organisms, some microbes have 
evolved to excrete siderophore-antibiotic conjugates, also known as sideromycins.75 
Sideromycins typically contain a siderophore moiety for targeting and import via siderophore 
uptake machinery, an antibiotic warhead to take effect inside the cell, and a covalent linker that 
may or may not be cleaved in the cell. Using a Trojan horse strategy, sideromycins turn 
siderophore utilization from strength into weakness, decreasing MIC by increasing intracellular 
antibiotic concentration and overcoming issues of cell permeability (active transport rather than 
passive diffusion). The first natural sideromycin (albomycin, 12) was discovered before 
siderphores and is composed of an ornithine-derived trihydroxamate siderophore conjugated by 
amide linkage to cytosine-based tRNA synthetase inhibitors.76 Other natural sideromycins 
include: salmycins (structures 13-16) as danoxamine conjugated to aminoglycosides,77 
ferrimycins (structure 17) as DFOB conjugated to a heterobicyclic protein synthesis inhibitor,78 
siderophore-conjugated microcin (structure 18) as a short ribosomal antimicrobial peptide,79 and 
the recently discovered tetroazolemycins (structure 19) as two phenolate-oxazoline-thiazolones 
flanking a diketopiperazine disulfide, which is likely a prodrug of a metalloenzyme inhibitor.80 
 Drawing inspiration from nature, efforts to design synthetic siderophore-antibiotic 
conjugates have received significant attention from academia and industry. Cefiderocol 
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(structure 20), a catechol-cephalosporin, has shown positive results in Phase 3 clinical trials 
against complicated UTIs.81 Choice of siderophore, antibiotic warhead, and linker have all 
proven to be important considerations. Capability to strongly bind iron is necessary for the 
siderophore moiety to cause cellular targeting. Truncation of the siderophore portion of a 
danoxamine-ciprofloxacin conjugate (structure 21) shows that all three hydroxamates are 
required for transport into gram-positive S. aureus.82 Targeting a siderophore pathway that is 
critical for virulence is a strategy to prevent resistance by down-regulation of siderophore import 
proteins.83 The final intracellular destination of the siderophore dictates the options for antibiotic 
warhead. A mixed hydroxamate-catecholate fimsbactin analog conjugated to a β-lactam 
antibiotic (structure 22) is potent against A. baumannii but when conjugated to a fluoroquinolone 
(structure 23) it has no activity, indicating that the siderophore accumulates in the periplasm.84 
This strategy has also been used to turn vancomycin and daptomycin, both gram-positive agents, 
into gram-negative agents by conjugation to the same siderophore moiety (structures 24 and 25, 
respectively).85,86 Siderophore choice may also be used to narrow the spectrum of activity, 
thereby selectively inhibiting invading pathogens while preserving commensal gut microbes, 
although level of selectivity will likely need significant optimization. 
 As demonstrated in studies on the fimsbactin analog above, the antibiotic warhead must 
be rationally chosen in tandem with the siderophore. Sideromycins against gram-positive 
bacteria require antibiotics with cytoplasmic targets, as many traditional antibiotics have surface 
exposed targets (cell wall biosynthesis) and would gain no selectivity enhancement from a 
Trojan horse mechanism. Inversely to the fimsbactin analog studies against gram-negative A. 
baumannii, when danoxamine was conjugated to a β-lactam or a fluoroquinolone (FQ), only the 
fluoroquinolone conjugate had activity against gram-positive S. aureus.82 Resistance against the 
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warhead by direct action on the antibiotic (efflux, degradation, etc.) can sometimes be totally 
circumvented by conjugation to a siderophore.87 However, in cases of resistance by target 
modification, switching the antibiotic may be necessary. In general β-lactams and 
fluoroquinolones strongly tolerate side chain derivatization and have therefore been widely 
studied in the sideromycin field.  
 Linker cleavage is only required if conjugation to the siderophore interferes with target 
recognition and antibiotic activity.88 While β-lactams and fluoroquinolones may tolerate 
functional group diversity, many antibiotics target small, highly specific enzymatic active sites, 
and therefore require intracellular cleavage from the siderophore moiety. Cleavage can be 
achieved by peptidases,89 esterases,90 phosphatases,90 or reductases91 found in the target cell. 
Pyoverdine-FQ conjugates with non-cleavable (structure 26) and cleavable (structure 27) linkers 
have been explored, demonstrating the importance of cleavage but also highlighting that 
cleavable linkers create problems with stability and therefore activity.92 A particularly interesting 
“trimethyl-lock” linker has been used to take advantage of either enzyme catalysis or redox 
chemistry for cleavage.90,91 The linker can either be kept in a p-benzoquinone-like form or in a 
hydroxyl-protected p-hydroquinone-like form to prevent an intramolecular cyclization. In the 
latter case, the phenolic oxygen can be capped with an ester or phosphate group that can be 
cleaved once inside of the target cell by an enzyme. In the former case, reducing conditions will 
transform the p-benzoquinone into a p-hydroquinone. Iron is often extracted from siderophore 
complexes by an intracellular reductase, which would expose the sideromycin to reducing 
conditions. Once deprotected or reduced, the now-reactive trimethyl-lock linker can react 
intramolecularly to form a stable 6-membered ring and release the antibiotic (Figure 9). 
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Non-Iron Siderophore Functions 
 Structures referenced in this subsection are shown in Figure 10. 
 It has been posited that siderophores are designed to be selective for iron (III) over iron 
(II) as a method of excluding other di-positive metals. More recently, however, the broader use 
of these molecules as general metallophores has been recognized. A recent review by Nolan and 
Johnstone details the non-iron functions of siderophores.93 Some of the most studied and critical 
siderophore-metal relationships are outlined below.  
 Zinc, another essential micronutrient in bacteria, is withheld in the host body by the 
proteins calprotectin and psoriasin.94,95 This evolutionary pressure has resulted in high-affinity 
bacterial zinc acquisition systems, although it is unknown whether these systems were evolved as 
a direct response to low-zinc conditions or if already evolved iron-uptake molecular machinery 
was repurposed. Some Streptomyces produce two such molecules, coelibactin (structure 28) and 
coelichelin (structure 29).96 Coelibactin genes are down-regulated in high-zinc media.97 Zinc 
Uptake Regulator (Zur) represses coelibactin biosynthesis in zinc-replete conditions.98 
Coelichelin’s role as a metallophore remains undetermined. Pseudomonads produce pyridine-
2,6-dithiocarboxylate (pdtc, structure 30), previously assumed to be a siderophore.99 It is a softer 
chelator than typical siderophores because of the polarizable nature of sulfur, leading researchers 
to question its presumed role in metal homeostasis and discover that the zinc complex is 
recognized and transported by the pdtc utilization machinery in Pseudomonas putida.100 A 
siderophore from Yersinia pestis and some UPEC, yersiniabactin (structure 31), has been shown 
to play a role in zinc acquisition by a different pathway than yersiniabactin mediated iron 
acquisition.101,102 It is self-evident that differences in the chelation modes of ligands to iron (III) 
and zinc (II) would likely play a role in biological function, but the differences themselves and 
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the effect they have remains unknown. A lipophilic yersiniabactin analog from Pseudomonas sp. 
No. 57-250, micacocidin (structure 32), has been crystalized with iron (III), copper (II), and zinc 
(II).103 Notably, while protonation states differ between the complexes to maintain charge 
neutrality, coordination denticity is the same, implying that three-dimensional ligand geometry is 
not the explanation for differing import pathway recognition.  
 While no molecule has been conclusively identified as a dedicated manganese-
transporting metabolite, evidence suggests that bacteria most likely produce chelators that 
facilitate manganese acquisition.104 Many microbes are known to catalyze oxidation of insoluble 
manganese (II) to manganese (IV) through the intermediate manganese (III). The most studied 
are fluorescent pseudomonads that produce pyoverdine (structure 33) siderophores.105 By a one-
electron oxidation to the tri-positive intermediate, the organism is able to prime the metal for 
high-affinity binding. Indeed, multiple pyoverdines have manganese (III) binding constants up to 
three orders of magnitude greater than their iron (III) binding constants .106 The fungal 
siderophore rhizoferrin (structure 34) also has a higher affinity for manganese (III) than iron 
(III).107 This difference is thought to occur due to the Jahn-Teller effect, whereby the chelators 
are able to accommodate elongation to the preferred tetragonal coordination geometry of high-
spin manganese (III). It is worthy of note that a Manganese uptake regulator (a member of the 
Fur superfamily) has been characterized in vitro108 (111) and that some manganese transporter 
genes are Fur-regulated.109 
 In order to fix atmospheric molecular nitrogen into a usable form, some bacteria produce 
enzymes that reduce di-nitrogen into two ammonia, aptly named nitrogenases. While nitrogenase 
activity can be achieved with only an iron-sulfur moiety, other metals such as molybdenum and 
vanadium can help facilitate the transformation.110,111 The siderophore aminochelin (structure 35) 
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from Azobacter vinelandii is able to chelate molybdenum out of silicates.112 The siderophores 
protochelin (structure 36), azotochelin (structure 37), and azotobactin (structure 38) all form 
high-affinity 1:1 Mo- and V- chelates that are transported into the cell (116-118).113–115 Counter-
intuitively, protochelin and azotobactin share structural similarity and are upregulated in low 
Mo- and V- conditions, but knockout studies show that they are preferentially used to for iron 
acquisition, and azotobactin for molybdenum.116 
 Perhaps the most nuanced siderophore-metal relationship is that of copper. Bacteria 
finely tune intracellular copper concentration due to its role in harmful Fenton-like oxidative 
reactions and its resulting toxicity.117,118 However, some beneficial processes require copper and 
thus bacteria use a combination of proteins/chaperones and small molecule chelators to maintain 
homeostasis. Some small molecules produced under copper-deficient conditions are thought to 
import copper into the cell to participate in enzymatic processes, such as methane 
monooxygenation (methanobactin from methanotrophs)119 (122) and denitrification 
(coproporphyrin III from Paracoccus denitrificans).120 Others chelate copper as a means of 
detoxification, such as yersiniabactin (structure 31) from UPEC, which prevents reduction to the 
extremely toxic Cu(I),121 sequesters the copper in a form that is not recognized by the 
siderophore import pathways and thus remains extracellular,121 and engages in superoxide 
dismutation to reduce harmful superoxide anion concentration within macrophages.122 
 While they will not be covered here, it is worthy of note that the relationship of 
siderophores to other metals and metalloids such as chromium, cobalt, aluminum, gallium, 
indium, plutonium, gold, and in marine bacteria even boron, have been studied to various 
degrees.93 Siderophores also play roles in regulation of gene expression and potentially as 
quorum sensing molecules.93 
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1.5  The Siderophores of Acinetobacter baumannii 
 
 The CDC lists MDR Acinetobacter strains as a serious threat with 7,300 of the ~12,000 
annual nosocomial infections being entirely resistant to at least 3 classes of frontline antibiotics 
(63% MDR rate).2 Clinical isolates of MDR A. baumannii are routinely resistant to all or nearly 
all FDA approved antibiotics with one outbreak strain in China harboring a plasmid containing 
45 antibiotic resistance genes.123 The rising threat of MDR A. baumannii has increased clinical 
use of polymyxins, which had been largely abandoned due to nephrotoxicity.124 Resistance to 
even these last resort drugs has inspired the search for new, nontraditional therapeutics including 
antivirulence strategies.3 Interruption of iron acquisition systems has garnered attention as an 
attractive antivirulence approach for targeting A. baumannii.125–129 Most highly virulent strains 
produce a cocktail of three siderophores to scavenge iron from the host. The A. baumannii 
siderophore cocktail typically includes acinetobactin,130 fimsbactins,131 and baumannoferrins132 
(Figure 11), the most widely studied of which is acinetobactin. 
 Genome sequence analysis of 50 A. baumannii clinical isolates revealed that the 
siderophore acinetobactin is universally conserved for virulence.128 The fish pathogen 
Aeromonas salmonicida also produces acinetobactin.133 Acinetobactin was first reported in 1994 
containing an oxazoline heterocycle.130 However, in 2009 Walsh and coworkers showed that 
acinetobactin and related siderophores pseudomonine and anguibactin are biosynthesized on 
homologous nonribosomal peptide synthase (NRPS) modular assembly lines.74 Walsh and 
coworkers were the first to definitively report that acinetobactin is produced in a “pre” form 
containing an oxazoline heterocycle and is then released from the NRPS after attack of N-
hydroxy-histamine on the thioester carbonyl of the penultimate enzyme-linked biosynthetic 
intermediate. At pH 8 the oxazoline structure rapidly isomerizes nonenzymatically to an 
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isoxazolidinone. Thus, the oxazoline was re-named pre-acinetobactin and the isoxazolidinone 
was named acinetobactin. The NMR spectra of enzymatically produced acinetobactin matched 
the reported spectra from the original isolation paper thus correcting a 15-year misconception in 
the literature and firmly establishing acinetobactin as the isomer present at pH ~8.74  
 Gene clusters and other essential genes encoding acinetobactin biosynthesis enzymes 
(entA, basABCDEFGHIJ), efflux a.k.a. “release” proteins (barAB), and uptake/utilization 
proteins (bauABCDE) have been annotated and functionally characterized in nonpathogenic and 
highly virulent strains.74,134–138 An EntA ortholog (found also in the enterobactin biosynthetic 
gene cluster in all enterobactin-producing genera) is found outside of the acinetobactin gene 
cluster but is required for 2,3-dihydroxybenzoic acid production, and therefore acinetobactin 
synthesis and ultimately virulence. Genes for production of N-hydroxyhistamine are found 
within the acinetobactin gene cluster. BasG is a decarboxylase that converts readily bioavailable 
histadine into histamine, and BasC is a monooxygenase that hydroxylates the terminal amine. 
The third building block, threonine, is readily bioavailable. To prepare substrates for anchoring 
onto the NRPS, BasE and BasA each use one equivalent of ATP to create 2,3-DHB aryl-
adenylate and threonine acyl-adenylate, respectively. BasI primes the NRPS domains BasF and 
BasB by attaching pantetheinyl arms with terminal thiols. The thiols of holo-BasF and holo-
BasB then attack the 2,3-DHB and threonine adenylates, respectively, thereby anchoring them as 
thioesters onto separate modules of the assembly line. The free amine of the anchored threonine 
attacks the carbonyl of anchored 2,3-DHB via a condensation domain, and the threonine residue 
is then transformed via the cyclase BasD to create the phenolate-oxazoline moiety. Finally, BasB 
cleaves the structure from the assembly line by condensation with the non-anchored N-
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hydroxyhistamine to give the final product, pre-acinetobactin, which isomerizes spontaneously to 
acinetobactin (Figure 12).  
 Inhibition of pre-acinetobactin biosynthesis and utilization has been validated as a 
potential anti-virulence strategy for treating infections caused by A. baumannii. Mutants with 
non-functional biosynthesis or outer-membrane receptor genes show reduced ability to establish 
infection and produce apoptosis in human epithelial cells, a result that is mirrored in 
infection/killing assays of G. mellonella moth larvae and mice.139 Inhibitors of BasE that mimic 
the 2,3-DHB aryl-adenylate intermediate with stable sulfamates in place of the reactive 
phosphate have been developed.140 Due to concerns over unfavorable pharmacokinetic properties 
caused by polarity, a high throughput screen against BasE was performed to find non-nucleoside 
BasE inhibitors. A pyrazolopyridine-based scaffold with potent in vitro BasE inhibitory activity 
was identified.127 While extensive SAR was performed directly against BasE, none of the 
pyrazolopyridine derivatives exhibited significant antibiotic activity against A. baumannii, most 
likely due to issues of cell permeability (efflux pumps or exclusion through down-regulation of 
porins). Recently, four other hits from the high throughput screen were revisited and SAR was 
performed on one.141 A single derivative was found to have sub-millimolar whole cell activity 
against A. baumannii under iron deficient conditions. While these results are promising, further 
optimization is needed before this can be a viable strategy. 
 Six molecules of similar structure termed the fimsbactins have been identified from A. 
baylyi and A. baumannii culture under iron-deficient conditions.131 The major compound (~80% 
by stoichiometry), fimsbactin A, was isolated and rigorously characterized by 2D-NMR. 
Fimsbactins B-F were structurally elucidated by feeding studies with radiolabeled 13C and 15N, as 
well as unlabeled siderophore building blocks, and detailed mass spectrometry. The fimsbactin 
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gene cluster was identified in A. baylyi and A. baumannii and knockout mutants were used to 
predict the biosynthetic pathway of fimsbactin. A total synthesis of fimsbactin B and methylated 
analogs of fimsbactins D and F has been published, but the primary compound fimsbactin A has 
eluded synthetic efforts due to epimerization of the stereocenter on the non-methylated 
oxazoline.142 Surprisingly, fimsbactin B and methyl fimsbactin D display inhibitory activity at 
millimolar concentrations. As discussed in section 1.4, a synthetic fimsbactin analog has been 
successfully conjugated to periplasmic-targeting antibiotics to inhibit A. baumannii growth. This 
may indicate that fimsbactin accumulates in the periplasm, although this result has not been 
replicated with the natural scaffold. 
 The A. baumannii AYE strain is deficient in 2,3-DHB, and therefore acinetobactin, 
biosynthesis due to a point mutation in entA. However, this strain is still a competent grower 
under iron deficient conditions. Fermentation yielded two hydroxamate siderophores differing by 
one double bond, the baumannoferrins.132 In silico gene cluster analysis showed sequence 
similarity to genes found in two previously characterized siderophore gene clusters, acinetoferrin 
and achromobactin. The production of baumannoferrin likely involves both NRPS and NRPS-
independent biosynthetic enzymes. The baumannoferrin gene cluster is present in A. baumannii 
ATCC 19606T, although for reasons not yet explored it does not appear to produce 
baumannoferrin. The questions of why pathogenic A. baumannii produce multiple high-affinity 
iron chelators, whether they serve individual functions, and if they work in tandem with one 
another remain largely unanswered.  
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1.6  Figures and Tables 
 
 
Figure 1. General schematic for bacterial iron acquisition in a host-body environment. OMR = 
Outer Membrane Receptor. PBP = Periplasmic Binding Protein. ABC = ATP-binding cassette. 
Iron can be made available for binding to an OMR by transferrin/lactoferrin, heme and heme-
containing proteins, or bacterial secondary metabolite iron-chelators (siderophores). 
 
 
Figure 2. (A.) Crystal structure of human transferrin bound to two iron (III) ions. (B.) Crystal 
structure of human transferrin complexed with transferrin binding protein (TbpA) from 
Neisserial meningitidis. The extracellular L3 helix finger of TbpA is important in extracting the 
iron (III) from the binding pocket of transferrin. Point mutations have been identified in human 
transferrin that prevent TbpA binding while maintaining iron-sequestration functionality. 
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Figure 3. Crystal structure of bacterial hemophore HasA from Serratia marcescens bound to two 
equivalents of protoporphyrin IX containing Fe-Heme. Arrows show the opening and closing 
motion of the binding pocket, described in the literature as a “fish-bite”. 
 
 
Common Bidentate Chelators Ligand Names (and pKa values) 
 
Catecholate (9.2, 13.0) 
 
Hydroxamate (9.0) 
 
Hydroxyphenyl oxazoline/thiazoline (9.0) 
 
α-hydroxycarboxylate (3.0, 14.5) 
 
α-aminocarboxylate (2.5, 9.5) 
 
α-hydroxyimidazole (6.0, 14.5) 
Table 1. Bidentate chelating moieties commonly found in siderophore structures with pKa 
values. 
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Figure 4. Siderophore structures discussed in the Chapter 1.4 subsection titled Chemistry, 
Biology, and Biosynthesis of Siderophores. 
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Figure 5. Crystal structure of the outer membrane receptor FptA from Pseudomonas aeruginosa 
bound to pyochelin-Fe3+. 
 
 
Figure 6. Schematic showing Ferric uptake regulator (Fur) suppression of siderophore protein 
machinery under iron-replete conditions by complexation with a Fur-box genetic motif preceding 
siderophore genes. 
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Figure 7. Crystal structure of human siderocalin (NGAL, lipocalin 2) bound to ferric-
enterobactin. 
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Figure 8. Natural sideromycin structures discussed in the Chapter 1.4 subsection titled 
Sideromycins. Siderophore moieties are represented in black, antibiotic moieties in blue, and 
linker moieties in red. 
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Figure 9. Synthetic sideromycin structures discussed in the Chapter 1.4 subsection titled 
Sideromycins, as well as a general schematic for the trimethyl-lock linker system. Siderophore 
moieties are represented in black, antibiotic moieties in blue, and linker moieties in red. 
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Figure 10. Siderophores structures with non-iron biological functions discussed in the Chapter 
1.4 subsection titled Non-iron Siderophore Functions. 
 
 
 
 
Figure 11. Siderophores produced by pathogenic strains of Acinetobacter baumannii. 
Coelibactin (28)
OH
N
O
S
N N
H
S O
OH
N H
O
NH
N
OH
H
N N
OH
O
H
O
NH2
O
HO O
HO
O
NH2
OH
Coelichelin (29)
Pyridine-2,6-dithiocarboxylic acid
(pdtc) (30)
OH
N
S
S
H
N S
N
OH
O
Yersiniabactin (31)
OH
OH
N
S
S
N S
N
OH
O
OH
Micacocidin (32)
N
H
N
O
NH
NH
O
HO
HO
HO
HN O
O
H
N
HN NH
NH2
O
N
H
N
H O
H
N
O
N
H
H
N
HN
HN
OO
O
O
HO
HO
N
HO
O
HO
H
HO
Group I Pyoverdine (33)
N
H
H
N
HO
O
OH
O
HO O
O
O
OH
OH
O
Rhizoferrin (34)
OH
OH
O
N
H
NH2
Aminochelin (35)
N
O
HS
O
SH
N N
O
HO
HO
H
N
O
R Azotobactin (38)
NH
HN
O
HO
HO
O
HN
HN
O
OHHO
O
OH
OH
Protochelin (36)
OH
OH
O
N
H
Azotochelin (37)
OHO
N
H
O
HO
OH
30 
 
 
 
Figure 12. The gene cluster and biosynthetic pathway for acinetobactin. bas = baumannii 
acinetobactin synthesis genes; bar = baumannii acinetobactin release genes; bau = baumannii 
acinetobactin uptake/utilization genes. The “F” and “T” circles represent putative Fur boxes and 
transcriptional termination signals, respectively. In the NRPS domains, “C” stands for 
condensation, “T” stands for thiolation, and “ICL” stands for isochorismate lyase. 
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2.1 Preface 
 
 This chapter was adapted with permission from [Shapiro, J. A. & Wencewicz, T. A. 
ACS Infect. Dis. 2, 157–168 (2016)]. Copyright © 2016 American Chemical Society. Both 
authors contributed to writing of the manuscript. JAS performed all experiments. TAW served as 
principal investigator and oversaw experimental design. 
2.2 Abstract  
 
 Pathogenic strains of Acinetobacter baumannii excrete multiple siderophores that 
enhance iron scavenging from host sources. The oxazoline siderophore pre-acinetobactin 
undergoes an unusual non-enzymatic isomerization producing the isoxazolidinone acinetobactin. 
In this study we explored the kinetics, mechanism, and biological consequence of this 
siderophore swapping. Pre-acinetobactin is excreted to the extracellular space where the 
isomerization to acinetobactin occurs with a pH-rate profile consistent with 5-exo-tet cyclization 
at C5’ with clean stereochemical inversion. Pre-Acinetobactin persists at pH < 6 and 
acinetobactin is rapidly formed at pH > 7 matching each siderophore’s pH preference for iron 
(III)-chelation and A. baumannii growth promotion. Acinetobactin isomerization provides two 
siderophores for the price of one enabling A. baumannii to sequester iron over a broad pH range 
likely to be encountered during the course of an infection. 
2.3 Introduction 
 
 As discussed in Chapter 1.5, acinetobactin is a critical virulence factor siderophore 
for A. baumannii and is biosynthesized by an NRPS assembly line as the oxazoline pre-
acinetobactin, which spontaneously isomerizes at pH = 8.1,2 Pre-pseudomonine, a siderophore 
produced by some Pseudomonads,3 differs from pre-acinetobactin only by the hydroxylation 
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state of the phenyl ring. Walsh and coworkers found that pre-pseudomonine undergoes an 
analogous post-biosynthetic isomerization reaction at pH ~8 to produce pseudomonine4 (Figure 
1B). A third member of this siderophore class, pre-anguibactin, differs from pre-acinetobactin 
and pre-pseudomonine in that it is built from l-cysteine, instead of l-threonine, producing a 
thiazoline heterocycle compared to the oxazoline heterocycles of pre-acinetobactin and pre-
pseudomonine. Unlike pre-acinetobactin and pre-pseudomonine, pre-anguibacin does not 
isomerize at pH 8 and is locked in as the thiazoline-containing isomer (Figure 1C).4 Pre-
anguibactin has been rigorously characterized as a functional siderophore for Vibrio 
anguillarum5 and a crystal structure of pre-anguibactin bound to gallium(III) has been solved.6 
Studies with pre-anguibactin suggest that the “pre” form of this siderophore class is biologically 
relevant and demands investigation of both pre-acinetobactin 1a and acinetobactin 1b as 
contributors in A. baumannii iron acquisition. 
 Acinetobacter baumannii pathogens are capable of growth over a wide pH range with 
most sites of infection being acidic.7,8 We hypothesized that the isomerization of pre-
acinetobactin 1a would be faster if the hydroxamic acid (pKa ~9) nucleophile was partially 
deprotonated. Therefore, we predicted that the isomerization of pre-acinetobactin 1a to 
acinetobactin 1b would be slower at acidic pH favoring pre-acinetobactin 1a as the major 
isomeric form of the siderophore present at acidic A. baumannii infection sites. To test our 
hypothesis we probed the kinetics and mechanism of acinetobactin isomerization and established 
a pH-rate profile of the reaction over a pH range of 5.5-8.0. We also probed the role of pH on 
iron (III)-chelation and A. baumannii growth promotion. Our studies suggest a role for both 
acinetobactin siderophore isomers in A. baumannii iron acquisition during the course of an 
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infection reshaping our chemical understanding of these important virulence molecules in a 
relevant biological context. 
2.4 Results and Discussion 
 
Synthesis and Isolation of Acinetobactin 
 A total synthesis by Takeuchi and coworkers was adapted to produce the key 
intermediate benzyl protected pre-acinetobactin 12 and is described in Scheme 1. In previous 
chemical synthesis9 and biosynthesis4 studies with acinetobactin no method was reported for 
stabilizing and storing pre-acinetobactin 1a. We found that the TFA salt of pre-acinetobactin 1a 
was stable in methanol (pH ~2) after hydrogenolysis of benzyl protected precursor 12 (Scheme 
2). Performing the same benzyl deprotection reaction and subsequently adjusting to pH 7 
provided acinetobactin 1b in quantitative yield. Standardized solutions of 1a TFA salt and 1b 
were prepared in deuterated methanol spiked with an acetonitrile internal standard and were 
stable at -80 C for >1 year. All characterization data of 1b matched a natural analytical standard 
of acinetobactin 1b isolated from fermentation of A. baumannii ATCC 17978 (Appendix A). We 
report the first detailed 2D-NMR characterization of pure pre-acinetobactin 1a TFA salt 
(Appendix A). Iron complexes of pre-acinetobactin, 1a-Fe(III), and acinetobactin, 1b-Fe(III), 
were prepared by treating methanolic solutions of iron free siderophores, 1a and 1b, with 
tris(acetylacetonato) iron (III). The structure of these complexes is still unknown, but 1a-Fe(III) 
( = 515 nm, magenta solution) and 1b-Fe(III) ( = 570 nm, purple solution) form stable, unique 
iron (III) complexes as determined by UV-Vis and MS-MS. This synthetic route provides 
efficient access to both acinetobactin isomers and is amenable to the synthesis of acinetobactin 
analogs or other members of this siderophore family including pseudomonine and anguibactin. 
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Acinetobactin Isomerization is pH Dependent 
 With pure, stable pre-acinetobactin 1a in hand we explored a variety of analytical 
techniques (UV-Vis, LC-MS, and NMR) to measure variable pH isomerization kinetics.  
Previous reports showed that pre-acinetobactin 1a and acinetobactin 1b have different UV-Vis 
spectra.24 Analysis of the changes in the optical absorption spectra (200 – 400 nm) of 1a over 
time in phosphate buffers (pH 4.6, 7.0, and 8.8) gave time- and pH-dependent spectral changes 
(Figure 2ACE). Single wavelength kinetic experiments of 1a produced single-phase exponential 
growth curves of absorbance vs time (Figure 2BDF) with a clear pH-rate profile: t1/2 pH 4.6 >> 
7.0 > 8.0. We were able to separate isomers 1a and 1b by LC-MS, identify each isomer by its 
UV-Vis spectra in the diode array (Figure 3), and monitor the isomerization over time to 
confirm pH-rate relationship (Figure 4). With further optimization these could be valuable 
techniques for acquisition of kinetic data in a wide range of sample matrices. 
 Ultimately we found 1H-NMR to be most useful for accurately measuring isomerization 
kinetics with high reproducibility. We measured kinetics in 10% D2O/90% H2O and used peak 
integration from the diagnostic methyl doublets of pre-acinetobactin 1a (1.42 ppm, J = 6.3 Hz) 
and acinetobactin 1b (1.34 ppm, J = 6.3 Hz) to generate first order reaction plots (Figure 5A). A 
pH-rate profile for the reaction was established: t1/2 at pH 5.5 >> 7.0 > 8.0. The isomerization 
was slow at pH 5.5 (t1/2 = 944  105 min), faster at pH 7.0 (55  14 min) and fastest at pH 8.0 
(18  3 min) (Figure 5B) consistent with previous reports that at pH  8 acinetobactin 1b forms 
rapidly and is stable.4,10 However, at pH 5.5 these data suggest that pre-acinetobactin 1a will be 
the major isomer. Taken with knowledge that A. baumannii infection sites are often acidic (pH 
~5)7,8 these data suggest that pre-acinetobactin may play an active role in iron acquisition during 
infection. Most A. baumannii pathogens grow over a wide pH range (5-8) during establishment 
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and spread of an infection, so acinetobactin 1b may also play a role in iron acquisition at pH > 7. 
The isomerization kinetics suggest that pre-acinetobactin 1a and acinetobactin 1b will be present 
during A. baumannii infections and thus supports our hypothesis that both siderophore isomers 
contribute to iron acquisition in A. baumannii pathogens. 
 Kinetic isotope effects were minimized by conducting isomerization studies in 90% 
H2O/10% D2O phosphate buffer confirmed by an experiment conducted at pH 7 in phosphate 
buffered D2O (Table 1). In pure D2O the reaction was two times slower (t1/2 = 105 min  1 min) 
compared to 10% D2O/90% H2O (t1/2 = 55 min  14 min). By extrapolation it is reasonable to 
assume that 10% D2O does not affect this t1/2 by more than the margin of error. All isomerization 
kinetics were performed at room temperature (27 C). Conducting kinetic experiments at human 
body temperature (37 C) gave faster kinetics, a noisier baseline, and increased experimental 
error. It is safe to say that the same trend in pH dependence exists at 37 C with increased 
isomerization rate for all pH values.  
Acinetobactin Isomerization Proceeds via Clean Inversion at C5' 
 To prove that reaction pH does not influence the structure and stereochemistry of 
acinetobactin 1b we analyzed synthetic acinetobactin 1b generated at pH 5.5, 7.0, and 8.0 using 
C18 HPLC (Figure 5CD), chiral HPLC (Figure 5E), CD spectrophotometry (Figure 6), and 
high-resolution MS-MS (Figures 7-9). Acinetobactin 1b isolated from isomerization of pre-
acinetobactin 1a at pH 5.5, 7.0, and 8.0 gave identical retention times and UV-Vis spectra when 
analyzed by C18 HPLC individually and as a mixture (Figure 5C). A mixture of acinetobactin 
1b samples generated at pH 5.5, 7.0, and 8.0 showed identical retention times and UV-Vis 
spectra when analyzed by C18 HPLC compared to a natural analytical acinetobactin 1b standard 
purified from A. baumannii (Figure 5D). High-resolution MS-MS analysis of synthetic and 
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natural acinetobactin samples supported the matching identity of these samples through 
confirmation of molecular formula (Figures 7-9) and characteristic mass fragmentation patterns 
(Scheme 3). To assess the stereochemical purity of the various samples, chiral HPLC and CD 
spectrophotometry were performed. The natural and synthetic acinetobactin 1b samples 
generated at all pH values showed identical retention times on chiral HPLC (Figure 5E) and 
identical CD spectra (Figure 6). These data suggest that the synthetic acinetobactin samples 
match the natural samples in both enantiomeric and diastereomeric identity and purity and that 
the pH does not influence stereochemical outcome of the isomerization reaction. 
 The acinetobactin isomerization reaction was slow at pH 5.5 and fast at pH >7 (Figure 
5B), consistent with a proposed mechanism where the hydroxamate of 1a acts as nucleophile at 
C5’ of the oxazoline. If the hydroxamate attacks the oxazoline C5’ in SN2 manner inducing a 
Baldwin-favored, 5-exo-tet cyclization33 the result would be clean stereochemical inversion at 
C5’ (R to S) while maintaining stereochemistry at C4’ (S) (Figure 10A). If this type of 
mechanism were at play, then both the pre-acinetobactin 1a oxazoline and the acinetobactin 1b 
isoxazolidinone heterocycles would have a trans orientation of the C4’ and C5’ stereogenic 
centers. Indeed, ROESY 2D NMR analysis of pre-acinetobactin (Figure 10B and Appendix A) 
and acinetobactin (Figure 10C and Appendix A) showed strong signals for through-space 
interactions between C4’-C6’ protons and C5’-C6’ protons for both 1a and 1b structures. There 
were no observable ROESY correlations for C4’-C5’ protons in both acinetobactin isomers 
which is consistent with a trans orientation of C4’ and C5’ stereocenters in the oxazoline and 
isoxazolidinone heterocycles of pre-acinetobactin 1a and acinetobactin 1b, respectively. We used 
enantiomerically pure l-Threonine in our synthesis of pre-acinetobactin 1a and acinetobactin 1b 
which allows assignment of the stereochemistry at C4’ and C5’ for each isomer (pre-
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acinetobactin 1a: C4’ (S) and C5’ (R); acinetobactin 1b: C4’ (S) and C5’ (S).  Collectively, our 
chiral HPLC, multidimensional NMR, high-res MS-MS, and CD studies indicate high diastereo- 
and enantiomeric purity (>95%) and equivalence between the synthetic acinetobactin 1b samples 
generated at pH 5.5, 7.0, and 8.0 and authentic acinetobactin isolated from A. baumannii ATCC 
17978. Considering the general pKa of a hydroxamic acid (~9)34, the pH-rate profile for the pre-
acinetobactin isomerization (Figure 2B; pH-rate profile: t1/2 pH 5.5 >> 7.0 > 8.0) is consistent 
with deprotonation of the hydroxamic acid at neutral or higher pH values which increases the 
rate of nucleophilic attack on C5’. A 5-exo-tet cyclization mechanism where the hydroxamate 
attacks C5’ in SN2 manner accounts for the stereochemical outcome of the reaction and is 
consistent with the measured first order pH-rate profile. There are likely subtle electronic factors 
and proton transfer events that contribute to the mechanism and kinetics of pre-acinetobactin 
isomerization that require further study. 
Acinetobactin and Pre-Acinetobactin Form Unique, Stable Complexes with Fe(III) 
 Pre-acinetobactin isomerization kinetics suggest that the oxazoline isomer 1a is stable at 
pH 5.5 (t1/2 =944 min) and relatively unstable at pH 7.0 (t1/2 = 55min) and 8.8 (t1/2 = 18 min) 
(Figure 5B). We propose that pre-acinetobactin 1a will be stable at acidic sites of A. baumannii 
infection and acinetobactin 1b will be stable at neutral to basic sites of infection. If both isomers 
are to be considered biologically relevant siderophores over this pH range it is critical to 
investigate the ability of each isomer to form stable complexes with iron (III). We prepared pre-
acinetobactin- and acinetobactin-iron (III) complexes, 1a-Fe(III) and 1b-Fe(III) respectively, by 
treating methanolic solutions of the iron free siderophores, 1a and 1b, with 1.1 equivalents of 
tris(acetylacetonato) iron (III)  (Scheme 2). Upon addition of tris(acetylacetonato) iron (III) the 
reactions instantly turned dark purple/black indicating that a metal complex was formed for both 
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isomers. Both the pre-acinetobactin-iron (III) complex 1a-Fe(III) and the acinetobactin-iron (III) 
complex 1b-Fe(III) are soluble in methanol and aqueous buffers upon sonication. 
 Each siderophore-iron (III) complex gives a unique UV-Vis absorbance spectrum 
(Figure 11). The pre-acinetobactin-iron (III) complex 1a-Fe(III) is clear and magenta in color 
with a broad peak at 515 nm. The acinetobactin-iron (III) complex 1b-Fe(III) is clear and purple 
with a broad peak at 570 nm. Titrating NMR quantified solutions of the apo-siderophores with 
tris(acetylacetonato) iron (III) indicated a ligand:metal ratio of ~2:1 (Figure 12). Extinction 
coefficients were calculated for the apo-siderophores and iron complexes (assuming a 2:1 
siderophore:Fe(III) stoichiometry). 
 The pre-acinetobactin-iron (III) complex 1a-Fe(III) was stable in phosphate buffered M9 
media at pH 5.7, 6.5, and 7.5 at room temperature for >3 weeks with no measurable change in 
the UV-Vis spectrum. Iron-free pre-acinetobactin 1a isomerizes rapidly at pH 7.5 (t1/2 <55 min), 
but the iron (III) complex 1a-Fe(III) does not which suggests that the metal protects pre-
acinetobactin from isomerizing. This is consistent with the hydroxamate N-O making a strong 
interaction with the iron (III) center in a conformation that does not favor the 5-exo-tet 
cyclization (Figure 3A). The acinetobactin-iron (III) complex 1b-Fe(III) was stable in 
phosphate buffered M9 media at pH 6.5 and 7.5 at room temperature for >3 weeks, but was 
unstable at pH 5.7. Addition of the purple acinetobactin-Fe(III) complex to pH 5.7 M9 media 
resulted in a clear, colorless solution suggesting instability of the complex under these 
conditions. This is consistent with a catecholate participating as a bidentate ligand for iron (III) 
compared to the phenolateoxazoline bidentate ligand in pre-acinetobactin. Protonation of the 
more basic catecholate at acidic pH will block its ability to chelate Fe(III). A similar dual mode 
of catecholate versus phenolateoxazoline is observed for the siderophore vibriobactin from 
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Vibrio cholerae where swapping coordination modes influences siderocalin binding.11 We 
observed a blue spectral shift when comparing the 1a-Fe(III) complex ( = 515 nm) to the 1b-
Fe(III) complex ( = 570 nm). Such spectral shifts are observed for other strong-field catechol 
ligands such as bis-catecholate-Fe(III) ( = 575 nm) and tris-catecholate enterobactin-Fe(III) ( 
= 498 nm).12 In the observed case, such a spectral shift indicates unique ligand to metal 
coordination modes for the 1a-Fe(III) and 1b-Fe(III) complexes that might be explained when 
considering catecholate versus phenolateoxazoline chelation modes. The stability of the pre-
acinetobactin-Fe(III) complex at pH 5.7, and corresponding instability of the acinetobactin-
Fe(III) complex at pH 5.7, supports our hypothesis that pre-acinetobactin acts as a siderophore 
for A. baumannii at acidic infection sites and acinetobactin serves as a siderophore under more 
basic conditions. Improved knowledge of coordination chemistry in the pre-acinetobactin and 
acinetobactin family of siderophores is important for understanding iron transport in A. 
baumannii and other pathogens.13 
Both Acinetobactin Isomers Serve as pH-Dependent Iron Sources for A. baumannii 
 The capacity to biosynthesize and transport acinetobactin has been validated in several 
studies using A. baumannii wild type and knock-out strains both in vitro and in vivo.2 
Acinetobactin is an important virulence factor for pathogenic A. baumannii. All genome 
sequenced clinical isolates possess a functional acinetobactin gene cluster with biosynthesis and 
utilization genes (>50 in total; Only A. baumannii AYE clinical isolate is believed to not produce 
acinetobactin although it does possess the biosynthetic gene cluster with a functional mutation in 
entA.14).1 However, there are no reports clarifying which siderophore isomer, pre-acinetobactin 
1a or acinetobactin 1b, or both, is biologically relevant.  
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 We investigated pre-acinetobactin- and acinetobactin-Fe(III) complexes as iron sources 
for A. baumannii by performing feeding studies in defined M9 medias buffered at pH 5.7, 6.5, 
and 7.5. As described in the previous section, pre-acinetobactin-Fe(III) complex 1a-Fe(III) is 
stable and does not undergo isomerization at pH 5.7, 6.5, and 7.5 which allowed for testing the 
growth promoting activity of this isomer without substantial conversion to acinetobactin-Fe(III) 
complex 1b-Fe(III). Acinetobacter baumannii ATCC 17978 grows well in the buffered M9 
media at all pH values.  For each buffered M9 media, we initially performed growth studies with 
increasing amounts of 2,2’-dipyridyl (DIP) to make the growth media iron replete enough to 
entirely halt the growth of A. baumannii ATCC 17978 (200 M for pH 5.7, 250 M for pH 6.5, 
and 250 M for pH 7.5; Figure 13 black control growth curves).15 We next performed the same 
growth studies where cultures were supplemented with a gradient of either pre-acinetobactin-
Fe(III), 1a-Fe(III), or acinetobactin-Fe(III), 1b-Fe(III), at concentrations spanning 50 – 0.84 M 
(Figure 13). Growth curves were generated by measuring optical density at 700 nm (OD700) with 
a final reading taken after 45 hours (Figure 14).  
 Comparison of full growth curves (Figure 13) and the 45 hour OD700 reading (Figure 
14ABC) show that both pre-acinetobactin-Fe(III) and acinetobactin-Fe(III) promote the growth 
of A. baumannii ATCC 17978 under iron deficient conditions at all pH values in a dose-
dependent manner. At pH 5.7, pre-acinetobactin-Fe(III) boosted growth starting at 1.68 M 
while acinetobactin-Fe(III) did not promote growth substantially relative to the control until 
reaching 25 – 50 M. At pH 6.5, pre-acinetobactin-Fe(III) and acinetobactin-Fe(III) both 
promoted A. baumannii growth starting at 0.84 M with more pronounced growth promotion 
from pre-acinetobactin-Fe(III) from 0.84 – 25 M. At pH 7.5, the growth promotion from both 
isomers is comparable starting at 3.375 M. These data support that both siderophore isomers, 
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pre-acinetobactin-Fe(III) and acinetobactin-Fe(III), are capable of serving as iron sources for A. 
baumannii ATCC 17978. Furthermore, there is a pH preference for each siderophore isomer. 
Pre-Acinetobactin-Fe(III) is more competent to promote A. baumannii growth under acidic 
conditions (pH 5.7). At pH 5.7, the acinetobactin-Fe(III) complex was found to be unstable, as 
discussed previously, which is consistent with the observation that it serves poorly as an iron 
source at pH 5.7 compared to pre-acinetobaction-Fe(III). Collectively, these growth promotion 
studies (Figure 14) are consistent with pre-acinetobactin isomerization kinetics (Figure 5B) and 
support a model where pre-acinetobactin 1a serves as siderophore for A. baumannii at acidic pH 
 and isomerizes to acinetobactin 1b under neutral to basic conditions to continuing serving as a 
competent siderophore. These studies also suggest that A. baumannii ATCC 17978 possesses 
uptake machinery for internalizing both pre-acinetobactin- and acinetobactin-Fe(III) complexes.  
Pre-acinetobactin and Acinetobactin use the Same Outer-Membrane Transport Protein 
 We performed growth promotion studies using siderophore transport and biosynthesis 
mutants to test if pre-acinetobactin 1a-Fe(III) and acinetobactin 1b-Fe(III) utilize the same 
membrane transport system in A. baumannii pathogens (Figures 15 and 16). Actis and 
coworkers prepared and characterized gene insertion mutants of the clinical isolate A. baumannii 
ATCC 19606, a producer of acinetobactin, with functionally disabled outer membrane receptor 
bauA (mutant t6), inner membrane ABC transporter bauD (mutant t7), or biosynthetic oxazoline 
cyclization enzyme basD (mutant s1).15 As expected, we found that both 1a-Fe(III) and 1b-
Fe(III) promoted the growth of wild type and s1 biosynthesis mutant A. baumannii strains which 
have fully functional transport systems (Figure 15). Also as expected, the t6 outer membrane 
receptor mutant was unable to utilize either siderophore isomer as a source of iron suggesting 
that both siderophore-iron (III) complexes rely on the same outer membrane receptor, bauA, for 
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entry into the periplasmic space of the cell. Surprisingly, the t7 inner membrane ATP-dependent 
transporter bauD mutant was still able to utilize 1b-Fe(III) (Figure 15B), and to a lesser extent 
1a-Fe(III) (Figure 15A), as a source of iron. Since A. baumannii ATCC 19606 also produces the 
fimsbactin and baumannoferrin siderophores it is possible that certain siderophore utilization 
proteins, such as the inner membrane ABC transporters and periplasmic siderophore binding 
proteins,16 can be shared between various siderophore systems leaving the outer membrane 
receptors as the gatekeepers for selective siderophore transport. 
A. baumannii excretes Pre-Acinetobactin to the Extracellular Space 
 In order for pre-acinetobactin and acinetobactin to act as siderophores, pre-acinetobactin 
must be excreted by A. baumannii to the extracellular space where it can isomerize to 
acinetobactin or acinetobactin might also be excreted after intracellular isomerization. Walsh and 
coworkers detected pre-acinetobactin production directly from in vitro reconstitution of the 
pseudomonine NRPS assembly line (PmsEDG).4 Under these conditions (pH 8.0), enzymatically 
produced pre-acinetobactin rapidly isomerized to acinetobactin as monitored by HPLC. There 
are no reports of pre-acinetobactin detected in the extracellular space of growing A. baumannii 
cultures. By growing A. baumannii ATCC 17978 in M9 media buffered to pH 5.7, we were able 
to detect pre-acinetobactin and acinetobactin in the culture supernatant using LC-MS (Figure 
17A). As expected, based on isomerization kinetics reported in this study (Figure 5B), no pre-
acinetobactin was detected in cultures grown at pH 6.5 and 7.5 (Figure 17B). Detection of pre-
acinetobactin and acinetobactin in A. baumannii culture supernatants implies that A. baumannii 
possesses efflux machinery capable of exporting pre-acinetobactin. Acinetobactin might also be 
exported after intracellular isomerization, or it could isomerize in the extracellular space 
following pre-acinetobactin efflux. This model accounts for use of both siderophore isomers, in 
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an adaptable manner, for iron acquisition over a wide pH range and diverse infection 
environments. 
2.5 Outlook and Conclusions 
 
 Many highly virulent bacterial pathogens such as uropathogenic E. coli, P. aeruginosa, 
and Vibrio cholerae produce a cocktail of siderophores for iron acquisition during host 
invasion.16–18 Advantages of siderophore combinations might include tuning iron acquisition 
towards specific tissues and iron sources (i.e. different infection pH or sequestration from host 
lactoferrin or transferrin repositories19), evasion of the human immune system (i.e. sequestration 
by siderocalin), chemical signaling (i.e. quorum sensing and biofilm formation), or metal 
detoxification (i.e. copper detox by yersiniabactin).13,20,21 Pathogenic A. baumannii produce 
multiple sideorphores, typically the fimsbactins22, baumannoferrins14, and acinetobactin10. 
Acinetobactin, the focus of this work, is the best studied of the A. baumannii siderophores and it 
is a validated, highly conserved virulence factor.2 
 The fimsbactins are mixed ligand, bis-catecholate mono-hydroxamate siderophores that 
are reminiscent of enterobactin, salmochelin, vibriobactin, and petrobactin catechol siderophores 
that act as high-affinity iron (III) chelators (enterobactin KFe ~10
49) and play important roles as 
siderocalin binding substrates or stealth siderophores for evasion of host immune system.12,16 
Baumannoferrin is also a mixed ligand bis-alpha-hydroxy-carboxylate mono-hydroxamate 
siderophore with a C10-acyl lipid tail. Baumannoferrin resembles another siderophore, 
acinetoferrin23 from nonpathogenic, environmental A. haemolyticus ATCC 17906T, which has 
been shown to be membrane associated.24 Baumannoferrin might serve as a hydrophobic, 
membrane-associated siderophore that does not diffuse far from the A. baumannii cell surface or 
it might enhance in iron sequestration in more hydrophobic infection environments. 
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 Although A. baumannii pathogens only produce three siderophores, we have shown that 
both isomers of acinetobactin, oxazoline-containing pre-acinetobactin 1a and isooxazolidinone-
containing acinetobactin 1b, likely contribute to iron acquisition making an overall net effective 
total of four siderophores. Additionally, A. baumannii pathogens are known to express 
receptor/transport proteins for xenosiderophores further expanding capacity for siderophore 
useage.25 Acinetobactin isomerization appears to be an adaptation strategy for A. baumannii to 
expand the pH window for iron acquisition. Siderophores, as iron (III) chelating ligands, are in 
constant competition for binding to metals or protons.16 The fimsbactins will likely be unable to 
form high-affinity iron (III) complexes under acidic pH, which is required for successful iron 
(III) sequestration, because the bis-catecholate ligands will be protonated (pKa ~ 9.2, 13.0). 
Baumannoferrin will likely be able to bind iron (III) under acidic conditions because the -
hydroxy carboxylate (pKa ~ 3.0) and hydroxamate (pKa ~ 9.0) ligands are more deprotonated 
and therefore more effective than catecholates at acidic pH. However, it is unknown if 
baumannoferrin will be diffuse or membrane bound during the infection. This leaves pre-
acinetobactin as a viable siderophore to service iron acquisition at acidic infection sites. Pre-
acinetobactin is stable at acidic pH (t1/2 = 944 min at pH 5.5) and capable of iron (III) chelation 
from pH 5.7-7.5. Acinetobactin is rapidly formed via pre-acinetobactin spontaneous 
isomerization at pH > 7 (t1/2 < 55min) and is capable of iron (III) chelation at pH >6.5. Pre-
acinetobactin is excreted by A. baumannii and the external pH ultimately determines which 
isomer will serve as siderophore. Acinetobactin isomerization is a flexible siderophore swapping 
strategy for A. baumannii to adapt to its environment and maximize its capacity for iron 
acquisition (Figure 18). 
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 Other siderophores, including vibriobactin11 from V. cholerae and the staphyloferrins A 
and B,26 produced by MRSA as a virulence factor, are capable of nonenzymatic ligand 
isomerizations and metal chelation isomerizations. Perhaps this strategy has been evolved 
broadly amongst siderophore classes to enable more flexibility in metal chelation and 
environmental adaptability to ultimately enhance microbial iron acquisition. Acinetobactin 
isomerization and coordination chemistry require firm understanding in order to properly frame 
biological findings. Siderophore pathways are attractive targets for novel antibacterial agents (i.e. 
antibiotic drug delivery27,28), antivirulence therapeutics (i.e. siderophore biosynthesis inhibitors29 
and gallium quenching30), vaccine development,31 and infection diagnostics (i.e. siderophore 
imaging32 and diagnostic agents33). Our work establishes that pre-acinetobactin and acinetobactin 
are both biologically relevant siderophores for pathogenic A. baumannii and directs future 
studies in pathogenesis and siderophore-based therapeutics/diagnostics to consider both isomers 
of this siderophore family. 
2.6 Materials and Methods 
 
Strains, Materials, and Instrumentation 
 Growth studies were conducted using Acinetobacter baumannii ATCC 17978, 19606,  
and 19606 derivatives t6 (bauA::EZ::TN<R6Kcori/KAN-2>), t7 (bauD::EZ::TN<R6Kcori/KAN-
2>), and s1 (basD::aph) provided by Dr. Luis Actis. Acinetobactin production was conducted 
using Acinetobacter baumannii ATCC 17978. Glycerol stocks of A. baumannii were made from 
cells grown in LB media and stored at -80 C. Precultures and 96-well plate A. baumannii 
growth assays were performed in pH adjusted, filter sterilized M9 minimal media (see 
Supporting Information for recipe). Samples for HPLC and LC-MS were prepared in 0.45 μm 
PTFE Mini-UniPrep™ vials from Agilent. All pH measurements were recorded using an Orion 
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Star A111 pH meter and a PerpHecT® ROSS® Micro Combination pH Electrode from Thermo 
Scientific. Analytical HPLC was performed using Beckman Coulter SYSTEM GOLD® 126 
solvent module, 508 autosampler, and 168 detector. A Luna 5 μm C18(2) 100A column, 250 x 
4.6 mm with guard column was used for achiral separations and a Lux 5u Cellulose-1 column, 
100 x 4.6 mm was used for chiral separations, both from Phenomenex. All preparatory HPLC 
was performed using a Beckman Coulter SYSTEM GOLD® 127P solvent module and 168 
detector with a Phenomenex Luna 10u C18(2) 100A column, 250 x 21.20 mm, 10 micron with 
guard column. Analytical and prep HPLC were performed with mobile phases of 0.1% 
trifluoroacetic acid in (A) water and (b) acetonitrile and data were processed using 32 Karat 
software, version 7.0. All LC-MS was performed on an Agilent 6130 Quadropole LC-MS with 
G1313 autosampler, G1315 diode array detector, and 1200 series solvent module. A 
Phenomenex Gemini C18 column, 50 x 2 mm, 5 micron with guard column was used for all LC-
MS separations. LC-MS mobile phases were 0.1% formic acid in (A) water and (B) acetonitrile 
and data were processed using G2710 ChemStation software.  NMR was performed on Varian 
Unity Plus-300 MHz and Varian Unity Inova-500 MHz instruments. UV-Vis spectroscopy was 
performed on a Cary 50 fit with an autosampler and water peltier thermostat system using 1 cm 
quartz cuvettes. CD spectroscopy was performed on a Jasco-J715 spectropolarimeter in a 0.1 cm 
cuvette. Bacterial growth studies were performed using polystyrene 96-well plates with lids 
sealed using parafilm and OD700 measurements were taken on a Molecular Devices SpectraMax 
Plus 384 plate reader. 
Synthesis of Acinetobactin and Pre-Acinetobactin 
 Pre-acinetobactin TFA salt (1a). Benzyl pre-acinetobactin 12 was synthesized as 
described previously9 (Scheme 1) and purified by prep HPLC as the TFA salt using a gradient of 
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5% B to 95% B over 20 minutes. Pure 12 TFA salt was stirred in methanol with ~1:10 mass 
equivalent of 10% Pd/C under a hydrogen atmosphere. Once complete as judged by LC-MS (1 
hr), the mixture was flushed with argon, filtered, and concentrated by rotary evaporation. 
Solutions of 1a TFA salt in deuterated methanol were quantified by 1H-NMR using an 
acetonitrile internal standard. This material was >95% pure and used without further purification. 
1H-NMR (500MHz, (CD3)2SO) δ (ppm) 10.40 (br. s., 1 H), 8.97 (s, 1 H), 8.49 (br. s., 1 H), 7.43 
(s, 1 H), 7.04 (dd, J = 1.6, 7.8 Hz, 1 H), 6.96 (dd, J = 1.6, 7.8 Hz, 1 H), 6.74 - 6.70 (m, 1 H), 5.00 
(d, J = 6.3 Hz, 1 H), 4.80 (td, J = 6.2, 11.9 Hz, 1 H), 4.00 - 3.72 (m, 2 H), 3.05 - 2.90 (m, 2 H), 
1.42 (d, J = 6.3 Hz, 3 H); 13C-NMR (500 MHz, (CD3)2SO) δ (ppm) 21.7, 23.0, 47.0, 71.5, 80.1, 
117.8, 119.2, 120.0, 120.8, 131.7, 135.4, 147.0, 150.0, 167.3, 170.9; HRMS (ESI) calculated 
mass for [M+H] (C16H19O5N4
+): m/z 347.1350, found 347.1355; Molar extinction coefficient (10 
mM HEPES buffer, pH 7.4): 3147 M-1cm-1 at 315 nm. See Supporting Information for MS-MS 
fragmentation and tabulated 2D NMR data. 
 Acinetobactin TFA salt (1b). Pre-acinetobactin 1a TFA salt was dissolved in 0.2 M 
phosphate buffer (pH 5.5-8) and left overnight. The product was purified by preparatory HPLC 
using a gradient of 5% B to 95% B over 20 minutes. Solutions in D2O were quantified by 
1H-
NMR using an acetonitrile internal standard. 1H-NMR (500MHz, (CD3)2SO) δ (ppm) 9.33 (br. s., 
1 H), 9.05 (d, J = 8.6 Hz, 1 H), 8.98 (s, 1 H), 7.51 (s, 1 H), 7.24 (d, J = 7.0 Hz, 1 H), 6.93 (d, J = 
7.8 Hz, 1 H), 6.75 - 6.63 (m, 1 H), 4.61 (dd, J = 8.2, 10.6 Hz, 1 H), 4.46 - 4.34 (m, 1 H), 3.81 (t, 
J = 6.7 Hz, 2 H), 3.04 - 2.86 (m, 2 H), 1.34 (d, J = 6.3 Hz, 3 H); 13C-NMR (500 MHz, (CD3)2SO) 
δ (ppm) 18.0, 23.3, 45.2, 58.4, 79.0, 116.3, 118.2, 119.0, 119.7, 120.7, 131.3, 135.4, 147.6, 
150.5, 169.0, 171.0; HRMS (ESI) calculated mass for [M+H] (C16H19O5N4
+): m/z 347.1350, 
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found 347.1350; Molar extinction coefficient (10 mM HEPES buffer, pH 7.4): 3176 M-1cm-1 at 
330 nm. See Supporting Information for MS-MS fragmentation and tabulated 2D NMR data. 
 Pre-Acinetobactin-Fe(III) Complex (1a-Fe(III)). Pre-acinetobactin 1a was dissolved in 
methanol and treated with 1.1 equivalents of tris(acetylacetonato) iron (III). The solution was 
concentrated by rotary evaporation and the residue was triturated with diethyl ether. Product 1a-
Fe(III) was isolated in >95% purity as a black powder. HRMS (ESI) calculated mass for [M+Fe-
2H] (C16H16FeO5N4
+) m/z 400.0465, found 400.0451; Molar extinction coefficient (10 mM 
HEPES buffer, pH 7.4): 2829 M-1cm-1 at 515 nm and 1269 M-1cm-1 at 650 nm. 
 Acinetobactin-Fe(III) Complex (1b-Fe(III)). Acinetobactin iron complex 1b-Fe(III) 
was isolated as a black powder following an analogous procedure described for 1a-Fe(III). 
HRMS (ESI) calculated mass for [M+Fe-2H] (C16H16FeO5N4
+) m/z 400.0476, found 400.0447; 
Molar extinction coefficient (10 mM HEPES buffer, pH 7.4): 3171 M-1cm-1 at 570 nm and 2165 
M-1cm-1 at 650 nm. 
Isolation and purification of Acinetobactin from A. baumannii cultures 
 A 5 mL preculture of A. baumannii ATCC 17978 in M9 minimal media was grown 
overnight at 37 C. Preculture (100 μL) was added to 1 L of sterile M9 in a 3L shaker flask and 
incubated at 37 C with shaking (225 rpm) for 48 hours. Cells were pelleted (5,000 rpm, 20 min) 
and the supernatant was adjusted to pH 6 with saturated citric acid. Resin (XAD-7HP, 25 grams) 
was added and the mixture was shaken at 125 rpm for 2 hours. The mixture was filtered and the 
resin was washed with diH2O (3 x 500 mL). The resin was treated with 200 mL MeOH, shaken 
at 125 rpm for 30 minutes, filtered, and washed with 900 mL MeOH. The MeOH was 
concentrated by rotary evaporation and purified by preparatory HPLC using a gradient of 5% B 
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to 95% B over 20 minutes to yield 50 mg pure acinetobactin, 1b, TFA salt. All characterization 
data matched synthetic acinetobactin.16 
A. baumannii Growth Studies in Minimal Media 
 Acinetobacter baumannii ATCC 17978 preculture was grown overnight at 37 C in M9 
media. A McFarland 0.5 standard was prepared in sterile 0.9% aqueous sodium chloride 
solution. M9 media (29.8 mL) was inoculated with 0.2 mL of the 0.5 McFarland standard 
making a 1 x 105 cfu/mL inoculum. All growth studies were performed in triplicate in 96-well 
plates. 
  Totally inhibitory concentrations of 2,2’-dipyridyl (DIP) were determined for buffered 
M9 medias (pH 5.7, 6.5 and 7.5) using 200 L total volume per well of inoculated M9 media at 
varying DIP concentrations (200, 100, 50, 25 M). Each well was filled with 100 L of sterile 
M9 media. Next, 100 L of a filter sterilized 4x solution of DIP (800 M) in M9 media was 
added to the first well of each row.  Two-fold serial dilutions were performed across each row 
providing a gradient of 200-25 M DIP. Inoculated M9 media (100 L) was added to each well 
and the plate was incubated at 37 C shaking at 150 rpm. The OD700 of each well was collected 
every hour for 48 hours. 
 To determine restorative concentrations of supplemented siderophore-iron (III) 
complexes in the presence of total inhibitory DIP, growth assays were performed using 200 L 
total volume per well of inoculated M9 media (pH 5.7 + 200 M DIP, pH 6.5 + 250 M DIP, pH 
7.5 + 250 M DIP) with gradient concentrations of 1a-Fe(III) and 1b-Fe(III). Each well was 
filled with 100 L of sterile, non-inoculated M9 media + DIP. The first well of each row was 
filled with 100 L of a filter sterilized 4x solution of 1a-Fe(III) (800 M) in M9 media + DIP or 
100 L of a filter sterilized 4x solution of 1b-Fe(III) (800 M) in M9 media + DIP. Two-fold 
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serial dilutions were performed across each row providing a 200 M-0.1 M gradient of 1a-
Fe(III) or 1b-Fe(III). Inoculated M9 media + DIP (100 L) was added to each well. A control 
plate was prepared for each pH, with no siderophore supplement, using 100 L sterile M9 media 
+ DIP and 100 L inoculated M9 media + DIP in each well (200 L final volume). The plates 
were incubated at 37 C shaking at 150 rpm. The OD700 of each well was collected over 48 
hours. 
 Growth studies on A. baumannii ATCC 19606 and associated derivatives were conducted 
in M9 minimal media pH 6.5 + 250 M DIP. Each well was filled with 100 L of either 2x 1a-
Fe(III) or 2x 1b-Fe(III) dissolved in M9 media + DIP to give a concentration gradient from left 
to right (240 M, 220 M, 200 M, 180 uM…20 M). Inoculated M9 media + DIP (100 L) 
was added to each well and plates were incubated at 37 C shaking at 150 rpm. The OD700 of 
each well was collected over 48 hours. 
Detection of Acinetobactin Isomers in A. baumannii Cultures 
 Overnight cultures of A. baumannii ATCC 17978 in LB broth were used to prepare a 0.5 
McFarland standard in sterile saline as inoculum (100 L) for 5 mL of M9 media (pH 5.7, 6.5, 
and 7.5). Cultures were incubated at 37 C and aliquots of 200 L were collected at various time 
points, centrifuged, and the supernatant was analyzed by LC-MS. 
Recipe for M9 Minimal Media 
 Na2HPO47H2O       12.8 g* 
 KH2PO4        5 g* 
 NaCl         0.5 g 
 NH4Cl         1.0 g 
 1 M MgSO4 solution, filter sterilized     2 mL 
 1 M CaCl2 solution, filter sterilized     0.1 mL 
 20 weight % succinate solution, filter sterilized   20 mL 
 Tap water        978 mL 
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 Add the Na2HPO47H2O, KH2PO4, NaCl, and NH4Cl as solids to the tap water. Shake to 
dissolve. Autoclave for 15 minutes at 15 psi (1.05 kg/cm2) on liquid cycle. Once cooled to room 
temperature, add the 1 M MgSO4, the 1 M CaCl2, and the 20 weight % succinate and shake to 
mix. 
 * Values are for standard pH=7 M9 minimal media. For pH adjusted M9, values were 
taken from the Phosphate Buffer Table – 0.2 M solution that can be found on the Buffer 
Reference Center of the Sigma-Aldrich website. 
Procedures for Intermediate Compound Synthesis 
 All chemical synthesis was performed using reagents and solvents from commercial 
suppliers Alfa Aesar, Fluka, Sigma Aldrich, Chem Impex International, Nova Biochem, and 
BACHEM. Our ability to study the acinetobactin isomerization reaction and other properties of 
acinetobactin isomers required a scalable total synthesis of pre-acinetobactin 1a and 
acinetobactin 1b in stable forms. We adapted a total synthesis reported by Takeuchi and 
coworkers to produce the key intermediate benzyl protected pre-acinetobactin 12 (Scheme 1). 
Synthesis of 12 was executed in three parts. First, oxazoline benzyl ester 6 was synthesized by 
converting commercially available 2,3-dihydroxybenzaldehyde 3 to imidate 5 which was 
cyclized with l-threonine benzyl ester (Scheme 1A). Next, N-Boc-O-Bn-hydroxyhistamine 9 was 
prepared from commercially available histamine 7 through conversion to 4-(2-haloethyl)-1H-
imidazole 8 followed by SN2 displacement of the halide with N-Boc-O-Bn-hydroxylamine under 
strong base (NaH) conditions (Scheme 1B). We were able to reproducibly generate grams of 
intermediates 6 and 9 that are stable to storage for years at -20 C. To produce hundreds of 
milligrams of 12, the protecting groups were removed from intermediates 6 and 9 in parallel and 
the resulting O-Bn-hydroxylamine 10 was coupled to carboxylate 11 using EDC/HOBt under 
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basic conditions to give benzyl protected pre-acinetobactin 12 (Scheme 1C). While the final 
amide coupling reaction was low yielding (typically ~30%) it was scalable and readily provided 
hundreds of milligrams of 12 as the TFA salt after purification by preparative HPLC. 
 2,3-Dihydroxybenzenenitrile (4).  Nitrile 1 was synthesized as described previously.9 
Briefly, 2,3-dihydroxybenzaldehyde was refluxed while stirring for five hours in formic acid 
with 1.3 equivalents of hydroxylamine hydrochloride and 1.3 equivalents of sodium formate. 
The reaction mixture was diluted with ice water and neutralized with saturated sodium 
bicarbonate. The mixture was extracted with Et2O, dried over MgSO4, and concentrated by 
rotary evaporation to yield an orange solid in 69% yield. 1H NMR (300MHz, (CD3)2SO) δ (ppm) 
10.34 - 9.78 (br. s., 2 H), 7.00 (t, J = 8.8 Hz, 2 H), 6.74 (t, J = 7.9 Hz, 1 H) 
 2,3-Dihydroxybenzeneimidate (5). Imidate 2 was synthesized as described previously.9 
Briefly, nitrile 1 was dissolved in roughly 48 equivalents of freshly distilled methanol and 
sealing under argon gas. An argon balloon was fit to the septa as a vent. Using a syringe, roughly 
32 equivalents of acetyl chloride were added dropwise, causing heat and the evolution of gas into 
the vent balloon. The mixture was stirred for 48 hours and turned dark orange. The mixture was 
cooled in an ice bath and neutralized with saturated sodium bicarbonate. The aqueous mixture 
was extracted with Et2O and the organic layer was washed with water and brine, dried over 
MgSO4, and concentrated by rotary evaporation to yield a yellow-brown solid in 65% yield. 
1H-
NMR 1H NMR (300MHz, (CD3)2SO) δ (ppm) 9.04 (br. s., 1 H), 8.72 (br. s., 1 H), 7.10 (dd, J = 
1.2, 8.2 Hz, 1 H), 6.81 (dd, J = 1.2, 7.6 Hz, 1 H), 6.56 - 6.48 (m, 1 H), 3.84 (s, 3 H) 
 Benzyl protected oxazoline (6). Oxazoline 3 was synthesized as described previously.9 
Briefly, imidate 2 was refluxed with 1 equivalent of O-benzyl-L-threonine:oxalate in 1,2 
dichloroethane overnight. The reaction mixture was allowed to cool and concentrated by rotary 
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evaporation. The concentrated mixture was dissolved into 5% citric acid and extracted with ethyl 
acetate. The organic layer was washed with water and brine, concentrated by rotary evaporation 
and purified on a normal phase silica gel column with a gradient of ethyl acetate and hexanes. 
Fractions containing product were concentrated by rotary evaporation to yield a viscous, dark 
brown oil in 50% yield. 1H NMR (300MHz, (CD3)2SO) δ (ppm) 11.90 (br. s., 1 H), 9.27 (s, 1 H), 
7.40 - 7.32 (m, 5 H), 7.05 (dd, J = 1.5, 7.9 Hz, 1 H), 6.96 (dd, J = 1.5, 7.9 Hz, 1 H), 6.77 - 6.69 
(m, 1 H), 5.20 (d, J = 1.8 Hz, 2 H), 5.08 - 4.97 (m, 1 H), 4.77 (d, J = 6.4 Hz, 1 H), 1.46 (d, J = 
6.4 Hz, 3 H) 
 2-Bromo(Chloro)ethyl-imidazole (8). Imidazole 5 was synthesized as described 
previously.9 Briefly, histamine dihydrochloride* was stirred with roughly 3 equivalents of 
potassium bromide in 1.5 M sulfuric acid (8 mL/gram of histamine salt) and the solution was 
cooled to -15° C. A saturated solution of sodium nitrite (0.7 mL/gram of histamine) was added 
all at once, causing the solution to change from colorless to orange-brown. The mixture was 
stirred cold for 30 minutes and then allowed to warm to room temperature while stirring. After 
~2.5 hours, the mixture changed from orange-brown to pale yellow and was cooled again to -15° 
C. The pH of the solution was brought to 10 with 5M NaOH, and the basic solution was 
extracted with chloroform. A 0.5 N HCl/ethyl acetate solution was prepared (12 mL/gram of 
histamine) and the chloroform layer was added to this solution. The product was concentrated by 
rotary evaporation to yield a white-brown cake like solid in 52% yield. *Working with histamine 
can evoke an immune response/sensitization. Utilize appropriate safety precautions. 1H NMR 
(300MHz, D2O) δ (ppm) 8.46 (d, J = 1.2 Hz, 1 H), 7.21 (s, 1 H), 3.69 (t, J = 6.4 Hz, 1 H), 3.58 - 
3.52 (m, 3 H), 3.17 (t, J = 6.4 Hz, 3 H), 3.06 (t, J = 5.9 Hz, 1 H) 
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 N-Boc-O-Benzylhydroxyhistamine (9). Hydroxyhistamine 6 was prepared as described 
previously.9 Briefly, N-Boc-O-Benzyl-Hydroxyhistamine was stirred in anhydrous DMF at 0° C 
and 3 equivalents of sodium hydride (60% in oil) were added as a solid. The reaction mixture 
was allowed to warm to room temperature and stirred under argon atmosphere. After 30 minutes, 
1 equivalent of imidazole 5 was added as a solid, causing bubbling and evolution of heat. The 
mixture was put back under argon and allowed to react overnight. The reaction mixture was 
concentrated by rotary evaporation to a red-brown sludge, which was purified by reverse-phase 
liquid chromatography (gradient from 100% water to 100% acetonitrile) to give a yellow oil in a 
65% yield. 1H NMR (300MHz, CDCl3) δ (ppm) 8.36 (s, 1 H), 7.35 (s, 5 H), 6.92 (s, 1 H), 4.80 
(s, 2 H), 3.74 (t, J = 6.4 Hz, 2 H), 2.94 (t, J = 6.4 Hz, 2 H), 1.43 (s, 5 H) 
 O-Benzylhydroxyhistamine TFA salt (10). Hydroxyhistamine 7 was prepared as 
described previously.9 Briefly, hydroxyhistamine 6 was dissolved in excess trifluoroacetic acid 
and allowed to react, open to air, for 1 hour. The product was concentrated by rotary evaporation 
and immediately taken on to the synthesis of 8. 
 Carboxy oxazoline (11). Oxazoline 4 was synthesized as described previously.9 Briefly, 
oxazoline 3 was stirred in methanol with ~1/10 mass equivalent of 10% Pd/C under hydrogen 
atmosphere. Once the reaction was complete by LC-MS (1 hour), the reaction mixture was 
flushed with argon gas, the solid catalyst was filtered off, and the product was concentrated by 
rotary evaporation. The product was immediately taken on to the synthesis of 8. 
 O-Benzyl-Pre-acinetobactin TFA salt (12). Benzyl protected pre-acinetobactin 8 was 
prepared as described previously.9 Briefly, oxazoline 4 and hydroxyhistamine 7 were dissolved 
in anhydrous DMF with 4 equivalents of EDC and 4 equivalents of HOBt. The mixture was 
made basic with NEt3, put under inert atmosphere, and allowed to react overnight. The reaction 
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mixture was concentrated by rotary evaporation, and the crude sludge was purified by 
preparatory HPLC. The TFA salt was isolated as a pale oil in 52% yield over 2 steps from the 
protected starting materials 3 and 6. 1H NMR (300MHz, (CD3)2SO) δ (ppm) 11.90 (br. s., 1 H), 
9.27 (s, 1 H), 7.40 - 7.32 (m, 5 H), 7.05 (dd, J = 1.5, 7.9 Hz, 1 H), 6.96 (dd, J = 1.5, 7.9 Hz, 1 H), 
6.77 - 6.69 (m, 1 H), 5.20 (d, J = 1.8 Hz, 2 H), 5.08 - 4.97 (m, 1 H), 4.77 (d, J = 6.4 Hz, 1 H), 
1.46 (d, J = 6.4 Hz, 3 H) 
Kinetic UV-Vis Analysis of Pre-acinetobactin Isomerization 
 Aqueous solutions of pre-acinetobactin in 250 L total volume were prepared using 0.1 
M potassium phosphate buffers at pH 4.6, 7.0, and 8.8 in a quartz cuvette.  Scanning kinetics 
were performed at 37 C over the wavelength range of 200 nm – 400 nm for pH 4.6 (A), 7.0 (C), 
and 8.8 (D). Single wavelength kinetic experiments were performed at wavelengths selected 
based on the scanning kinetic experiments for each pH value (pH 4.6, 320 nm, B; pH 7.0, 330 
nm, D; pH 8.8, 340 nm, F). Plots of relative percent absorbance at selected single wavelengths 
versus time generated exponential growth curves with relative rates that matched the kinetic 1H-
NMR experiments (Figure 5A); relative rate of isomerization: 8.8 >> 7.0 > 4.6. Single 
wavelength experiments were performed in triplicate with standard deviations represented as the 
grey shadowing around the black curves in Figure 2 B, D, and F. 
Kinetic LC-MS Analysis of Pre-acinetobactin Isomerization 
 One milligram of pre-acinetobactin TFA salt was isolated and dissolved in 0.6 mL of 
ddH2O buffered with 0.1 M phosphates to pH 5.5, 7, or 8. The solution was vortexed and 
transferred to an LC-MS vial. LC-MS timepoints were taken every 10 minutes. Pre-acinetobactin 
and acinetobactin peaks were identified by UV-Vis spectra and relative abundance was measured 
over time. 
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Kinetic 1H-NMR Analysis of Pre-acinetobactin Isomerization 
 One milligram of pre-acinetobactin TFA salt was isolated and dissolved in 0.6 mL of 
90% D2O/10% H2O buffered with 0.1 M phosphates to pH 5.5, 7, or 8. The solution was 
immediately vortexed and transferred to an NMR tube. Using a 500 MHz NMR at room 
temperature (27 C), spectra were taken at preset time points* and the integration of the pre-
acinetobactin methyl peak and the acinetobactin methyl peak were recorded. The integration 
ratio of pre-acinetobactin methyl over the total integration of both methyls was plotted against 
time. The natural log of this ratio was also plotted against time, and the slope of this plot was 
taken to be the first-order rate constant of isomerization. 
 * For all trials at pH 5.5 and 7, spectra were taken as an average of 32 scans and a 
spectrum was collected every 10 minutes. For trial 1 at pH 8, spectra were taken as an average of 
8 scans and a spectrum was collected every 40 seconds. For trials 2 and 3 at pH 8, spectra were 
taken as an average of 20 scans and a spectrum was collected every 2 minutes. Time windows 
for the plots were selected to minimize baseline noise. All reported kinetic constants are derived 
from an average of three independent experiments. 
Titrations of Apo-Siderophores with Tris(acetylacetonato) Iron (III) 
 Stock solutions of apo-pre-acinetobactin 1a (14.52 mM) and apo-acinetobactin 1b (12.83 
mM) were prepared in D2O and quantified with an acetonitrile internal standard. A stock solution 
of tris(acetylacetonato) iron (III) (12.74 mM) was prepared in methanol by use of an analytical 
balance and volumetric glassware. Stock siderophore solutions were diluted into 10 mM HEPES 
(pH 7.4) (20 μL stock into 980 μL buffer) and the sample was scanned. Then 5 μL of 
tris(acetylacetonato) iron (III) stock was added and the sample was scanned. The solutions 
quickly went from colorless to colored (magenta for pre-acinetobactin and purple for 
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acinetobactin). Tris(acetylacetonato) iron (III) stock was added 1 μL at a time and a scan was 
taken after each addition. For pre-acinetobactin titration, all solution transfers and scans were 
taken as quickly as possible to avoid isomerization. The titration curves are based off of 
absorbance at 650 nm to avoid interference from excess tris(acetylacetonato) iron (III), which 
absorbs at the peaks for 1a-Fe(III) and 1b-Fe(III) (515 nm and 570 nm, respectively) but not at 
650 nm. 
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2.7 Figures and Tables 
 
 
Figure 1. Isomerization of siderophores in the acinetobactin family. Pre-acinetobactin (A) and 
pre-pseudomonine (B) isomerize at pH 8 from oxazoline (red heterocycle) to isoxazolidinone 
(blue heterocycle). Pre-anguibactin (C) is locked in thiazoline form (red heterocycle). 
 
 
Scheme 1. The total synthesis of the key intermediate, benzyl protected pre-acinetobactin, 
adapted from Takeuchi and coworkers. 
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Scheme 2. Synthesis of pre-acinetobactin TFA salt (1aTFA), acinetobactin TFA salt 
(1bTFA), and corresponding iron (III) complexes (structure unknown). 
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Figure 2. Kinetic UV-Vis analysis of pre-acinetobactin isomerization in phosphate buffers. 
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Figure 3. UV-Vis spectra of pre-acinetobactin (left) and acinetobactin (right) from the diode 
array of LC-MS. Spectra matched those from literature and allowed for the differentiation of the 
two signals on the chromatogram by a diagnostic peak shift from 260 nm (pre-acinetobactin) to 
250 (acinetobactin). 
 
 
Figure 4. Example of LC-MS kinetic analysis of pre-acinetobactin isomerization in 0.1M 
phosphate buffer at pH 4.6. LC-MS experiments matched general trends observed in the NMR 
and UV-Vis kinetic studies; relative rate of isomerization: 8.8 >> 7.0 > 4.6. 
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Figure 5. (A) Representative 1H-NMR kinetic study of the first-order isomerization of pre-
acinetobactin to acinetobactin at pH 7, 27 °C in 10% D2O/90% H2O. (B) Half-lives of pre-
acinetobactin at pH 5.5, 7.0, and 8.0 at 27 °C, with error bars showing standard deviation. (C) 
C18 HPLC analysis of acinetobactin from isomerization of pre-acinetobactin at pH 5.5, 7.0, and 
8.0. (D) C18 HPLC analysis of natural acinetobactin isolated from A. bauamnnii and synthetic 
acinetobactin produced at pH 5.5, 7.0, and 8.0. (E) Chiral HPLC analysis of natural and synthetic 
acinetobactin (mixture of samples generated at pH 5.5, 7.0, and 8.0).  
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Table 1. Average Half-Lives and Standard Deviations for Pre-Acinetobactin Isomerization 
Buffer pH Half-Life (min) Standard Deviation (min) 
pH = 5.5, 10% D2O (3 trials) 944 105 
pH = 7.0, 10% D2O (3 trials) 55 14 
pH = 8.0, 10% D2O (3 trials) 18 3 
pH = 7.0, 100% D2O (2 trials) 105 1 
 
 
 
 
 
Figure 6. CD spectrum of natural acinetobactin (black trace) isolated from A. baumannii ATCC 
17978 and synthetic acinetobactin (gray trace) prepared by the method shown in Scheme 1 of the 
main text. CD spectra were obtained on 25 μM acinetobactin solutions in methanol using a 
Jasco-J715 spectropolarimeter in a cuvette with a 1 cm path length. 
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Figure 7. High-resolution MS-MS analysis of synthetic acinetobactin. 
 
Figure 8. High-resolution MS-MS analysis of natural acinetobactin. 
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Figure 9. High-resolution MS-MS analysis of mixed synthetic and natural acinetobactin. 
 
Scheme 3. Proposed fragmentation of acinetobactin. All fragment masses were identified in the 
high-resolution MS-MS spectra shown in Figures 7-9 for natural and synthetic acinetobactin. 
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Figure 10. (A) Proposed mechanism of isomerization of pre-acinetobactin to acinetobactin. 
Through-space correlations on the oxazoline ring of pre-acinetobactin (B) and isoxazolidinone 
ring of acinetobactin (C), as observed by ROESY. Correlations between the C4’ and C5’ protons 
were not observed for either isomer which supports trans orientation. 
 
Figure 11. (A) The UV-Vis absorption spectra for 290 mM apo-pre-acinetobactin 1a, 256 mM 
apo-acinetobactin 1b, pre-acinetobactin-iron (III) 1a-Fe(III) and acinetobactin-Fe(III) 1b-Fe(III) 
(apo-siderophores fully titrated with Fe3+) (10 mM HEPES, pH 7.4). (B) Solutions of pre-
acinetobactin-Fe(III) (left) and acinetobactin-Fe(III) (right) (10 mM HEPES, pH 7.4).  
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Figure 12. Titration curves for pre-acinetobactin and acinetobactin by tris(acetylacetonato) iron 
(III). The endpoint of the titration was considered to be 11 uL for each siderophore. The 
siderophore:metal ratios at the endpoint for pre-acinetobactin and acinetobactin were calculated 
to be 2.07:1 and 1.84:1, respectively. 
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Figure 13. Growth promotion of A. baumannii ATCC 17978 in iron deficient M9 minimal media 
at 37 C. (A) M9 minimal media, pH 5.7, 200 μM DIP, serial dilution of preacinetobactin-
Fe(III), (B) M9 minimal media, pH 5.7, 200 μM DIP, serial dilution of acinetobactin-Fe(III), (C) 
M9 minimal media, pH 6.5, 250 μM DIP, serial dilution of preacinetobactin-Fe(III), (D) M9 
minimal media, pH 6.5, 250 μM DIP, serial dilution of acinetobactin-Fe(III), (E) M9 minimal 
media, pH 7.5, 250 μM DIP, serial dilution of preacinetobactin-Fe(III), (F) M9 minimal media, 
pH 7.5, 250 μM DIP, serial dilution of acinetobactin-Fe(III). 
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Figure 14.  Growth as measured by OD700 (y-axis) of A. baumannii ATCC 17978 microplate 
cultures in buffered M9 media at pH 5.7 with 200 μM DIP (A), 6.5 with 250 μM DIP (B), and 
7.5 with 250 μM DIP (C) at 45 hours supplemented with a 0 – 50 M (x-axis) gradient of pre-
acinetobactin-Fe(III), 1a-Fe(III), or acinetobactin-Fe(III), 1b-Fe(IIII).  
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Figure 15. Growth of A. baumannii ATCC 19606 and mutants t6, t7, and s1 in M9 minimal 
media pH 6.5 + 250 μM DIP. (A) Media supplemented with 40 μM 1a-Fe(III). (B) Media 
supplemented with 50 μM 1b-Fe(III). 
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Figure 16. Growth promotion of A. baumannii ATCC 19606 and mutant strains in iron deficient 
M9 minimal media at 37 C. All experiments were performed in M9 minimal media pH 6.5 + 
250 μM DIP, gradient concentration of pre-acinetobactin-Fe(III) and acinetobactin-Fe(III). 
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Figure 17. Detection of pre-acinetobactin and acinetobactin in A. baumannii ATCC 17978 
culture supernatants by LC-MS via extracted-ion chromatograms of [M+H]=347. Retention 
times are normalized to acinetobactin standards and confirmed by UV-Vis analysis. (A) 
Chromatograms from single culture grown in M9 media at pH 5.7 and measured at set time 
points. (B) Chromatograms from cultures grown in M9 medias at pH 5.7, 6.5, and 7.5, taken 
after 18 hours of growth. Peak heights do not represent absolute concentration. 
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Figure 18. Proposed model of pH-triggered siderophore swapping in pathogenic A. baumannii. 
Pre-acinetobactin, 1a, is biosynthesized in the cytoplasm and excreted via efflux pump BarAB. 
Under acidic infection conditions pre-acinetobactin serves as the siderophore to sequester iron 
(III) and gain access into the cell via BauA outer membrane receptor and the TonB/ExbB/ExbD 
complex, BauB periplasmic siderophore binding protein, and BauCDE inner membrane 
transporter. Once in the cytoplasm BauF, a predicted hydrolase, assists in assimilation of iron. 
Alternatively, if the infection site is neutral or basic the excreted pre-acinetobactin 1a will 
rapidly isomerize to acinetobactin 1b which sequesters iron (III) and gains entry into the cell 
using the same pathway described for 1a. Our results clearly show that the isomerization can 
happen in the extracellular space (Figure 17), but it is also possible that the isomerization takes 
place in the cytoplasm and both 1a and 1b are directly effluxed. The intracellular fate of both 
siderophore isomers 1a and 1b after influx of the siderophore-iron (III) complex is currently 
unknown. 
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Acinetobactin Analogs 
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3.1 Preface 
 
 This chapter was adapted with permission from [Shapiro, J. A. & Wencewicz,  
T. A. Metallomics 9, 463-470 (2017)] from the Royal Society of Chemistry. Both authors 
contributed to writing of the manuscript. JAS performed all experiments. TAW served as 
principal investigator and oversaw experimental design. 
3.2 Abstract 
 
 Pathogenic Acinetobacter baumannii excrete the siderophore pre-acinetobactin as 
an iron-scavenging virulence factor. Pre-acinetobactin is a 2,3-dihydroxy-phenyl 
oxazoline that undergoes pH-dependent isomerization to the isooxazolidinone form 
acinetobactin in order to expand the pH range for iron acquisition by A. baumannii. In 
this study we establish important structure-function relationships for the kinetics of 
isomerization, iron (III) binding, and siderophore utilization by A. baumannii. We 
showed that electronic properties of the phenyl oxazoline influence isomerization kinetics 
and iron (III) binding. We found that iron (III) chelation is a requirement for siderophore 
activity and A. baumannii utilization. Our studies provide important structural and 
mechanistic insight for understanding how pathogenic A. baumannii uses pre-
acinetobactin as a 2-for-1 iron-scavenging siderophore virulence factor. 
3.3 Introduction 
 
 As discussed in previous chapters, pre-acinetobactin is found in two isomeric 
forms during infection, the oxazoline pre-acinetobactin (1a) and the isooxazolidinone 
acinetobactin (2a) (Figure 1).1 Oxazoline 1a is the product of the non-ribosomal peptide 
assembly line and is effluxed to the extracellular space where non-enzymatic 
88 
 
isomerization to isooxazolidinone 2a occurs.1–3 The isomerization is pH-dependent (slow 
under acidic conditions and fast under basic conditions) and occurs with clean 
stereochemical inversion at C5’. The oxazoline form 1a predominates under acidic 
conditions and the isooxazolidinone 2a predominates under basic conditions. Both 
isomers are capable of forming stable 2:1 complexes with iron (III) and promote the 
growth of A. baumannii under iron restrictive conditions. Iron (III) complexation blocks 
isomerization and locks the siderophore in the oxazoline structure 1a. Previous studies 
show that the imidazole ring and hydroxamate N-hydroxyl group are important 
recognition elements for receptor-mediated active transport, but the structural 
requirements for iron (III) binding and utilization by A. baumannii remain unclear.4,5 
 In this work we synthesized a panel of pre-acinetobactin (1b–1k) and 
acinetobactin analogs (2b–2j) to probe structure-function relationships of pre-
acinetobactin isomerization, iron (III) binding, and A. baumannii growth promotion 
(Figure 2). We showed that both isomers 1a and 2a promote A. baumannii growth under 
iron restrictive conditions. We discovered that the 2,3-dihydroxybenzoate group is critical 
for the siderophore function of 2a and related isooxazolidinone analogs and the 2-
hydroxybenzoate group is required for growth promotion by 1a and related oxazoline 
analogs. We found that the N-hydroxy group of 1a is not required for siderophore 
function. We also showed that the rate of isomerization is strongly influenced by the 
electronic properties of the benzoate group. Our studies provide important structural and 
mechanistic insight for understanding how pathogenic A. baumannii uses pre-
acinetobactin as a 2-for-1 siderophore virulence factor to enhance iron acquisition.  
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3.4 Results and Discussion 
 
Synthesis of Acinetobactin and Pre-Acinetobactin Analogs 
 We synthesized pre-acinetobactin (1a) and analogs (1b–1k) using a head-to-tail 
strategy (Scheme 1, Figure 2).1,6,7 Phenyloxazoline head groups were prepared via 
conversion of benzaldehydes to methyl imidates followed by cyclization with l-Thr 
benzyl ester. Hydrogenation gave the corresponding phenyl oxazoline carboxylic acids 
that were coupled via amide bond formation with O-benzyl-N-butylhydroxylamine, N-(2-
(1H-imidazol-4-yl)ethyl)-O-benzylhydroxylamine, or N-(2-(1H-imidazol-4-yl)propyl)-O-
benzylhydroxylamine to provide the O-benzylhydroxylamine variants of 1a–1j. 
Hydrogenation under acidic conditions gave pre-acinetobactin analogs 1a–1j in >95% 
purity. Isomerization in pH 7 phosphate buffer gave the corresponding isooxazolidinone 
analogs 2a–2j in quantitative yield. deoxy-Pre-acinetobactin 1k was prepared by amide 
coupling between the 2,3-dihydroxy-phenyloxazoline carboxylate to the primary amine 
of histamine. 
Electronics of the Phenyloxazoline Influence Isomerization Rate 
 The isomerization of pre-acinetobactin (1a) is faster than the isomerization of pre-
pseudomonine (1e).1–3 We hypothesized that electronics of the phenyloxazoline and 
proximity of the imidazole ring to the nucleophilic hydroxamate would influence the 
isomerization rate. To test this hypothesis we used 1H-NMR spectroscopy to measure 
half-lives (t1/2) for the isomerization of pre-acinetobactin analogs 1a–1j at pH 7 in 10% 
D2O/90% H2O (Figure 3). All of the pre-acinetobactin analogs showed first-order 
isomerization kinetics with t1/2 values ranging from 39–247 min (Figure 4). Analogs 1a 
and 1d–1i alter the degree and sites of hydroxylation on the phenyl ring. We measured 
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t1/2 = 59  4 min for pre-acinetobactin (1a), which is hydroxylated at the 2- and 3-
positions of the phenyl ring. Removing the hydroxyl groups resulted in a 3.5-fold 
increase in t1/2 for analog 1d (t1/2 = 206  6 min). Monohydroxylation at position 2, 
analog 1e (t1/2 = 98  1 min), and position 4, analog 1g (t1/2 = 102  2 min), of the phenyl 
ring gave a 1.7-fold increase in t1/2 relative to 1a, while monohydroxylation at position 3, 
analog 1f (t1/2 = 202  8 min), resulted in a 3.4-fold increase in t1/2. Dihydroxylation at 
positions 2 and 5 of the phenyl ring, analog 1h (t1/2 = 164  4 min), and positions 3 and 5, 
analog 1i (t1/2 = 247  5 min) resulted in 2.8-fold and 4.2-fold increases in t1/2, 
respectively. Our results suggest that hydroxylation at positions 2 and 4 of the phenyl 
ring increase the relative rate of isomerization relative to hydroxylation at positions 3 and 
5. One explanation is that the 5-exo-tet cyclization reaction might proceed through an 
ortho-quinone methide tautomeric intermediate that is favored when the 2- or 4-position 
of the phenyl is hydroxylated (Figure 1b).8–10 An alternative stereoelectronic explanation 
is that donation of electron density into the phenyl ring causes favorable orbital overlap 
between the aromatic π system and the π* orbital of the carbon-nitrogen double bond. By 
this model, increased negative charge density on the 1-position of the phenyl ring would 
donate more electron density into the anti-bonding orbital of C=N, weakening the double 
bond and causing the reaction to go faster. The 2,3-dihydroxylation pattern of pre-
acinetobactin 1a seems to be optimal for enhancing the isomerization rate. Methylation of 
the hydroxyl groups, analog 1j, had no effect on isomerization rate (t1/2 = 66  4 min) 
suggesting that intramolecular proton transfers do not enhance reaction rate. 
 Analogs 1b and 1c were designed to test the role of the imidazole in the 
isomerization reaction. Extending the imidazole by one methylene unit, analog 1b (t1/2 = 
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77  8 min), resulted in a t1/2 increase of 1.3. Removing the imidazole ring, analog 1c (t1/2 
= 39  2 min), had the opposite effect giving a 1.5-fold decrease in t1/2. We hypothesize 
that the imidazole is a pH-dependent trigger for pre-acinetobactin isomerization. Under 
acidic conditions the imidazole is protonated and might electrostatically attract the 
hydroxamate nucleophile slowing its attack on C5’ of the oxazoline. At pH 7 the 
imidazole (pKa ~5.8) is not protonated,
11 which may decrease intramolecular interactions 
with the hydroxamate leading to a rate enhancement for nucleophilic attack on C5’ 
(Figure 1b). This model fits the pH-dependence1 and first-order kinetics of isomerization 
for pre-acinetobactin 1a, analog 1b, and analog 1c. 
Structural Requirements for Iron (III) Binding 
 We used optical absorbance spectroscopy and a chromeazurol s (CAS) 
colorimetric agar diffusion assay to evaluate the ability of pre-acinetobactin analogs 1a–
1k and acinetobactin analogs 2a–2j to form stable complexes with iron (III) in M9 
minimal media at pH 7 (Figure 5 and Figure 6).12–14 All compounds that gave a colored 
iron (III) complex in M9 media that was observable by optical absorbance spectroscopy 
also gave a positive color change from blue to orange in the CAS assay. Pre-
acinetobactin 1a and acinetobactin 2a formed highly water soluble 2:1 complexes with 
iron (III) that were stable and colored (Figure 5a).1 Both siderophore isomers, 1a and 2a, 
produced a blue-to-orange color change in the CAS assay consistent with ligand 
exchange of iron (III) from CAS to the siderophores (Figure 5b). In the pre-isomerized 
oxazoline form hydroxylation at the 2-position of the phenyl ring was required for iron 
(III) binding. Analogs 1b, 1c, 1e, 1h, and 1j, all formed colored complexes with iron (III) 
and gave positive results in the CAS assay (Fig. 5b,d,e,f and Figure 6). Oxazoline 
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analogs lacking the 2-hydroxyl group (1d, 1g, and 1i) gave no color change (Figure 
5c,e,f). Methylation of the 2,3-hydroxyl groups (analog 1j) prevented iron (III) chelation 
(Figure 5f). In the oxazoline form the N-hydroxyl group was not required for iron (III) 
binding. Analog 1k lacking the N-hydroxyl group produced a colored iron (III) complex 
and a positive color change in the CAS assay (Figure 5f). The imidazole group was not 
required for iron (III) binding in both the oxazoline and isooxazolidinone forms. Post-
isomerized analog 2c, lacking the imidazole ring, produced a colored complex with iron 
(III) and a positive color change in the CAS assay (Figure 5c). In the isooxazolidinone 
form a 2,3-catechol motif was required for iron (III) binding. Monohydroxylated analogs 
2e–2g, unsubstituted analog 2d, and the 2,5-catechol and 3,5-catechol analogs 2h and 2i, 
respectively, gave no color change in the CAS assay or upon direct addition of iron (III) 
to buffered M9 media solutions of the compounds (Figure 5d,e,f and Figure 6). The 
acinetobactin structure is capable of iron (III) chelation in both isomeric forms, while the 
closely related natural siderophore pseudomonine, the 2-hydroxyl analog, can only form 
a stable iron (III) complex in the pre-isomerized oxazoline form.  
Structural Requirements for Siderophore Utilization by A. baumannii 
 We hypothesized that pre-acinetobactin and acinetobactin analogs with a positive 
color change in the CAS assay will be utilized by A. baumannii as siderophores for iron 
acquisition. To test this hypothesis we generated growth curves for A. baumannii ATCC 
19606–s1, a basD insertional mutant strain deficient in pre-acinetobactin biosynthesis,15 
under iron restrictive conditions (Figure 7 and Figure 8).1 We observed a positive 
correlation between iron (III) binding in the CAS assay and A. baumannii growth 
promotion. 2-Hydroxy-phenyl-oxazoline analogs (1a–1c, 1e, and 1h) promoted A. 
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baumannii growth relative to the control while analogs lacking the 2-hydroxyl group (1d, 
1f, 1g, and 1i) did not promote growth. Isooxazolidinone analogs with a 2,3-catechol 
group (2a, 2b, and 2c) promoted A. baumannii growth relative to the control while 
analogs lacking this moiety did not. The deoxy-pre-acinetobactin analog 1k showed 
strong growth promotion of A. baumannii suggesting that an amide is sufficient for iron 
(III) binding and molecular recognition. The hydroxamate is required for oxazoline to 
isooxazolidinone isomerization reaction. While modifications to the imidazole tail 
(analogs 1b, 1c, 2b. 2c) do not completely eliminate growth promotion, they do seem to 
diminish siderophore activity relative to endogenous pre-acinetobactin 1a and 
acinetobactin 2a. The imidazole ring does influence the rate of pre-acinetobactin 
isomerization and might be a recognition element that enhances siderophore utilization.4,5 
Our results suggest that the ability to form a stable iron (III) complex is a prerequisite for 
siderophore utilization. Isomerization of pre-acinetobactin 1a to acinetobactin 2a expands 
siderophore utility so long as the isomerized isooxazolidinone form contains a 2,3-
catechol moiety for iron (III) chelation. 
3.5 Outlook and Conclusions 
 
 Pre-acinetobactin 1a and acinetobactin 2a are both biologically relevant 
siderophores that enhance A. baumannii virulence and growth under iron restrictive 
conditions.1 The isomerization of pre-acinetobactin 1a, the oxazoline form, to 
acinetobactin 1b, the isooxazolidinone form, is sensitive to substitutions on the benzene 
ring of the phenyl oxazoline group. Hydroxylation at the 2- and 4-positions of the phenyl 
ring enhances the isomerization rate relative to hydroxylation at the 3- and 5-positions. 
This may be a result of access to a quinone-methide tautomer or a stereoelectronic 
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contribution of electron density into the anti-bonding orbital of the carbon-nitrogen 
double bond. The 2,3-hydroxylation pattern found in pre-acinetobactin 1a gives the 
greatest rate enhancement for isomerization and methylation of the hydroxyl groups has 
no influence on the reaction rate. The imidazole group slows the isomerization rate and 
might be a pH-dependent trigger that controls the isomerization reaction.11 The N-
hydroxy group of the hydroxamate is the required nucleophile for isomerization. 
Although the desoxy-pre-acinetobactin analog 1k cannot isomerize it is still capable of 
iron (III) chelation and potent growth promotion of A. baumannii ATCC 1606-s1 under 
iron restrictive conditions. Only pre-acinetobactin analogs with hydroxylation at the 2-
postion of the phenyl oxazoline were capable of iron (III) chelation and A. baumannii 
growth promotion. The isomerized isooxazolidinone acinetobactin analogs require a 2,3-
catechol group in order to form stable complexes with iron (III) and promote the growth 
of A. baumanniii ATCC 19606-s1. The imidazole group is not required for siderophore 
activity, but might enhance utilization by A. baumannii (Figure 9).4,5 Pre-acinetobactin is 
an important virulence factor for human pathogenic A. baumannii.16 Our structure-
function studies of pre-acinetobactin and acinetobactin analogs will serve as a guide for 
designing small molecule therapeutics aimed at neutralizing A. baumannii virulence 
through disruption of siderophore-mediated iron acquisition.17–22 
 The acinetobactin siderophore family has three naturally occurring members that 
are reported in the literature: pre-acinetobactin23 (1a), pre-pseudomonine24 (1e), and pre-
anguibactin.25–28 Pre-anguibactin contains a 2-hydroxy-phenylthiazoline head group and 
does not undergo the thiazole to isooxazolidinone isomerization.2,3 Thus, producing 
Vibrio species can only rely on using the pre-anguibactin form as the biologically active 
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siderophore isomer. Pre-pseudomonine (1e) contains a 2-hydroxy-phenyloxazoline head 
group and does undergo the oxazoline to isooxazolidinone isomerization reaction to give 
pseudomonine (2e).2,3 Pre-pseudomonine 1e forms a stable complex with iron (III) and 
promotes A. baumannii growth under iron restrictive conditions while pseudomonine 2e 
cannot chelate iron (III) and does not stimulate A. baumannii growth. Thus, the producing 
Pseudomonads will rely on the pre-pseudomonine oxazoline isomer 1e as the biologically 
active siderophore. Iron (III) complexation protects pre-pseudomonine from 
isomerization, but in the iron-free state isomerization to the isooxazolidinone isomer 2e 
will result in a loss of siderophore function. Pre-acinetobactin (1a) has a 2,3-dihydroxy-
phenyloxazoline head group and readily isomerizes to the acinetobactin isooxazolidinone 
form 2a. Pre-acinetobactin forms a stable 2:1 complex with iron (III) that does not 
isomerize in the metal chelated state. Unlike pseudomonine, the isomerized form of 
acinetobactin still forms a stable complex with iron (III) presumably by shifting from a 2-
phenolateoxazline binding mode to a 2,3-catecholate binding mode.29,30 Thus, pre-
acinetobactin holds a privileged status amongst its structural counterparts pre-
pseudomonine and pre-anguibactin in its ability to function as a siderophore in both the 
pre-isomerized oxazoline form 1a and the isomerized isooxazolidinone form 2a, which 
expands the capacity for iron sequestration under a broader range of infection conditions 
leading to enhanced iron acquisition and virulence of pathogenic A. baumannii. 
3.6 Materials and Methods 
 
Strains, Materials, and Instrumentation 
 Growth studies were conducted using A. baumannii ATCC 19606 derivative s1 
(basD::aph) provided by Dr. Luis Actis.15 Precultures and 96-well plate A. baumannii 
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growth assays were performed in filter-sterilized M9 minimal media. Samples for LC-MS 
were prepared in 0.45 μM PTFE mini-UniPrep vials from Agilent. All preparatory HPLC 
was performed using a Beckman Coulter SYSTEM GOLD 127P solvent module and 168 
detector with a Phenomenex Luna 10u C18(2) 100A column, 250 × 21.20 mm, 10 μm 
with guard column. Prep HPLC was performed with a mobile phase of 5 mM ammonium 
acetate in (A) water and (B) acetonitrile, and data were processed using 32 Karat 
software, version 7.0. All LC-MS was performed on an Agilent 6130 quadrupole LC-MS 
with G1313 autosampler, G1315 diode array detector, and 1200 series solvent module. A 
Phenomenex Gemini C18 column, 50 × 2 mm, 5 μm with guard column was used for all 
LC-MS separations. LC-MS mobile phases were 0.1% formic acid in (A) water and (B) 
acetonitrile, and data were processed using G2710 ChemStation software. NMR was 
performed on a Varian Inova-500 MHz or Varian Unity Inova-600 MHz instrument fit 
with a cold probe. Bacterial growth studies were performed using polystyrene 96-well 
plates with polystyrene lids. OD600 measurements were taken on a Molecular Devices 
SpectraMax Plus 384 plate reader. 
Acinetobactin Isomerization Kinetics 
 Isomerization half-lives (t1/2) were determined for compounds 1a – 1j using 
kinetic 1H NMR. One milligram of pre-acinetobactin analogs 1a – 1j was isolated and 
dissolved in 0.6 mL of 0.1 M phosphate buffered 10% D2O/H2O (pH = 7). The solution 
was immediately transferred into an NMR tube and spectra (average of 32 scans) were 
taken once every 10 min on a 500 MHz NMR at 27 °C. Integration values for the 
resonance signal corresponding to the methyl group of the pre-acinetobactin compounds 
1a – 1j and corresponding acinetobaction products 2a – 2j were recorded. The ratio of 
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integration values for the pre-acinetobactin methyl peak over the combined integration 
values of the pre-acinetobactin and acinetobactin peaks was calculated. The natural log of 
this ratio was also plotted against time to give a straight line. The slope of this line was 
taken as the first-order isomerization rate constant, which was used to calculate a t1/2 
values as an average of 3 independent trials. Time windows for data collection used to 
calculate t1/2 values were chosen to minimize baseline noise. Error bars represent standard 
deviation. For data points where error bars would be smaller than the symbol, error bars 
were omitted. 
CAS Assay 
 CAS agar plates were prepared as described previously.13,14 Wells (~9 mm) were 
cut in the solid agar and 800 μM solutions (made by diluting 50 μL 0.016 M DMSO 
stock into 950 μL M9 minimal media) of pre-isomerized 1a–1k and post-isomerized 2a–
2j were pipetted into the wells. Color change was observed after 12 hours at room 
temperature. 
A. baumannii Growth Studies in Iron Deficient Minimal Media 
 Stock solutions of 800 μM pre-isomerized analogs 1a–k and post-isomerized 
analogs 2a–2j were filter sterilized. 1 μL of 0.1 M Fe(acac)3 in MeOH was added to 1 mL 
of the analog stock solution to give a final concentration of 100 μM Fe(acac)3. Optical 
absorbances were measured using a Cary 50 UV-Vis spectrophotometer. A control was 
made by diluting 50 μL pure DMSO and 1 μL of 0.1 M Fe(acac)3 in MeOH to 950 μL 
M9 media.  96-well plates were first filled with 50 μL of M9 minimal media per well. 50 
μL of the analog-Fe(III) solution or Fe(acac)3 control was added to the first column and 
were serially diluted down to 1 μM. An inoculum of A. baumannii ATCC 19606-si was 
98 
 
made from a fresh overnight culture by adding 200 μL of a 0.5 McFarland standard to 
29.8 μL of M9 minimal media1 containing 300 μM 2,2’-dipyridyl. Inoculum (50 μL) was 
added to every well of the plate giving a final concentration of 150 μM 2,2’-dipyridyl in 
each well and a serial dilution of pre-isomerized analogs 1a–k and post-isomerized 
analogs 2a–2j ranging from 200 μM – 1 μM. Pates were incubated at 37 C and optical 
absorbance at 600 nm (OD60) were recorded over a 48 hr growth period. Analogs were 
determined to promote or inhibit growth as compared to the control wells with equivalent 
concentration of Fe(III). All OD600 measurements were taken in triplicate (Figure 8). 
Procedures for Chemical Synthesis 
 Refer to Scheme 1 for compound numbers and structures. 
 General Procedure A. Nitriles 20 – 27 were synthesized by following a literature 
protocol.6 Briefly, benzaldehydes 12 – 19 were refluxed and stirred for 5 hrs in formic 
acid with 1.3 equivalents of hydroxylamine hydrochloride and 1.3 equivalents of sodium 
formate. The reaction mixture was diluted with ice water, neutralized with a saturated 
aqueous solution of sodium bicarbonate, extracted with Et2O, dried over MgSO4, filtered, 
and concentrated by rotary evaporation under reduced pressure. Nitriles 20 – 27 were 
obtained in 50 – 75% yield and used without purification or characterization. 
 General Procedure B. Imidates 28 – 35 were synthesized following a literature 
protocol.6 Briefly, nitriles 20 – 27 were dissolved in approximately 48 equivalents of 
freshly distilled MeOH in a round bottom flask fit with a rubber septum under positive 
pressure from a balloon of dry argon.  Acetyl chloride (32 equivalents) was added 
dropwise via syringe causing heat and the evolution of gas into the balloon. After stirring 
for 48 hrs the reaction mixture was cooled in an ice bath and quenched by addition of a 
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saturated aqueous solution of sodium bicarbonate. The aqueous mixture was extracted 
with Et2O and the organic layer was washed with water and brine, dried over MgSO4, 
filtered, and concentrated by rotary evaporation under reduced pressure. Imidates 28 – 35 
were obtained in 45 – 68% yield and used without purification or characterization. 
 General Procedure C. Oxazoline benzyl esters 36 – 43 were synthesized 
following a literature protocol.6 Briefly, imidates 28 – 35 were refluxed overnight with 1 
equivalent of O-benzyl-l-threonine oxalate salt in 1,2-dichloroethane. The reaction 
mixture was allowed to cool and was concentrated by rotary evaporation under reduced 
pressure. The concentrated mixture was dissolved into 5% aqueous citric acid and 
extracted with EtOAc. The organic layer was washed with water and brine and then 
concentrated by rotary evaporation under reduced pressure. Oxazoline benzyl esters 36 – 
43 were obtained in 42 – 59% yield, characterized by confirmed by 1H NMR, and used 
without purification. 
 General Procedure D.  Oxazoline carboxylic acids 44 – 51 were synthesized 
using a literature protocol.6 Briefly, oxazoline benzyl esters 36 – 43 were dissolved in 
MeOH and approximately 10 wt. % of 10% palladium/carbon was added under argon. 
The reaction flask was flushed with hydrogen gas and left to stir for 2 hrs under positive 
pressure from a hydrogen balloon. The flask was flushed with argon and the reaction 
mixture was filtered and concentrated by rotary evaporation under reduced pressure. 
Oxazoline carboxylic acids 44 – 51 were obtained in quantitative mass yield and used 
without purification or characterization. 
 General Procedure E. N-Boc-O-Benzylhydroxylamines 4, 8, and 11 were 
prepared via SN2 reaction of N-Boc-O-benzylhydroxylamin with alkyl halides 3, 5, and 
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10, respectively, following a literature protocol.6 Briefly, N-Boc-O-Benzylhydroxylamine 
was stirred in anhydrous DMF at 0 °C and 3 equivalents of sodium hydride (60% in oil) 
was added as a solid. The reaction was warmed to room temperature and stirred for 30 
min under dry argon. After 30 min, 1 equivalent of alkyl bromide 3, 5, or 10 was added 
dropwise, causing bubbling and the evolution of heat. The mixture was stirred for 2 hours 
under dry argon and then quenched by slow addition of ddH2O. The mixture was 
extracted with 3 portions of EtOAc and the organic layer was washed with brine, dried 
over anhydrous MgSO4, filtered and concentrated by rotary evaporation under reduced 
pressure. N-Boc-O-Benzylhydroxylamines 4, 8, and 11 were used without purification or 
characterization. 
 General Procedure F. The N-Boc was removed from N-Boc-O-
benzylhydroxylamines 4, 8, and 11 following a literature protocol.6 Briefly, N-Boc-O-
benzylhydroxylamines 4, 8, and 11 were dissolved in neat TFA and allowed to react for 1 
hr. TFA was removed via rotary evaporation under reduced pressure to give the TFA 
salts of O-benzylhydroxylamines 52 – 54 as confirmed by LC-MS in quantitative yield. 
Compounds 52 – 54 were used without purification. 
 General Procedure G. Oxazoline carboxylic acids 44 – 51 were coupled via 
amide bond formation with amines 52, 53, 54, or 9 following a literature protocol.1,6 
Briefly, one equivalent of the oxazoline carboxylic acid 44 – 51 was added to one 
equivalent of amine 52, 53, 54, or 9 dissolved in anhydrous DMF. Four equivalents of 
EDC·HCl and four equivalents of HOBt·H2O were added and the reaction mixture was 
brought to pH = 9 by the dropwise addition of Et3N. The mixture was sealed under argon 
and stirred overnight at room temperature. The reaction mixture was then extracted with 
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2 x 25 mL portions of EtOAc and the organic layer was concentrated by rotary 
evaporation under reduced pressure. The crude residue was purified by preparatory 
HPLC with a gradient of MeCN/H2O buffered to pH 4.8 with 5 mM ammonium acetate 
to give oxazoline amides 55 – 64 in 25 – 45% yield. Compounds 55 – 64 were analyzed 
by LC-MS and taken onto the final benzyl deprotection step. Compound 1k was analyzed 
by LC-MS and characterized by 2D-NMR (Appendix B). 
 General Procedure H. Pre-acinetobactin analogs 1a – 1j were obtained via 
hydrogenation of oxazoline amides 55 – 64 following a literature protocol.1 Briefly, 
oxazoline amides 55 – 64  were dissolved in MeOH and approximately 10 wt. % of 10% 
palladium/carbon was added under argon. The reaction flask was purged with hydrogen 
gas and the mixture was left stirring under positive pressure from a hydrogen balloon for 
2 hours. The mixture was filtered and concentrated under reduced pressure using rotary 
evaporation. Analogs 1a – 1j were obtained in quantitative yield were characterized by 
2D-NMR (Appendix B). 
 General Procedure I. Acinetobactin analogs 2a – 2j were synthesized following 
a literature protocol.1 Pre-acinetobactin analogs 1a – 1j were dissolved in phosphate 
buffered 10% D2O/H2O at pH 7 for 1H NMR kinetic studies.  Pre-acinetobactin analogs 
1a – 1j were stirred overnight in pH 7 phosphate buffered ddH2O to give quantitative 
conversion to the corresponding acinetobactin analogs 2a – 2j for evaluation in CAS 
assays and A. baumannii growth assays. Solutions of acinetobactin analogs 2a – 2j were 
concentrated by rotary evaporation prior to characterization by 2D-NMR (Appendix B). 
 Compound 11 was synthesized and characterized as described previously by our 
group.1  
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 Compound 4 was synthesized from starting material 3 using general procedure E. 
The product was obtained in 70% yield with no need for purification. 1H NMR (300 
MHz, CDCl3)  (ppm) 7.35 (m, 5 H), 4.81 (s, 2 H), 3.40 (t, J = 7.1 Hz, 2 H), 1.59 (m, 2 
H), 1.50 (s, 9 H), 1.35 (m, 2 H), 0.89 (t, J = 7.5 Hz, 3 H). 
 Compound 6 was synthesized from starting material 5 by general procedure E. 
Compound was purified by silica gel column using 10% EtoAc in hexanes. Product was 
obtained in 90% yield. 1H NMR (300 MHz, CDCl3)  (ppm) 7.40 – 7.33 (m, 5 H), 4.80 
(s, 2 H), 4.16 (s, 1 H), 3.49 - 3.40 (m, 2 H), 2.40 (t, J = 7.3 Hz, 2 H), 1.90 (dd, J = 5.9, 7.6 
Hz, 2 H), 1.52 – 1.47 (m, 9 H).  
 Compound 7 was synthesized following a literature protocol.7 Briefly, one 
equivalent of compound 6 and one equivalent of N-methyl morpholine-N-oxide were 
dissolved in 1:1 acetone:H2O mixture. A catalytic amount of OsO4 was added at room 
temperature. The reaction mixture was stirred for 6 hrs and quenched with an aqueous 
solution of 0.2 M NaHSO3. The mixture was extracted with 3 portions of EtOAc. The 
organic layer was washed with brine, dried over anhydrous MgSO4, filtered, and 
concentrated by rotary evaporation under reduced pressure. The resulting oil was 
immediately dissolved in acetonitrile and treated with an aqueous solution of NaBrO3 and 
stirred at room temperature. An aqueous solution of NaHSO3 was added dropwise via 
syringe. After 5 hrs the reaction was quenched with an aqueous 0.2 M NaHSO3 solution 
and the mixture was extracted with 3 portions of Et2O. The organic layer was washed 
with brine, dried over MgSO4, filtered, and concentrated by rotary evaporation under 
reduced pressure. Product 7 was afforded in 68% yield over 2 steps. 1H NMR (300 MHz, 
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CDCl3)  (ppm) 7.40 – 7.33 (m, 5 H), 4.80 (s, 2 H), 4.16 (s, 1 H), 3.49 – 3.40 (m, 2 H), 
2.40 (t, J = 7.3 Hz, 2 H), 1.90 (dd, J = 5.9, 7.6 Hz, 2 H), 1.52 – 1.47 (m, 9 H). 
 Compound 8 was synthesized following a literature protocol.7 Briefly, one 
equivalent of compound 7 was dissolved in EtOH and diluted with half a volume of 
warm water. To this solution was added 2 equivalents of cupric acetate monohydrate, 1.2 
volumes 28% ammonia water, and 0.2 volumes 37% formalin. The mixture was allowed 
stirred for 3 hrs at 75 °C and then concentrated by rotary evaporation under reduced 
pressure. The residue was dissolved/partitioned between EtOAc and an aqueous solution 
of tetrasodium EDTA. The bilayer was stirred vigorously overnight and the layers were 
separated. The organic layer was washed with 2 portions of aqueous tetrasodium EDTA 
solution and brine, dried over anhydrous MgSO4, filtered, and concentrated by rotary 
evaporation under reduced pressure. The product was obtained in 82% yield. 1H NMR 
(300 MHz, CDCl3)  (ppm) 7.53 (s, 1 H), 7.43 – 7.33 (m, 5 H), 6.78 (s, 1 H), 4.84 (s, 2 
H), 3.52 (t, J = 6.4 Hz, 2 H), 2.60 (t, J = 6.7 Hz, 2 H), 1.93 – 1.80 (m, 2 H), 1.53 (s, 9 H). 
 Compound 36 was synthesized and characterized as described previously by our 
group.1 
 Compound 37 was synthesized by transforming compound 13 into compound 21 
by general procedure A, subsequently transforming compound 21 into compound 29 by 
general procedure B, and finally transforming compound 29 into compound 37 by 
general procedure C. 1H NMR (300 MHz, DMSO-d6)  (ppm) 7.80 (d, J = 7.9 Hz, 2 H), 
7.58 – 7.54 (m, 1 H), 7.50 – 7.46 (m, 2 H), 7.40 – 7.32 (m, 5 H), 5.20 (s, 2 H), 4.95 – 
4.90 (m, 1 H), 4.78 (d, J = 5.5 Hz, 1 H), 1.43 (d, J = 6.3 Hz, 3 H). 
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 Compound 38 was synthesized by transforming compound 14 into compound 22 
by general procedure A, subsequently transforming compound 22 into compound 30 by 
general procedure B, and finally transforming compound 30 into compound 38 by 
general procedure C. 1H NMR (300 MHz, DMSO-d6)  (ppm) 7.63 (dd, J = 1.6, 7.9 Hz, 
1 H), 7.48 (t, J = 8.3 Hz, 1 H), 7.42 –7.33 (m, 5 H) 7.01 (d, J = 7.9 Hz, 1 H), 6.98 – 6.92 
(m, 1 H), 5.20 (s, 2 H), 4.98 – 4.90 (m, 1 H), 4.73 (d, J = 5.5 Hz, 1 H), 1.45 (d, J = 6.3 
Hz, 3 H). 
 Compound 39 was synthesized by transforming compound 15 into compound 23 
by general procedure A, subsequently transforming compound 23 into compound 31 by 
general procedure B, and finally transforming compound 31 into compound 39 by 
general procedure C. 1H NMR (300 MHz, DMSO-d6)  (ppm) 7.41 – 7.33 (m, 5 H), 7.29 
– 7.25 (m, 2 H), 7.22 (s, 1 H), 6.88 – 6.82 (m, 1 H), 5.20 (s, 1 H), 4.92 – 4.84 (m, 1 H), 
4.75 (d, J = 6.3 Hz, 1 H), 1.40 (d, J = 6.3 Hz, 3 H). 
 Compound 40 was synthesized by transforming compound 16 into compound 24 
by general procedure A, subsequently transforming compound 24 into compound 32 by 
general procedure B, and finally transforming compound 32 into compound 40 by 
general procedure C. 1H NMR (300 MHz, DMSO-d6)  (ppm) 7.72 (d, J = 8.7 Hz, 2 H), 
7.37 – 7.29 (m, 5 H), 6.85 (d, J = 8.7 Hz, 2 H), 5.20 (s, 1 H), 4.82 (m, 1 H), 4.65 (d, J = 
6.3 Hz, 1 H), 1.34 (d, J = 6.3 Hz, 3 H). 
 Compound 41 was synthesized by transforming compound 17 into compound 25 
by general procedure A, subsequently transforming compound 25 into compound 33 by 
general procedure B, and finally transforming compound 33 into compound 41 by 
general procedure C. 1H NMR (300 MHz, DMSO-d6)  (ppm) 7.40 – 7.32 (m, 5 H), 7.01 
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(d, J = 3.1 Hz, 1 H), 6.82 (d, J = 3.1 Hz, 1 H), 6.84 - 6.82 (s, 1 H), 5.20 (s, 1 H), 4.92 (m, 
1 H), 4.74 (d, J = 5.5 Hz, 1 H), 1.46 (d, J = 6.3 Hz, 3 H). 
 Compound 42 was synthesized by transforming compound 18 into compound 26 
by general procedure A, subsequently transforming compound 26 into compound 34 by 
general procedure B, and finally transforming compound 34 into compound 42 by 
general procedure C. 1H NMR (300 MHz, DMSO-d6)  (ppm) 7.38 – 7.29 (m, 5 H), 6.73 
(d, J = 1.6 Hz, 2 H), 6.38 - 6.30 (m, 1 H), 5.18 (s, 1 H), 4.92 – 4.88 (m, 1 H), 4.79 – 4.68 
(m, 1 H), 1.41 (d, J = 6.3 Hz, 3 H). 
 Compound 43 was synthesized by transforming compound 19 into compound 27 
by general procedure A, subsequently transforming compound 27 into compound 35 by 
general procedure B, and finally transforming compound 35 into compound 43 by 
general procedure C. 1H NMR (300 MHz, DMSO-d6)  (ppm) 7.21 – 7.19 (m, 1 H), 7.18 
(br. s., 1 H), 7.13 (d, J = 7.9 Hz, 1 H), 5.20 (s, 1 H), 4.82 (m, 1 H), 4.74 (d, J = 5.5 Hz, 1 
H), 3.84 (s, 3 H), 3.75 (s, 3 H), 1.38 (d, J = 5.5 Hz, 3 H). 
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3.7 Figures and Tables 
 
Figure 1. (a) Structures of pre-acinetobactin (1a) and acinetobactin (2a). (b) Proposed 
mechanism for the isomerization of pre-acinetobactin oxazoline (1a) to acinetobactin 
isooxazolidnone (2a). 
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Figure 2. Structures of pre-acinetobactin (1a–1k) and acinetobactin (2a–2j) siderophores 
synthesized for this study. 
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Scheme 1. Synthesis of pre-acinetobactin analogs 1a – 1k  and acinetobactin analogs 2a 
– 2j. 
109 
 
 
Figure 3. (a) Isomerization of pre-acinetobactin analogs 1a–1j to acinetobactin analogs 
2a–2j. (b) Comparison of isomerization half-lives derived from first-order kinetic rate 
plots. Error bars represent standard deviation. 
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Figure 4. First-order rate plots for the isomerization of pre-acinetobactin analogs 1a – 1j 
to acinetobactin analogs 2a – 2j. 
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Figure 5. Evaluation of iron (III)-binding. (a) From left to right, 1a-Fe(III) in M9 media, 
2a-Fe(III) in M9 media, and pure M9 media. (b) – (f) Compounds 1a–1k and 2a–2j on 
solid CAS agar. 
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Figure 6. Optical absorbance spectra for 2:1 mixtures of pre-acinetobactin analogs 1a – 
1k and acinetobactin analogs 2a – 2j with Fe(acac)3 in M9 media at pH 7. 
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Figure 7. Growth promotion assay of A. baumannii ATCC 19606-s1 in M9 minimal 
media supplemented with 150 μM 2,2’-dipyridyl and varying concentrations of the iron 
(III) complexes of compounds 1a–1k and 2a–2j. Percent growth relative to control 
represents the OD600 of compound supplemented culture broth compared to the OD600 of 
Fe(acac)3 supplemented culture broth after 43.5 hrs of growth at 37 C. Error bars 
represent standard deviation. Full growth curves and p-values can be found in Figure 8 
and Table 1. 
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Figure 8. Growth of A. baumannii ATCC 19606 s1 in pH 7 M9 minimal media 
supplemented with 150 μM 2,2’-dipyridyl as measured by OD600 from 0 to 48 hours at 37 
C. Each analog was dissolved to 0.016 M in DMSO, diluted to 800 μM in M9 media (50 
μL DMSO stock into 950 μL media), and treated with 1 μL of 0.1 M Fe(acac)3 in MeOH. 
The M9 media stock solution of Fe(acac)3/analog was serially diluted in 96-well plates 
and inoculated with bacteria. The control M9 solution was prepared as above using pure 
DMSO. 
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Table 1: P-values for A. baumannii growth promotion bar graph in Figure 5. 
 
 200 
μM 
100 μM 50 μM 25 μM  200 μM 100 μM 50 μM 25 μM 
1a 0.0002 0.0037 0.0006 0.0203 1f 0.0002 <0.0001 0.0529* 0.0238 
2a 0.0007 0.0211 0.1199* 0.9525* 2f 0.0007 0.0003 0.0447 0.0424 
1b 0.0002 <0.0001 0.0014 0.1432* 1g <0.0001 <0.0001 0.0299 0.0320 
2b 0.0032 0.0418 0.3534* 0.5951* 2g 0.0001 <0.0001 0.0122 0.0434 
1c 0.001 <0.0001 0.0811* 0.8905* 1h 0.0005 0.0072 0.0007 0.0391 
2c 0.0077 0.0159 0.8942* 0.4231* 2h <0.0001 0.0003 0.0181 0.0227 
1d 0.0001 <0.0001 0.0158 0.0279 1i 0.0004 0.0008 0.0334 0.0533* 
2d 0.0002 0.0018 0.0205 0.0215 2i 0.0004 0.0037 0.0453 0.0843* 
1e 0.0004 <0.0001 0.0005 0.0075 1j 0.0001 <0.0001 0.0213 0.0241 
2e 0.0027 0.1696* 0.9956* 0.6180* 2j 0.0003 <0.0001 0.0186 0.0782* 
     1k 0.0007 0.0015 0.0221 0.1402* 
 
Each acinetobactin analog was dissolved in DMSO to 0.016 M, diluted in M9 minimal 
media to 800 μM (50 μL DMSO stock into 950 μL media) and treated with 1 μL 
Fe(acac)3 stock solution (0.1 M in methanol). This analog-Fe solution was then serially 
diluted in a growth promotion assay with A. baumnnii ATCC 19606 s1 mutant. To 
determine whether an analog was truly acting as a siderophore or if A. baumannii s1 was 
growing simply due to higher concentration of iron in solution, an Fe(acac)3 control for 
each concentration of analog was run by diluting pure DMSO into media and adding 1 μL 
of Fe(acac)3 stock. This control was serially diluted in the same manner as the analog 
solutions. A. baumannii s1 growth is depicted in Figure 7 as a percentage of the basal 
growth at the corresponding concentration of Fe(acac)3 after 43.5 hrs at 37 C. All data 
collected for 200 μM siderophore analog is compared to a 200 μM Fe(acac)3 control, all 
data collected for 100 μM siderophore analog is compared to a 100 μM Fe(acac)3  
control, etc. P-values of analogs at each concentration as compared to their corresponding 
controls are listed below in Table 1. P-values indicating that the difference between 
analog and control was not statistically significant are marked with an asterisk (*). 
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Figure 9. Summary of the structure–function relationships (a) and mechanistic model (b) 
for the isomerization of pre-acinetobactin (1a) to acinetobactin (2a). 
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Chapter 4: Rigid Oxazole Acinetobactin 
Analog Blocks Siderophore Cycling in 
Acinetobacter baumannii 
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4.1 Preface 
 
 This chapter was adapted in part with permission from [Bohac, T. J., Shapiro, J. 
A. & Wencewicz, T. A. ACS Infect. Dis. 3, 802-806 (2017)] Copyright © 2017 American 
Chemical Society, as well as from a manuscript in preparation by the same authors. All 
authors contributed to writing of the manuscript. TJB synthesized all compounds. JAS 
performed all chemical and biological evaluation of compounds. TAW served as 
principal investigator and oversaw experimental design. 
4.2 Abstract 
 
 The emergence of multi-drug resistant (MDR) Gram-negative bacterial pathogens 
has raised global concern. Non-traditional therapeutic strategies, including antivirulence 
approaches, are gaining traction as a means of applying less selective pressure for 
resistance in vivo. Here, we show that rigidifying the structure of the siderophore pre-
acinetobactin from MDR Acinetobacter baumannii via oxidation of the phenolate-
oxazoline moiety to a phenolate-oxazole results in a potent inhibitor of siderophore 
transport and imparts a bacteriostatic effect at low micromolar concentrations under 
infection-like conditions. Structure-activity studies show that the antibiotic effect relies 
on a planar tri-dentate chelating moiety. 
4.3 Introduction 
 
As discussed in previous chapters, acinetobactin is a highly conserved virulence 
associated siderophore from Acinetobacter baumannii that is biosynthesized as pre-
acinetobactin and spontaneously isomerizes. The isomzerization is slow at acidic pH and 
fast at neutral and basic pH. Both forms of the siderophore, 1 and 2, promote the growth 
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of A. baumannii ATCC 17978 under iron-restrictive conditions and use the same 
transport proteins. Given that most sites of A. baumannii infection are acidic, we 
hypothesize that both PreAcb and Acb will be present and functional as iron-sequestering 
virulence factors, providing a growth advantage under an expanded pH range. Consistent 
with this hypothesis, PreAcb accumulates in A. baummannii supernatants in acidic media, 
while only Acb is detectable in neutral media. Both PreAcb and Acb form stable, 2:1 
complexes with iron (III). Structure-function studies of PreAcb and Acb analogs showed 
that iron (III) chelation is required for growth promotion of A. baumannii in iron-
restrictive media.1–3 Based on growth studies conducted in Chapter 3, structural analogs 
incapable of promoting growth might competitively inhibit the Acb pathway.  
Subtle structural changes in a siderophore scaffold can dramatically influence 
function. A single carbon epimer of mycobactin was shown to block siderophore cycling 
in M. tuberculosis leading to high intracellular accumlulation of siderophores that 
induced a lethal phenotype.4 Mutasynthesis of pyochelin analogs by feeding substituted 
salicylate precursors to P. aeruginosa decreases the efficiency of iron uptake.5 The 
modified pyochelin analogs are potential competitive inhibitors that block pyochelin 
uptake. Furthermore, oxidation of the thiazoline in pyochelin to the corresponding 
aromatic thiazole was shown to block transport of ferric pyochelin in P. aeruginosa.6 
Oxidized des-methyl pyochelin binds tightly to the pyochelin outer membrane transporter 
FptA and blocks uptake, but not binding, of ferric pyochelin. Computational docking and 
molecular dynamics simulations showed that oxidized pyochelin is more rigid than 
pyochelin, which might limit its ability to form stable metal complexes and increase 
stability of the FptA complex. The des-methyl phenolate-bis-thiazoline precursor to 
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pyochelin is also a known intermediate in yersiniabactin biosynthesis.7 Recently, 
Henderson and coworkers showed that yersiniabactin-producing Enterobacteriaceae also 
excrete oxidized des-methyl pyochelin, a compound now identified as escherichelin, to 
block virulence of opportunistic P. aeruginosa during clinical bacteriuria.8 Escherichelin-
producing Enterobacteriaceae have potential as probiotic treatments for urinary tract 
infections and purified escherichelin might also be useful as an antivirulence agent. 
Similar to escherichelin blocking siderophore transport in pyochelin-utilizing pathogens, 
we hypothesize that oxidation of the PreAcb oxazoline to the corresponding aromatic 
oxazole (3) might rigidify the siderophore backbone, block isomerization to Acb, and 
result in inhibition of PreAcb/Acb uptake (Figure 1). 
4.4 Results and Discussion 
 
Synthesis of Oxidized Pre-Acinetobactin (3) 
 The synthesis of oxidized pre-acinetobactin (OxPreAcb, 3) commenced with two 
precursors, N-Boc-O-benzylhydroxy-histamine 6 and oxazole benzyl ester 8 (Scheme 1). 
Hydroxyhistamine 6 was synthesized starting from histamine, as previously reported.9,10 
Diazotization/halogenation of histamine dihydrochloride 4 with sulfuric acid and 
potassium bromide, followed by addition of sodium nitrite, provided the corresponding 
bromo- and chloro-ethylimidazoles 5 in 52% yield, as a ~3:1 bromo-/chloro-mixture. SN2 
displacement of halo-mixture 5 with the sodium salt of N-boc-O-benzylhydroxamine 
afforded N-Boc-O-benzylhydroxy-histame 6 in good yield. Oxazole 8 was synthesized in 
a one-pot, two- step synthesis adapted from Graham,11 via the condensation of 2,3-
dihydroxybenzyaldehyde with Bn-protected l-Thr and subsequent oxidation of the 
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intermediate aminal with BrCCl3. Hydrogenolytic debenzylation of 8 and TFA-mediated 
Boc-removal of 6 generated the free acid 9 and amine 10, respectively (Scheme 2). 
EDC/HOBt coupling of 9 and 10 provided O-benzyl protected N-hydroxyamide 11. 
Hydrogenolysis of 11 yielded OxPreAcb 3 to complete the synthesis in 5 longest linear 
steps (LLS) and 7 total steps. OxPreAcb is stable and does not spontaneously isomerize 
in aqueous buffer as observed for the oxazoline to isooxazolidinone isomerization from 
PreAcb and Acb.9 Thus, OxPreAcb is structurally “locked” in the PreAcb-like form via 
aromatization to the phenolate-oxazole heterocycle. 
OxPreAcb Inhibits A. baumannii Growth under Iron-Deficient Conditions 
 We investigated the effect of Acb and OxPreAcb on the growth of A. baumannii 
ATCC 19606T in M9 minimal medium under iron-restrictive (125 μM 2,2’-dipyridyl) 
conditions. We chose Acb over PreAcb because we have shown in previous work that 
both isomers have equivalent growth promoting effects at pH 7 and Acb is easier to 
isolate from A. baumannii cultures.9 As expected, Acb promoted the growth of A. 
baumannii ATCC 19606T in a dose-dependent manner (Figure 2A). In striking contrast, 
OxPreAcb strongly inhibited growth at all concentrations tested (0.78-50 μM) (Figure 
2B). Furthermore, growth inhibition by OxPreA was competitive and dose-dependent in 
the presence of 10 μM Acb (Figure 2C). Antagonism of OxPreAcb growth inhibitory 
activity by Acb supports competition for the same biological target or transport pathway. 
OxPreAcb activity was confirmed on two separate synthetic lots to confirm the observed 
biological activity (Figure 3). In medium supplemented with 100 μM 2,2’-dipyridyl, 
OxPreAcb inhibited A. baumannii ATCC 19606T growth with an MIC of 1.56 μM. The 
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overall growth inhibitory effect of OxPreAcb on A. baumannii appears to be 
bacteriostatic (Figure 4). 
 To probe the iron-dependence of OxPreAcb activity, wild-type A. baumannii 
ATCC 19606T and a biosynthesis deficient ATCC 19606T s1 mutant were grown in M9 
media in the presence of variable OxPreAcb with and without supplemented 10 μM 
Fe(acac)3 (Figure 5). Ciprofloxacin was included as a control antibiotic with activity that 
is not strongly affected by iron concentration.12 As expected, ciprofloxacin activity 
against A. baumannii ATCC 19606T and the s1 mutant was not affected by iron 
concentration. However, the growth inhibitory activity of OxPreAcb was strongly 
antagonized by iron supplementation. The amount of OxPreAcb required to fully inhibit 
growth of wild-type ATCC 19606T and ATCC 19606T s1 was 50 M (Figure 5AC). 
Upon supplementation with 10 μM Fe(acac)3, the concentration of OxPreAcb required to 
fully inhibit growth increased to 200 M (Figure 5BD). PreAcb biosynthesis is under the 
transcriptional control of ferric uptake repressors (FURs).13 FUR proteins repress 
transcription when bound to Fe(II) and allow transcription when no metal is bound. This 
level of transcriptional control ensures that expression of proteins in costly siderophore 
pathways remain reserved for times of iron restriction when the metal is needed most. 
Iron-dependence is commonly observed for siderophore-antibiotic conjugates and other 
antibiotics that rely on siderophore-binding proteins for cell entry.14 Thus, OxPreAcb 
might be entering cells via the Acb pathway. 
 To further probe the ability OxPreAcb to inhibit growth of clinically relevant 
bacteria, we performed growth studies of OxPreAcb against 13 strains of A. baumannii 
obtained from the CDC AR-BANK.15 These isolates have varying levels of resistance to 
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different drug classes (5-14 antibiotic genes) and serve as a representative panel of 
clinical multidrug resistant A. baumannii. The MIC90 and susceptible – intermediate – 
resistant (S-I-R) interpretation of these isolates against 21 common antibiotics are listed 
in Table 1. OxPreAcb showed inhibition against all 13 strains tested (Table 2), 
demonstrating the potential for OxPreAcb to treat clinical multidrug resistant infections. 
The increase in MIC90 values at 17 hours to 40 hours and the growth recovery over time 
is consistent with our previous hypothesis that OxPreAcb works in a bacteriostatic 
manner. 
Acb-Uptake Protein Machinery is Involved in OxPreAcb Activity 
 To investigate the role of Acb transport proteins on the growth inhibiting activity 
of OxPreAcb we performed growth studies in M9 medium using gene insertion mutants 
of A. baumannii ATCC 19606T t6 and t7, which are deficient in the outer membrane 
receptor protein BauA and inner-membrane transport protein BauD, respectively (Figure 
6).9 Wild type ATCC 19606T and the t7 mutant showed similar levels of growth, while 
the s1 and t6 mutants showed reduced growth across multiple concentrations of 
OxPreAcb (Figure 6A). Interestingly, when OxPreAcb was pre-complexed with iron (III) 
prior to growth studies, the growth of wild type A. baumannii ATCC 19606T and the s1, 
t6, and t7 mutants was promoted suggesting that the OxPreAcb-iron (III) complex can be 
used as a source of iron and only the metal-free form of OxPreAcb has growth inhibitory 
activity (Figure 6B). Disrupting Acb biosynthesis and transport systems does not 
strongly affect the growth inhibitory activity of OxPreAcb. The activity of OxPreAcb is 
antagonized by supplementing growth medium with iron (III). Thus, it remains unclear 
whether complexation of OxPreAcb truly abolishes the growth inhibitory effect or if that 
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added iron (III) is simply having the same antagonistic effect as supplementation with 
Fe(acac)3. During human infections, iron is a limiting nutrient so OxPreAcb would be 
presumably be metal free and growth inhibitory towards A. baumannii pathogens.16  
OxPreAcb Forms a High-Affinity 2:1 Iron (III) Complexe 
 The conversion of OxPreAcb from a growth inhibitor to a growth promoter upon 
iron (III) chelation inspired us to study the iron (III) binding properties. We used a 
fluorescence quenching assay to titrate OxPreAcb with iron (III) showing that a stable 2:1 
(OxPreAcb)2Fe(III) complex forms (Figure 7). PreAcb and Acb also form stable 2:1 
complexes with iron (III).3,9 We used an EDTA competition assay to measure the 
apparent stability constants (KFe) of the (PreAcb)2Fe(III), (Acb)2Fe(III), and 
(OxPreAcb)2Fe(III)  complexes (Figure 8). Apparent KFe values were 27.4 ± 0.2, 26.2 ± 
0.1, and 26.5 ± 0.3 for (PreAcb)2Fe(III), (Acb)2Fe(III), and (OxPreAcb)2Fe(III), 
respectively. Based on similarity of the apparent KFe values we predict that OxPreAcb 
will be competitive with PreAcb and Acb for iron (III) in a biological setting. 
Computational Comparison of Potential Coordination Geometries 
 Simple oxidation of the PreAcb oxazoline to the OxPreAcb oxazole is predicted 
to increase rigidity of the siderophore backbone. Energy minimization of the metal-free 
PreAcb and OxPreAcb structures revealed significant differences in 3D-orientations of 
the phenolate-oxazoline and phenolate-oxazole moieties, respectively (Figure 9). Both 
the phenolate-oxazoline and phenolate-oxazole systems are relatively flat, with the trans-
oxazoline of PreAcb slightly puckered and the oxazole of OxPreAcb appearing in plane 
with the phenyl ring. In the gas phase, a stable H-bond was predicted between the 2-
hydroxyl group of the phenyl ring with the oxazoline nitrogen of PreAcb, which 
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presumably stabilizes the planar structure and restricts rotation around the oxazoline C1 
to phenyl C1’ bond. The same type of H-bonding interaction was found in the OxPreAcb 
energy minimized structure except the H-bond was formed between the oxazole nitrogen 
and the hydroxyl group of the hydroxamic acid. PreAcb is capable of this same H-
bonding interaction, but it was not found during energy minimization. The origin for this 
difference in H-bonding modes might be the relative rotational barriers about the 
oxazoline/oxazole C4 to hydroxamate carbonyl carbon bond. The trans-orientation of the 
oxazoline methyl and hydroxamate substituents decreases steric clash in rotational 
isomers. The cis-planar orientation of the oxazole methyl and hydroxamate substituents 
introduces A1.3-strain. Computational analysis of the energy landscape for rotational 
isomers about the oxazoline/oxazole C4 to hydroxamate carbonyl carbon bond of PreAcb 
and OxPreAcb supported this model (Figure 10 and Figure 11). The sterically smaller 
carbonyl group of the hydroxamate prefers to eclipse the oxazole methyl group to 
minimize the A1,3-strain, which puts the bulky N-alkyl-N-hydroxy group closer to the 
oxazole nitrogen. Restricted rotation in the rigid phenolate-oxazole ligand set of 
OxPreAcb is predicted to limit the accessible number of theoretical modes for iron (III) 
chelation compared to the more flexible PreAcb and Acb structures. 
Synthesis of OxPreAcb Analogs 
 To probe the structure-activity relationship of OxPreAcb, we synthesized a panel 
of analogs using a similar strategy to that in Chapter 3. We aimed to investigate three 
parts of the OxPreAcb molecule: (1) the necessity and positioning of the hydroxyl groups 
on the aromatic ring of OxPreAcb, (2) the necessity of the imidazole ring, and (3) the 
necessity of the hydroxamate hydroxyl group. We probed the role of these moieties 
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through the synthesis of OxPreAcb and 8 structural analogs, generated from various 
commercially available substituted benzaldehydes (Scheme 3). Addition of L-threonine 
benzyl ester to each aldehyde, followed by the oxidation of the intermediate oxazoline, 
provided the corresponding oxazole benzyl esters. Hydrogenolysis of the benzyl ester 
afforded the corresponding carboxylic acids that when exposed to EDC, HOBt coupling 
with various amines, in the presence of facilitating base, afforded compound 12, along 
with the benzyl protected versions of OxPreAcb 3 and compounds 13-19. Final 
deprotection of these intermediates with H2 and Pd/C delivered title compounds 3, 13-19 
in excellent yield. 
OxPreAcb Relies on a Phenolate-Oxazole-Hydroxamate Moiety for Iron-Binding 
 We hypothesized that OxPreAcb utilizes the Acb uptake pathway and that the 
ability of OxPreAcb to bind iron (III) is instrumental to the mode of action. Therefore, 
with the panel of analogs in hand, the ability of each analog to bind iron (III) was 
determined by chrome azurol S assay (Figure 12). Compounds 3 and 13-16 demonstrated 
iron binding ability; these compounds contained both a 2’ hydroxyl group as well as the 
hydroxamate hydroxyl group. This result compliments the finding that the oxidized 
system of OxPreAcb adopts a planar geometry and is predicted to bind iron with these 
two hydroxyl moieties. We hypothesized that this binding mode was favored over 
binding iron through the 2’-hydroxyl and the carbonyl oxygen due to A1’3 strain induced 
between the methyl group and the imidazole side chain. 
Ability to Bind Iron a Necessity for OxPreAcb Antibiotic Activity 
 To test the inhibitory effect of our analogs, MIC90 values were obtained through 
growth studies in iron restricted minimal media. Briefly, OxPreAcb analogs were serially 
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diluted in M9 media supplemented with 100µm DIP. MIC90 values were read as the 
lowest concentration at which no visible growth was observed. These values are seen in 
Table 3 and directly correlate with ability to bind iron. This indicates that iron binding is 
crucial to this molecule’s mode of action. The presence of the imidazole ring was seen to 
not be required for iron binding nor for growth inhibition, indicating a potential site for 
further derivatization. The necessity of the hydroxamate for iron binding and growth 
inhibition in OxPreAcb contrasts with the natural pre-acinetobactin scaffold, which does 
not require the hydroxamate for iron binding or growth promotion. Implications of this 
result to a model of structural rigidity based bioactivity are illustrated in Figure 10. 
4.5 Outlook and Conclusions 
 
 In medicinal chemistry, rigidity is often used to increase the affinity of a ligand 
for a protein target.17 Escherichelin, a rigid pyochelin analog, was shown to tightly bind 
the outer membrane receptor FptA and block transport of ferric pyochelin.6 A similar 
phenomenon might be taking place in A. baumannii for OxPreAcb in the presence of 
Acb. Like escherichelin,8 In Figure 13 we outline potential modes of action of OxPreAcb 
inhibitory activity. OxPreAcb might be effective at blocking virulence of A. baumannii 
by disrupting siderophore utilization, which is required for growth during infection. 18 
Biosynthesis of PreAcb takes place in the cytoplasm. Efflux of PreAcb to the 
extracellular space provides a mixture of PreAcb and Acb after isomerization 
spontaneously occurs. PreAcb and Acb form stable complexes (PreAcb)2Fe(III) and 
(Acb)2Fe(III), respectively, that are transported to the periplasmic space by the outer 
membrane receptor BauA with assistance of the ExbB/ExbD/TonB complex. The 
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periplasmic binding protein BauB shuttles (PreAcb)2Fe(III) and (Acb)2Fe(III) to the 
ABC-transporter BauCDE for transport to the cytoplasm. The flavin reductase BauF is 
predicted to reduce Fe(III) to Fe(II) and provide PreAcb/Acb for the next siderophore 
cycle. OxPreAcb is competitive with Acb and inhibits the growth of A. baumannii. The 
mechanism of competition with Acb and growth inhibition is unknown. Competition for 
transport could take place at the level of BauA on the outside of the cell or BauB on the 
inside of the cell. Raymond proposed a shuttle mechanism for siderophore transport in 
Gram-negative bacteria that argues for the involvement of both an iron-bound 
siderophore and an iron-free siderophore that undergo metal swapping.19 The iron-free 
OxPreAcb might interfere with this siderophore shuttle process, but more fundamental 
studies of this membrane transport paradigm are required to test this hypothesis. 
Additionally, OxPreAcb might inhibit siderophore biosynthesis or iron assimilation 
processes by a competitive mechanism resulting from the structural similarity of 
OxPreAcb to PreAcb and Acb. Lastly, OxPreAcb was shown to strongly chelate iron (III) 
so a general mechanism of metalloenzyme inhibition or disruprtion of metal homeostasis 
might be at play. Here, the importance of molecular recognition is revealed by subtle 
structural changes (Figure 14).  
 A more detailed understanding of siderophore receptor binding and membrane 
transport paradigms in A. baumannii are required to fully appreciate how OxPreAcb 
competes with Acb for cellular uptake.19 It also remains unclear whether the net growth 
inhibitory effect of OxPreAcb is due exclusively to blocking siderophore cycling or if 
inhibition of metalloenzymes or disruption of metal homeostasis are contributing 
factors.20 Phenolate-oxazolines and phenolate-thiazolines are common motifs in many 
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siderophore scaffolds, including siderophores associated with virulence in bacterial 
pathogens.21 Simple oxidation of the oxazolines/thiazolines found in bacterial 
siderophores might be a general strategy for preparing rigid siderophore analogs as 
antivirulence agents that competitively block siderophore utilizaton in producing 
pathogens. Our SAR studies set the stage for further functionalization of these scaffolds 
to yield even more potent analogs. 
4.6 Materials and Methods 
 
Strains, Materials, and Instrumentation 
 Initial growth studies on oxidized pre-acinetobactin were conducted using A. 
baumannii ATCC 19606T and derivatives t6 (bauA::EZ::TN<R6Kcori/KAN-2>), t7 
(bauD::EZ::TN<R6Kcori/KAN-2>), and s1 (basD::aph) provided by Dr. Luis Actis.22 
Growth studies for the oxidized pre-acinetobactin analog panel were conducted using A. 
baumannii ATCC 19606T provided by Dr. Luis Actis. Growth studies for oxidized pre-
acinetobactin against clinical strains were conducted using A. baumannii AR-BANK 
#0273, #0275, #0278, #0284, #0287, #0290, #0293, #0296, #0299, #0302, #0305, #0308, 
#0311 from the Antimicrobial Resistance Bank (collected by the CDC and FDA), 
provided to us by Dr. Gautam Dantas. Precultures and 96-well plate A. baumannii growth 
assays were performed in filter-sterilized M9 minimal media. Samples for LC-MS were 
prepared in 0.45 μM PTFE mini-UniPrep vials from Agilent. All preparatory HPLC was 
performed using a Beckman Coulter SYSTEM GOLD 127P solvent module and 168 
detector with a Phenomenex Luna 10u C18(2) 100A column, 250 × 21.20 mm, 10 μm 
with guard column. Prep HPLC was performed with a mobile phase of 5 mM ammonium 
acetate in (A) water and (B) acetonitrile, and data were processed using 32 Karat 
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software, version 7.0. All LC-MS was performed on an Agilent 6130 quadrupole LC-MS 
with G1313 autosampler, G1315 diode array detector, and 1200 series solvent module. A 
Phenomenex Gemini C18 column, 50 × 2 mm, 5 μm with guard column was used for all 
LC-MS separations. LC-MS mobile phases were 0.1% formic acid in (A) water and (B) 
acetonitrile, and data were processed using G2710 ChemStation software. NMR was 
performed on a Varian Unity Inova-600 MHz instrument with a cold probe. Bacterial 
growth studies were performed using polystyrene 96-well plates with polystyrene lids.  
CAS Assay 
 CAS agar plates were prepared as described previously.23 Wells were made in the 
solid agar, and 50 μL each of 100 μM solutions of oxidized pre-acinetobactin analogs in 
M9 minimal media (diluted from calibrated DMSO-d6 stocks) were pipetted into the 
wells. Color change was observed after 4 hours. 
A. baumannii Growth Studies in Minimal Media 
 M9 minimal media was made as described previously.9 
 For biological assessment of acinetobactin 2 and oxidized pre-acinetobactin 3 
under iron-restrictive conditions, stock solutions of 800 μM 2 and 3 were prepared in M9 
minimal media and filter sterilized. A 96-well plate was filled with 50 μL of M9 minimal 
media per well. Into the first column, 50 μL of either acinetobactin stock or oxidized pre-
acinetobactin stock was added, and columns were serially diluted down to 1.56 μM. An 
inoculum was made by adding 200 μL of 0.5 McFarland standard (A. baumannii ATCC 
19606T s1) to 29.8 mL of M9 minimal media supplemented with 250 μM 2,2’-dipyridyl. 
Inoculum (50 μL) was added to each well for a final concentration of 125 μM 2,2’-
dipyridyl and a serial dilution of 200-0.78 μM acinetobactin and oxidized pre-
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acinetobactin. Growth promotion or inhibition was determined as compared to a control 
with 125 μM 2,2’-dipyridyl, 0 μM acinetobactin and 0 μM oxidized pre-acinetobactin. 
All experiments were performed in triplicate. For confirmation of biological activity of 
re-purified compound, procedure was reproduced but with 200 μM 2,2’-dipyridyl 
inoculum for a final concentration of 100 μM 2,2’-dipyridyl. 
 For biological assessment of competition between acinetobactin 2 and oxidized 
pre-acinetobactin 3, a stock solution of 800 μM 3 was prepared in M9 minimal media and 
filter sterilized. A 96-well plate was filled with 50 μL of M9 minimal media per well. 
Into the first column, 50 μL of oxidized pre-acinetobactin stock was added, and columns 
were serially diluted down to 1.56 μM. An inoculum was made by adding 200 μL of 0.5 
McFarland (A. baumannii ATCC 19606T s1) to 29.8 mL of M9 minimal media 
supplemented with 200 μM 2,2’-dipyridyl and 20 μM acinetobactin. Inoculum (50 μL) 
was added to each well for a final concentration of 100 μM 2,2’-dipyridyl, 10 μM 
acinetobactin, and a serial dilution of 200-0.78 μM oxidized pre-acinetobactin. Growth 
promotion or inhibition was determined as compared to a control with 100 μM 2,2’-
dipyridyl, 10 μM acinetobactin, and 0 μM oxidized pre-acinetobactin. All experiments 
were performed in triplicate. 
 For the biological evaluation of the Fe3+-complex of oxidized pre-acinetobactin, 
200 μM stocks of acinetobactin-Fe3+ and oxidized pre-acinetobactin-Fe3+ were prepared 
in M9 minimal media and filter sterilized. A 96-well plate was filled with 50 μL of M9 
minimal media per well. Into the first column, 50 μL of either acinetobactin-Fe3+ stock or 
oxidized pre-acinetobactin-Fe3+ stock was added, and columns were serially diluted down 
to 0.39 μM. An inoculum was made by adding 200 μL of 0.5 McFarland standard (A. 
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baumannii ATCC 19606T s1) to 29.8 mL of M9 minimal media supplemented with 300 
μM 2,2’-dipyridyl. Inoculum (50 μL) was added to each well for a final concentration of 
150 μM 2,2’-dipyridyl and a serial dilution of 50-0.19 μM acinetobactin and oxidized 
pre-acinetobactin. Growth promotion was determined as compared to a control with 125 
μM 2,2’-dipyridyl, 0 μM acinetobactin-Fe3+ and 0 μM oxidized pre-acinetobactin-Fe3+. 
All experiments were performed in triplicate. 
 For MIC evaluation of oxidized pre-acinetobactin 3, stock solutions of 800 μM 
oxidized pre-acinetobactin and ciprofloxacin were prepared in M9 minimal media and 
filter sterilized. Eight 96-well plates were filled with 50 μL of M9 minimal media per 
well. For the first column of each plate, 50 μL of either oxidized pre-acinetobactin stock 
or ciprofloxacin stock was added, and columns were serially diluted down to 1.56 μM. 
Seven separate inocula were prepared by diluting 200 μL of appropriate 0.5 McFarland 
standard (A. baumannii ATCC 19606T, A. baumannii ATCC 19606T t6, A. baumannii 
ATCC 19606T t7, or A. baumannii ATCC 19606T s1) in either plain M9 minimal media 
(all bacterial strains) or M9 minimal media supplemented with 20 μM Fe(acac)3 (just A. 
baumannii ATCC 19606T and A. baumannii ATCC 19606T s1). Inocula (50 μL) were 
added to each well of separate plates for a final concentration of either 0 μM or 10 μM 
Fe3+ and a serial dilution of 200-0.78 uM oxidized pre-acinetobactin and ciprofloxacin. 
Growth was measured by endpoint OD600. All experiments were performed in triplicate. 
 For biological evaluation of the OxPreAcb analog panel under iron-restrictive 
conditions, solutions of 800 μM oxidized pre-acinetobactin 3 and analogs 12-19 in M9 
media were filter sterilized. 96-well plates were filled with 50 μL of M9 minimal media 
per well. Into the first column, 50 μL of analog was added and columns were serially 
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diluted down to 0.39 μM. An inoculum was made by adding 200 μL of a 0.5 McFarland 
standard of A. baumannii ATCC 19606T to 29.8 μL of 200 μM 2,2’-dipyridyl in M9 
minimal media. Inoculum (50 μL) was added to each well for a final concentration of 100 
μM 2,2’-dipyridyl and a serial dilution of 200 μM-0.39 μM analog. An MIC90 was read 
visually as the concentration at which no growth was observed and recorded at 72 hours. 
 For biological evaluation of OxPreAcb 3 against clinical A. baumannii isolates 
under iron-restrictive conditions, a solution of 800 μM oxidized pre-acinetobactin in M9 
media was filter sterilized. 96-well plates were filled with 50 μL of M9 minimal media 
per well. Into the first column, 50 μL of oxidized pre-acinetobactin was added and 
columns were serially diluted down to 0.39 μM. For each AR-BANK strain described in 
Table 1 an inoculum was made by adding 200 μL of a 0.5 McFarland standard to 29.8 μL 
of 200 μM 2,2’-dipyridyl in M9 minimal media. Inoculum (50 μL) was added to each 
well for a final concentration of 100 μM 2,2’-dipyridyl and a serial dilution of 200 μM-
0.39 μM analog. An MIC90 was read visually as the concentration at which no growth 
was observed and recorded at 17 hours and 40 hours. 
Acinetobactin Isolation 
 Natural acintobactin was isolated and purified from A. baumannii cultures as 
previously reported.1 Briefly, liter cultures of A. baumannii ATCC 17978 were grown 
overnight in M9 minimal media. The cultures were centrifuged down and the supernatant 
was adjusted to pH 6. XAD-7HP resin was added and the supernatant was shaken. The 
resin was washed with methanol. The methanol extract was concentrated and preparatory 
HPLC purified to yield pure acinetobactin. 
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Determination of KFe 
 Stock solutions of 100 μM pre-acinetobactin 1 Fe(III) complex, acinetobactin 2 
Fe(III) complex, and oxidized pre-acinetobactin 3 Fe(III) complex were prepared in 10 
mM HEPES buffer and a UV-Vis scan was recorded. Next 120 μM EDTA was added and 
absorbance at 500 nm was measured over 800 minutes. Iron-binding affinity (KFe) was 
determined using the following calculations. 
 
(1)  𝐾𝐿 =  
[𝐹𝑒𝐿2]
[𝐹𝑒3+][𝐿]2
                            for the following equilibrium;  [Fe3+] + 2[L] ⇌ [FeL2] 
 
(2) 𝐾𝐹𝑒𝐸𝐷𝑇𝐴 =  
[𝐹𝑒𝐸𝐷𝑇𝐴]
[𝐹𝑒3+] [𝐸𝐷𝑇𝐴]
        for the following equilibrium; [Fe3+] + [EDTA] ⇌ [FeEDTA]  
 
(3) 𝐾𝐸𝑥𝑐ℎ𝑎𝑛𝑔𝑒 =  
𝐾𝐿
𝐾𝐹𝑒𝐸𝐷𝑇𝐴
          for the following equilibrium; [FeEDTA] + 2[L] ⇌ [FeL2] + [EDTA] 
 
(4) 𝐾𝐸𝑥𝑐ℎ𝑎𝑛𝑔𝑒 =  
[𝐹𝑒𝐿2][𝐸𝐷𝑇𝐴]
[𝐹𝑒𝐸𝐷𝑇𝐴][𝐿]2
 
 
(5) ∆  =  
𝐴𝑏𝑠𝐹𝑒𝐿2− 𝐴𝑏𝑠𝐹𝑒𝐿2+𝐸𝐷𝑇𝐴
𝜀𝐿
 
 
(6)        𝐾𝐿 = 𝐾𝐹𝑒𝐸𝐷𝑇𝐴  ×  
[𝐹𝑒𝐿2][𝐸𝐷𝑇𝐴]
[𝐹𝑒𝐸𝐷𝑇𝐴][𝐿]2
 
 
(7) [𝐹𝑒𝐿2] =  
𝐴𝑏𝑠𝐹𝑒𝐿2
𝜀𝐿
 
 
(8) [𝐸𝐷𝑇𝐴] = [𝐸𝐷𝑇𝐴]𝑇 −  ∆         where  [EDTA]T = total EDTA added 
 
(9)   [𝐹𝑒𝐸𝐷𝑇𝐴] =  ∆ 
 
(10)     [𝐿] =  2∆ 
 
(11) KFe = apparent KL 
 
Fluorescence Quenching Titration 
 A solution of 570 μM oxidized pre-acinetobactin 3 in methanol was prepared and 
a fluorescence emission spectra was recorded (λexcitation = 330 nm). To determine 
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stoichiometry of the complex between 3 and iron (III), Fe(acac)3 was added 0.0438 
equivalents at a time (1 μL of 10 mM Fe(acac)3 added by Hamilton syringe) and emission 
spectra were recorded from 300-500 nm after each addition. Peak fluorescence (Abs380nm) 
was plotted against iron (III) equivalents. 
Computational Studies 
 All calculations were performed using Spartan ’16. Oxidized pre-acinetobactin 3 
and pre-acinetobactin 1 were modeled in Spartan. The lowest energy conformations were 
obtained using the minimize energy function. The 3’-4’-9-8 dihedral (see Appendix C 
for atom numbers) was constrained in both molecules as the energy profile was created 
investigating the rotation around the oxazole-carbonyl bond. The energy profile was run 
at ground state in the gas state with molecular mechanics MMFF. The energy was 
calculated in kJ/mol as the heterocycle-carbonyl bond rotated 360 degrees over 25 steps. 
The energy was plotted as against the 25 conformations.  
OxPreAcb and Intermediate Compound Synthesis 
 Refer to Scheme 1 and Scheme 2 for compound numbers. 
 Benzyl 2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-carboxylate (8). The 
synthesis of 8 was adapted from a previously reported, one-pot synthesis of oxazoles.11 
To a clean, dry round bottom flask equipped with a stirbar and argon inlet was added L-
throenine benzyl ester oxalate ( 1.0 g, 3.34 mmol), potassium carbonate ( 0.92 g, 6.68 
mmol), and N,N’-dimethylacetamide (8.3 mL) (Note: a white, cloudy solution was 
formed). To the resultant mixture was added 2,3-dihydroxybenzaldehyde ( 0.46 g, 3.34 
mmol) [solid, in one portion], which resulted in the formation of a bright yellow solution 
which stirred at room temperature, under argon, for 12 hrs. After 12 hrs, the reaction was 
140 
 
cooled to 0°C, and bromotrichloromethane (0.99 mL, 10.02 mmol) and 1,8-
diazabicyclo[5.4.0]undec-7-ene (1.50 mL, 10.02 mmol) were added. The resulting deep 
orange solution was stirred at 0°C for 2 hrs, at which point the reaction was removed 
from the ice bath and warmed to rt. The mixture stirred at rt for an additional 10 hrs 
[monitored by LC-MS]. The reaction was diluted with DD-H2O (3x original volume) and 
extracted with MTBE (3 x 15 mL) and EtOAc (3 x 15 mL). The organic layers were 
combined, washed with brine, and dried over Na2SO4. The product was concentrated by 
rotary evaporation to yield a dark orange sticky solid (0.92 g, 85% crude yield). The 
crude product was then purified as needed by prep HPLC (gradient of 0% B to 95% B for 
17 min then hold at 100% B for 8 minutes) to provide the title compound as a pale yellow 
oil (5 mg per injection, yielded 3.5 mg of pure compound). 1H NMR (600 MHz, 
Chloroform-d) δ 7.46 (d, J = 7.1 Hz, 2H), 7.43 – 7.33 (m, 4H), 7.31 (d, J = 8.0 Hz, 1H), 
7.03 (d, J = 7.9 Hz, 1H), 6.86 (t, J = 7.9 Hz, 1H), 5.38 (s, 2H), 2.70 (s, 3H). 13C NMR 
(151 MHz, Chloroform-d) δ 161.5, 159.5, 155.4, 145.3, 144.7, 135.7, 128.8, 128.6, 128.4, 
127.0, 120.0, 117.6, 116.9, 110.2, 66.8, 12.3. LC-MS cald for C18H16NO5 (M + H)
+ 
326.1028; found 326.1. 
 2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-carboxylic acid (9). To a solution 
of oxazole 8 (20 mg, 0.06 mmol) in MeOH (2 mL) was added 10% P/C (2 mg) at rt. The 
vial was purged with H2 and allowed to stir under H2 atm (1 atm) for 1 hr [monitored by 
LC-MS]. Once complete, as judged by LC-MS, the solid catalyst was removed via 
syringe filtration, and the solution was concentrated under reduced pressure to provide 
pure carboxylic acid 9 as a clear colorless oil (99% yield). 1H NMR (600 MHz, 
Methanol-d4) δ 7.33 (d, J = 7.9 Hz, 1H), 6.94 (d, J = 7.9 Hz, 1H), 6.83 (t, J = 7.9 Hz, 
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1H), 2.72 (s, 3H). 13C NMR (151 MHz, Methanol-d4) δ 164.8, 160.8, 156.7, 147.2, 146.8, 
128.5, 120.8, 119.4, 117.6, 111.7, 12.0.  LC-MS cald for C11H10NO5 (M + H)
+ 236.0559; 
found 236.1. 
 N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(2,3-dihydroxyphenyl)-5-
methyloxazole-4-carboxamide (11). To a clean, dry round bottom flask equipped with a 
stirbar and argon inlet was added carboxylic acid 9 (60 mg, 0.25 mmol), DMF (8 mL), 
and hydroxyhistamine 7 (82 mg, 0.38 mmol). To the stirring solution was added EDC 
(198 mg, 1.28 mmol) and HOBt (172 mg, 1.28 mmol), and Et3N was added to the 
reaction dropwise until a pH of ~9 was obtained. The reaction stirred under argon for 12 
hrs (monitored by LC-MS), at which point the reaction mixture was concentrated by 
rotary evaporation and purified by prep HPLC (gradient of 0% B to 95% B in 17 minutes, 
95% B to 100% B in 2 minutes, hold 100% B for 8 minutes) to yield title compound 11 
as a pale yellow oil (64 mg, 58% yield). 1H NMR (600 MHz, DMSO-d6) δ 7.49 (s, 1H), 
7.38 – 7.26 (m, 5H), 7.20 (dd, J = 7.9, 1.6 Hz, 1H), 6.92 (d, J = 7.8 Hz, 1H), 6.79 (s, 1H), 
6.75 (t, J = 7.8 Hz, 1H), 4.95 (s, 2H), 4.06 (t, J = 7.2 Hz, 2H), 2.87 (t, J = 7.2 Hz, 2H), 
2.42 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ 172.0, 161.4, 157.9, 146.1, 145.1, 134.8, 
129.3, 129.1, 128.6, 128.3, 119.6, 118.2, 116.5, 111.1, 75.6, 25.0, 21.1, 11.4. HRMS cald 
for C23H23N4O5 (M + H)
+ 435.1663; found 435.1669 
 N-(2-(1H-imidazol-4-yl)ethyl)-2-(2,3-dihydroxyphenyl)-N-hydroxy-5-
methyloxazole-4-carboxamide (3). O-benzyl-oxidized-pre-acinetobactin 11 (12 mg, 
0.05 mmol) was stirred in MeOH with ~1/10 mass equivalent of 10% Pd/C under H2 
atmosphere (1 atm). Upon confirmation of reaction completion by LC-MS (~1 hr), the 
solid catalyst was removed through syringe filtration and the solution was concentrated 
142 
 
by rotary evaporation to provide oxidized preacinetobactin 3 as a colorless oil. 1H NMR 
(600 MHz, DMSO-d6) δ 7.54 (s, 1H), 7.23 (dd, J = 7.9, 1.6 Hz, 1H), 6.95 – 6.92 (m, 1H), 
6.86 (s, 1H), 6.80 (t, J = 7.9 Hz, 1H), 3.93 (s, br, 2H), 2.88 (t, J = 7.3 Hz, 2H), 2.50 (s, 
3H, under DMSO residual solvent peak). 13C NMR (151 MHz, DMSO-d6) δ 157.8, 151.4, 
146.2, 145.3, 134.8, 128.0, 119.5, 118.2, 116.1, 110.7, 48.6, 11.4.HRMS cald for 
C16H17N4O5 (M + H)
+ 345.1199; found 345.1193. 
Analog Panel and Intermediate Compound Synthesis 
 Refer to Scheme 3 and Scheme 4 for compound numbers 
 Compound 6 was synthesized and characterized as previously reported.9 
 Compound 10 was synthesized through the N-Boc removal of N-Boc-O-
benzylhydroxylamine (12). 20mg of 12 was dissolved in 5 mL of neat TFA. Reaction 
stirred for 1 hr, monitored by LC-MS. TFA was removed by rotary evaporation under 
reduced pressure to afford the TFA salt of O-benzylhydroxylamine 13 in quantitative 
yield. Compound 13 was used without purification.  
 Compound 21 was synthesized and characterized as previously reported.1 
 Compound 22 was synthesized through the N-Boc removal of N-Boc-O-
benzylhydroxylamine (15). 20mg of 15 was dissolved in 5 mL of neat TFA. Reaction 
stirred for 1 hr, monitored by LC-MS. Upon verification of completion, TFA was 
removed by rotary evaporation under reduced pressure to afford the TFA salt of O-
benzylhydroxylamine 16 in quantitative yield. Compound 16 was used without 
purification.  
 General Procedure A. The synthesis of oxazole benzyl esters 8 and 29-34 was 
adapted from a previously reported, one-pot synthesis of oxazoles.11 Briefly, L-throenine 
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benzyl ester oxalate (3.34 mmol), potassium carbonate (6.68 mmol), and N,N’-
dimethylacetamide (8.3 mL) were stirred under argon. To the resultant mixture was 
added various benzaldehyde (3.34 mmol), the solution stirred at room temperature, under 
argon, for 12 hrs. After 12 hrs, the reaction was cooled to 0°C, and 
bromotrichloromethane (10.02 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (10.02 
mmol) were added. The solution stirred at 0°C for 2 hrs, at which point the reaction was 
removed from the ice bath and warmed to rt. The mixture stirred at rt for an additional 10 
hrs [monitored by LC-MS]. The reaction was diluted with DD-H2O (3x original volume) 
and extracted with MTBE (3 x 15 mL) and EtOAc (3 x 15 mL). The organic layers were 
combined, washed with brine, and dried over Na2SO4. The product was concentrated by 
rotary evaporation to yield desired compound. The crude product was then purified as 
needed by prep HPLC (gradient of 0% B to 95% B for 17 min then hold at 100% B for 8 
minutes) to provide precursor for general procedure B. Characterization data (1H-NMR, 
13C-NMR, LC-MS) listed in text format below.   
 General Procedure B. Oxazole carboxylic acids 9 and 35-40 were synthesized 
through the hydrogenation of oxazole benzyl esters 8 and 29-34. Briefly, oxazole benzyl 
esters 8 and 29-34 (20 mg) were dissolved in MeOH (2 mL) 10% P/C (2 mg) was added 
at rt. The vial was purged with H2 and allowed to stir under H2 atm (1 atm) for 1 hr 
[monitored by LC-MS]. Once complete, as judged by LC-MS, the solid catalyst was 
removed via syringe filtration, and the solution was concentrated under reduced pressure 
to provide pure carboxylic acids 9 and 35-40 in quantitative yield. These compounds 
were used without purification or characterization.  
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 General Procedure C. Compounds 11, 12, and 41-47 were synthesized through 
the coupling of oxazole carboxylic acids 9 and 35-40 and amines 4, 10, or 22. Carboxylic 
acid (0.25 mmol) was dissolved in DMF (8 mL) under argon. Amine 4, 10 or 22 (0.38 
mmol) was added. To the stirring solution was added EDC (1.28 mmol) and HOBt (1.28 
mmol). Et3N was added to the reaction dropwise until a pH of ~9 was obtained. The 
reaction stirred under argon for 12 hrs (monitored by LC-MS), at which point the reaction 
mixture was concentrated by rotary evaporation and purified by prep HPLC (gradient of 
0% B to 95% B in 17 minutes, 95% B to 100% B in 2 minutes, hold 100% B for 8 
minutes) to yield title compound 11, 12, 41-47. Compound 12 was characterized by 
HRMS and 2D-NMR (Appendix C). Characterization data for 11, 41-47 (1H-NMR, 13C-
NMR, LC-MS) listed in text format below.   
 General Procedure D. OxPreA (3) and hydroxamate-containing analogs (13-19) 
were synthesized through hydrogenation to debenzylate 11, 41-47. Compounds 11, 41-47 
were stirred in MeOH with ~1/10 mass equivalent of 10% Pd/C under H2 atmosphere (1 
atm). Upon confirmation of reaction completion by LC-MS (~1 hr), the solid catalyst was 
removed through syringe filtration and the solution was concentrated by rotary 
evaporation to afford desired compounds 3, 13-19 in quantitative yield. Compounds were 
characterized by HRMS and 2D-NMR (Appendix C). 
 Compound 8 was synthesized by general procedure A starting with 2,3-
dihydroxybenzaldehyde. 1H NMR (600 MHz, Chloroform-d) δ 7.46 (d, J = 7.1 Hz, 2H), 
7.43 – 7.33 (m, 4H), 7.31 (d, J = 8.0 Hz, 1H), 7.03 (d, J = 7.9 Hz, 1H), 6.86 (t, J = 7.9 
Hz, 1H), 5.38 (s, 2H), 2.70 (s, 3H). 13C NMR (151 MHz, Chloroform-d) δ 161.5, 159.5, 
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155.4, 145.3, 144.7, 135.7, 128.8, 128.6, 128.4, 127.0, 120.0, 117.6, 116.9, 110.2, 66.8, 
12.3. LC-MS cald for C18H16NO5 (M + H)
+ 326.1028; found 326.1. 
 Compound 29 was synthesized by general procedure A starting with 2-
hydroxybenzyaldehyde. 1H NMR (600 MHz, Chloroform-d) δ 10.82 (s, 1H), 7.77 (dd, J 
= 7.9, 1.7 Hz, 1H), 7.46 (d, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.36 (d, 2H), 7.07 (d, J = 8.4, 
0.8 Hz, 1H), 6.94 (t, J = 8.0, 7.4, 0.9 Hz, 1H), 5.37 (s, 2H), 2.70 (s, 3H). 13C NMR (151 
MHz, Chloroform-d) δ 161.5, 159.4, 157.4, 155.3, 135.7, 132.8, 128.8, 128.5, 128.3, 
127.0, 126.0, 119.5, 117.5, 110.4, 66.7, 12.2. LC-MS cald for C18H16NO4 (M + H)
+ 
310.1074; found 310.1 
 Compound 30 was synthesized by general procedure A starting with 2,5-
dihydroxybenzyaldehyde. 1H NMR (600 MHz, DMSO-d6) δ 10.03 (s, 1H), 9.25 (s, 1H), 
7.47 (d, J = 7.2 Hz, 2H), 7.42 (t, J = 7.4 Hz, 2H), 7.38 – 7.34 (m, 1H), 7.16 (d, J = 2.7 
Hz, 1H), 6.91 – 6.84 (m, 2H), 5.36 (s, 2H), 2.67 (s, 3H).13C NMR (151 MHz, DMSO-d6) 
δ 160.8, 158.6, 155.9, 150.1, 149.2, 135.8, 128.6, 128.2, 128.1, 126.3, 120.7, 117.9, 
111.4, 110.2, 66.1, 11.9. LC-MS cald for C18H16NO5 (M + H)
+ 325.1023; found 326.1   
 Compound 31 was synthesized by general procedure A starting with 2,4-
dihydroxybenzyaldehyde. 1H NMR (600 MHz, Chloroform-d) δ 7.65 (d, J = 8.7 Hz, 1H), 
7.45 (d, 2H), 7.39 (t, J = 7.3 Hz, 2H), 7.35 (d, J = 7.3 Hz, 1H), 6.52 (d, J = 2.3 Hz, 1H), 
6.45 (dd, J = 8.6, 2.3 Hz, 1H), 5.37 (s, 2H), 2.68 (s, 3H). 13C NMR (151 MHz, 
Chloroform-d) δ 161.8, 159.7, 159.7, 159.7, 159.3, 154.7, 135.8, 128.8, 128.5, 127.7, 
126.8, 107.9, 103.7, 66.8, 12.2. LC-MS cald for C18H16NO5 (M + H)
+ 326.1023; found 
326.1 
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 Compound 32 was synthesized by general procedure A starting with 4-
hydroxybenzyaldehyde. 1H NMR (600 MHz, Chloroform-d) δ 7.90 (d, J = 8.9 Hz, 1H), 
7.43 (d, J = 6.9 Hz, 1H), 7.38 – 7.28 (m, 4H), 6.87 (d, J = 8.9 Hz, 1H), 5.37 (s, 2H), 2.66 
(s, 2H). 13C NMR (151 MHz, Chloroform-d) δ 162.5, 160.2, 158.6, 158.4, 156.0, 135.9, 
139.9, 128.7, 128.7, 128.6, 128.4, 116.0, 66.8, 12.4. LC-MS cald for C18H16NO4 (M + 
H)+ 310.1074; found 310.1 
 Compound 33 was synthesized by general procedure A starting with 
benzyaldehyde. 1H NMR (600 MHz, Chloroform-d) δ 8.09 – 8.00 (m, 2H), 7.52 – 7.46 
(m, 2H), 7.45 – 7.40 (m, 3H), 7.38 (t, J = 7.2 Hz, 2H), 7.35 – 7.30 (m, 1H), 5.41 (s, 2H), 
2.68 (s, 3H). 13C NMR (151 MHz, Chloroform-d) δ 162.4, 159.8, 156.5, 135.9, 130.8, 
128.8, 128.7, 128.7, 128.5, 128.4, 126.7, 66.7, 12.4. LC-MS cald for C18H16NO3 (M + 
H)+ 294.1125; found 294.1 
 Compound 34 was synthesized by general procedure A starting with 2,3 
dimethoxy-benzyaldehyde. 1H NMR (600 MHz, Chloroform-d) δ 7.55 (dd, J = 7.9, 1.5 
Hz, 1H), 7.47 (d, J = 7.4 Hz, 2H), 7.37 (t, J = 7.3 Hz, 2H), 7.35 – 7.30 (m, 1H), 7.11 (t, J 
= 8.0 Hz, 1H), 7.02 (dd, J = 8.2, 1.5 Hz, 1H), 5.40 (s, 2H), 3.92 (s, 3H), 3.90 (s, 3H), 2.69 
(s, 3H). 13C NMR (151 MHz, Chloroform-d) δ 162.5, 158.4, 156.8, 153.7, 148.0, 136.1, 
128.7, 128.5, 128.5, 128.4, 124.4, 122.1, 121.6, 114.9, 66.6, 61.5, 56.2, 12.5.  LC-MS 
cald for C20H20NO5 (M + H)
+ 354.1336; found 354.1 
 Compound 11 was synthesized by general procedure C through EDC/HOBt 
mediated couple of oxazole carboxylic acid 9 and O-benzylehydroxylamine 10 in the 
presence of facilitating base. 1H NMR (600 MHz, DMSO-d6) δ 7.49 (s, 1H), 7.38 – 7.26 
(m, 5H), 7.20 (dd, J = 7.9, 1.6 Hz, 1H), 6.92 (d, J = 7.8 Hz, 1H), 6.79 (s, 1H), 6.75 (t, J = 
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7.8 Hz, 1H), 4.95 (s, 2H), 4.06 (t, J = 7.2 Hz, 2H), 2.87 (t, J = 7.2 Hz, 2H), 2.42 (s, 3H). 
13C NMR (151 MHz, DMSO-d6) δ 172.0, 161.4, 157.9, 146.1, 145.1, 134.8, 129.3, 129.1, 
128.6, 128.3, 119.6, 118.2, 116.5, 111.1, 75.6, 25.0, 21.1, 11.4. HRMS cald for 
C23H23N4O5 (M + H)
+ 435.1663; found 435.1669 
 Compound 41 was synthesized by general procedure C through EDC/HOBt 
mediated couple of oxazole carboxylic acid 9 and O-benzylehydroxylamine 22 in the 
presence of facilitating base. 1H NMR (600 MHz, DMSO-d6) δ 7.95 (s, 1H), 7.42 (s, 2H), 
7.31 (s, 3H), 7.24 (dd, J = 7.9, 1.6 Hz, 1H), 6.95 (dd, J = 7.9, 1.5 Hz, 1H), 6.82 (t, J = 7.9 
Hz, 1H), 4.99 (s, 1H), 4.94 (s, 1H), 3.88 – 3.72 (m, 2H), 1.69 – 1.54 (m, 2H), 1.38 – 1.24 
(m, 2H), 0.94 – 0.76 (m, 3H). 13C NMR (151 MHz, DMSO-d6) δ 158.1, 146.0, 145.1, 
133.7, 129.4, 129.13 129.02 128.6, 128.6, 128.3, 119.7, 118.3, 118.1, 116.4, 76.6, 19.3, 
19.0, 13.6, 13.4. LC-MS cald for C22H25N2O5 (M + H)
+ 397.1758; found 397.2 
 Compound 42 was synthesized by general procedure C through EDC/HOBt 
mediated couple of oxazole carboxylic acid 35 and O-benzylehydroxylamine 10 in the 
presence of facilitating base. 1H NMR (600 MHz, DMSO-d6) δ 7.78 (dd, J = 7.8, 1.7 Hz, 
1H), 7.50 (s, 1H), 7.44 – 7.39 (m, 1H), 7.35 (s, 2H), 7.31 (s, 3H), 7.06 (dd, J = 8.3, 1.1 
Hz, 1H), 7.02 – 6.97 (m, 1H), 6.80 (s, 1H), 4.95 (s, 2H), 4.05 (t, J = 7.2 Hz, 2H), 2.88 (t, 
J = 7.2 Hz, 2H), 2.43 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ 172.1, 161.6, 157.2, 
156.1, 152.2, 135.0, 134.8, 132.6, 129.3, 128.5, 128.4, 128.3, 126.9, 119.7, 118.1, 117.0, 
111.0, 75.6, 25.1, 11.5. LC-MS cald for C23H22N4O4 (M + H)
+ 418.1641; found 418.2 
 Compound 43 was synthesized by general procedure C through EDC/HOBt 
mediated couple of oxazole carboxylic acid 36 and O-benzylehydroxylamine 10 in the 
presence of facilitating base.  
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1H NMR (600 MHz, DMSO-d6) δ 7.49 (s, 1H), 7.36 – 7.28 (m, 5H), 7.15 (d, J = 2.8 Hz, 
1H), 6.88 (d, J = 8.7 Hz, 1H), 6.86 (dd, J = 8.9, 2.8 Hz, 1H), 6.80 (s, 1H), 5.79 (s, 1H), 
4.94 (s, 2H), 4.03 (t, J = 7.2 Hz, 2H), 2.86 (t, J = 7.2 Hz, 2H), 2.41 (s, 3H). 13C NMR 
(151 MHz, DMSO-d6) δ 158.0, 157.6, 150.0, 149.0, 134.8, 129.3, 128.5, 128.4, 128.3, 
120.3, 117.9, 111.4, 110.5, 56.6, 45.0, 27.9, 15.7. LC-MS cald for C23H22N4O5 (M + H)
+ 
434.1590; found 434.2 
 Compound 44 was synthesized by general procedure C through EDC/HOBt 
mediated couple of oxazole carboxylic acid 37 and O-benzylehydroxylamine 10 in the 
presence of facilitating base. 1H NMR (600 MHz, DMSO-d6) δ 7.59 (d, J = 8.5 Hz, 1H), 
7.49 (s, 1H), 7.36 – 7.28 (m, 5H), 6.79 (s, 1H), 6.43 (dd, J = 8.6, 2.2 Hz, 1H), 6.41 (d, J = 
2.3 Hz, 1H), 5.78 (s, 2H), 4.93 (s, 2H), 4.02 (t, J = 7.3 Hz, 2H), 2.86 (t, J = 7.3 Hz, 2H), 
2.39 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ 161.6, 158.2, 158.0, 157.9, 134.8, 129.3, 
128.5, 128.3, 127.9, 108.3, 102.8, 102.6, 56.7, 45.6, 28.0, 15.7. LC-MS cald for 
C23H22N4O5 (M + H)
+ 434.1590; found 434.2 
 Compound 45 was synthesized by general procedure C through EDC/HOBt 
mediated couple of oxazole carboxylic acid 38 and O-benzylehydroxylamine 10 in the 
presence of facilitating base.  
1H NMR (600 MHz, DMSO-d6) δ 7.76 (d, J = 8.7 Hz, 2H), 7.49 (s, 1H), 7.41 (s, 1H), 
7.34 (s, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.77 (d, J = 6.4 Hz, 3H), 5.04 (s, 2H), 4.09 (s, 2H), 
2.89 – 2.83 (m, 2H), 2.44 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ 160.0, 158.1, 158.0, 
134.7, 129.0, 128.4, 128.3, 127.8, 117.3, 116.0, 56.8, 37.6, 28.0, 15.7. LC-MS cald for 
C23N22N4O4 (M + H)
+ 418.1641; found 418.2 
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 Compound 46 was synthesized by general procedure C through EDC/HOBt 
mediated couple of oxazole carboxylic acid 39 and O-benzylehydroxylamine 10 in the 
presence of facilitating base.  
1H NMR (600 MHz, DMSO-d6) δ 7.96 – 7.92 (m, 2H), 7.55 – 7.49 (m, 3H), 7.50 (s, 1H), 
7.41 (s, 2H), 7.33 (s, 3H), 6.81 (s, 1H), 5.06 (s, 2H), 4.11 (s, 2H), 2.89 (t, 2H), 2.47 (s, 
3H). 13C NMR (151 MHz, DMSO-d6) δ 135.3, 134.7, 131.0, 130.8, 129.2, 129.2, 129.1, 
128.4, 128.3, 126.4, 126.1, 126.0, 125.9, 75.7, 51.7, 24.9, 11.6. LC-MS cald for 
C23H22N4O3 (M + H)
+ 402.1692; found 402.2 
 Compound 47 was synthesized by general procedure C through EDC/HOBt 
mediated couple of oxazole carboxylic acid 40 and O-benzylehydroxylamine 10 in the 
presence of facilitating base. 1H NMR (600 MHz, DMSO-d6) δ 7.48 (s, 1H), 7.43 – 7.36 
(m, 2H), 7.36 – 7.31 (m, 3H), 7.23 (dd, J = 8.2, 1.8 Hz, 1H), 7.19 (t, J = 7.9 Hz, 1H), 6.79 
(s, 1H), 5.79 (s, 1H), 5.03 (s, 2H), 4.13 (s, 2H), 3.86 (s, 3H), 3.78 (s, 3H), 2.87 (t, J = 7.5 
Hz, 2H), 2.47 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ 162.1, 158.0, 155.9, 153.4, 
147.0, 135.4, 134.7, 129.1, 128.4, 128.3, 124.6, 121.0, 120.8, 115.1, 60.7, 56.8, 51.7, 
28.0, 15.7. LC-MS cald for C25H27N4O5 (M + H)
+ 463.1976; found 463.2 
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4.7 Figures and Tables 
 
Figure 1. Structures of pre-acinetobactin (1), acinetobactin (2), and oxidized pre-
acinetobactin (3). 
 
 
 
 
Scheme 1: Synthesis of precursors to OxPreAcb (3). 
 
 
 
 
Scheme 2: Synthesis of OxPre-Acb (3). 
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Figure 2. OxPreAcb (3) competes with Acb (2) to inhibit A. baumannii growth. 
Growth curves of A. baumannii ATCC 19606T in M9 minimal medium supplemented 
with 125 μM 2,2’-dipyridyl (DIP) and gradient concentrations of Acb (A.), 125 μM DIP 
and gradient concentrations of OxPreAcb (B.), 100 μM DIP, 10 μM Acb, and gradient 
concentrations of OxPreAcb (C.). Error bars represent s.d. for three independent trials. 
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Figure 3. Oxidized pre-acinetobactin (3) is a potent inhibitor of Acinetobacter 
baumannii ATCC 19606T growth in iron (III) controlled (100  μM DIP) M9 minimal 
media. A second lot of the target compound OxPreAcb was synthesized. Purified 
compound was then tested under new conditions to give an MIC90 reading. Compound 3 
totally inhibited growth at 1.56 μM under these conditions. NMR and LC-MS data of re-
purified compound can be found in Appendix C. 
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Figure 4. The antibiotic effect of oxidized pre-acinetobactin (3) is bacteriostatic. 
Images of 96 well microplates at 42 hours (top) and 72 hours (bottom) showing dose 
dependent and bacteriostatic antibiotic effect of serially diluted oxidized pre-
acinetobactin (3) against A. baumannii ATCC 19606T with a ciprofloxacin control. Wells 
in control rows contain no ciprofloxacin and no oxidized pre-acinetobactin. Growth curve 
analysis and regrowth studies of cells treated with OxPreAcb suggest no loss of viable A. 
baumannii cells upon treatment with OxPreAcb. 
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Figure 5. Growth inhibition by OxPreAcb (3) is attenuated by iron. OD600 taken at 42 
hrs of A. baumannii ATCC 19606T and 19606T s1 (Acb biosynthesis mutant) grown in 
M9 minimal medium supplemented with gradient concentrations of either OxPreAcb (3) 
(black bars) or ciprofloxacin (grey bars). No DIP was added to the media. (A.) Wild-type 
A. baumannii ATCC 19606T. (B.) Wild-type ATCC 19606T supplemented with 10 μM 
Fe(acac)3. (C.) ATCC 19606T s1. (D.) ATCC 19606T s1 supplemented with 10 μM 
Fe(acac)3. Error bars represent s.d. for three independent trials. 
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0273 9 R R R R R R S R R R 32 R R I R S R 1 R R 
0275 11 R R R R R R S R R R >32 R R I R S R 1 R R 
0278 14 R R R R R R S R R R >32 R R I R S R 1 R R 
0284 7 R R R R R R S R R R >32 R R S R S R 1 R R 
0287 6 I R R R R R S R S R >32 R R S R S R <0.5 R R 
0290 13 R R R R R R S R R R 32 R R I R S R 1 R R 
0293 5 I R R R R R S R R R >32 I R I R S R <0.5 R S 
0296 6 R R R R R R S R R R >32 R R S R S R 2 R R 
0299 14 R R R R R R S R R R 32 R R S R S R 2 R R 
0302 9 R R R R R R S R R R >32 R R I R S R 4 R R 
0305 7 I I R R R R S R R R >32 R R S R S S 2 R R 
0308 10 R R R R R R R R R R 16 R R R R R R 1 R R 
0311 11 R R R R R R S R R R >32 R R S R S R 1 R R 
Table 1. CDC clinical isolates strains resistances to current antibiotics (S – susceptible, I – intermediate, R – resistant) *No 
interpretation of S-I-R determined by CDC, micromolar MIC90 values listed
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CDC Isolate Strain MIC90 (17 hrs) 
µm 
MIC90 (40 hrs) 
µm 
0273 1.56 6.25 
0275 3.125 6.25 
0278 3.125 6.25 
0284 12.5 25 
0287 3.125 6.25 
0290 6.25 25 
0293 0.78 6.25 
0296 6.25 25 
0299 No growth 12.5 
0302 6.25 25 
0305 3.125 12.5 
0308 6.25 25 
0311 6.25 25 
 
Table 2: MIC90 values of OxPreAcb against CDC clinical isolates of A. baumannii 
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Concentration 
OxPreAcb (μM) 
p-value (t6) p-value (t7) p-value (s1) 
200 0.4929* 0.4452 0.0001*** 
100 0.002** 0.4935 0.0127* 
50 0.0213* 0.0871* 0.1401 
25 0.0450* 0.1042 0.7185 
12.5 0.0474* 0.5530 0.3827 
6.25 0.0084** 0.6228 0.2429 
3.125 0.0252* 0.0095** 0.0068** 
1.56 0.4204 0.0211* 0.4948 
0.78 0.0053** 0.0941 0.2769 
0.39 0.2244 0.0837 0.0001*** 
0 0.1018 0.0006*** 0.2460 
 
Concentration 
OxPreAcb-Fe(III) (μM) 
p-value (t6) p-value (t7) p-value (s1) 
25 0.0015** 0.0017** 0.3074 
12.5 0.0495* 0.7924 0.004** 
6.25 0.0016** 0.0112* 0.0072** 
3.125 0.0001*** 0.0363* 0.0001*** 
1.56 0.0001*** 0.0005*** 0.001** 
0.78 0.0006*** 0.0052** 0.0005*** 
0.39 0.0006*** 0.0432* 0.0023** 
0.195 0.0256* 0.5659 0.0033** 
0.98 0.7008 0.5602 0.1355 
0 0.2917 0.6997 0.1963 
All p-values are relative to the wild type strain at equal concentration of added molecule. 
* indicates a difference that is statistically significant.  
** indicates a difference that is very statistically significant.  
*** indicates a difference that is extremely statistically significant.  
 
Figure 6. OxPreAcb (3) promotes the growth of A. baumannii when complexed with iron 
(III). Endpoint OD600 measurements taken of bacterial growth of wild-type and mutants of A. 
baumannii ATCC 19606T in M9 minimal media. (A.) Media supplemented with gradient 
concentrations of oxidized pre-acinetobactin (3). Media contains 0 μM 2,2’-Dipyridyl. 
Measurements taken at 42 hours. (B.) Media supplemented with gradient concentrations of 
oxidized pre-acinetobactin (3) Fe(III)-Complex. Media contains 150 μM 2,2’-Dipyridyl. 
Measurements taken at 48 hours. Error bars represent standard deviations for three independent 
trials. All p-values and statistical significance are provided below in table format. 
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Figure 7. Oxidized pre-acinetobactin (3) forms a stable 2:1 complex with iron (III). Graph 
shows the peak absorbance at 380 nm of emission spectra (λex = 330 nm) of 3 (570 μM) with 
increasing quantities of Fe(acac)3. 
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Figure 8. Pre-acinetobactin, acinetobactin, and oxidized pre-acinetobactin all form colored, 
high-affinity complexes with iron (III). (A.) UV-Vis spectra of 100 μM pre-acinetobactin (1) 
complexed with iron (III) in 10 μM HEPES buffer. (B.) UV-Vis spectra of 100 μM oxidized pre-
acinetobactin (3) complexed with iron (III) in 10 μM HEPES buffer. (C.) Kinetic single-
wavelength (500 nm) scan of 100 μM pre-acinetobactin (1) complexed with iron (III) in HEPES 
supplemented with 120 μM EDTA. Black line represents average of two independent 
measurements and grey area represents standard deviation. Log(KFe) calculations provided in 
Equations 1–11. (D.) Kinetic single-wavelength (500 nm) scan of 100 μM oxidized pre-
acinetobactin (3) complexed with iron (III) in HEPES supplemented with 120 μM EDTA. Black 
line represents average of two indpendent measurements and grey area represents standard 
deviation. Log(KFe) calculations provided in Equations 1–11. The apparent KFe values for the 2:1 
PreAcb, Acb, and OxPreAcb iron (III) complexes were 27.4 ± 0.2, 26.2 ± 0.1, and 26.5 ± 0.3, 
respectively. 
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Figure 9. Oxidized pre-acinetobactin is more rigid than pre-acinetobactin. Gas phase 
minimum energy calculation structures of (A.) pre-acinetobactin (red) overlaid with oxidized 
pre-acinetobactin (blue), (B.) pre-acinetobactin, and (C.) oxidized pre-acinetobactin. Pre-
acinetobactin forms a stable intramolecular H-bond between the C2-hydroxyl group of the 
phenyl ring with the oxazoline nitrogen. Oxidized pre-acinetobactin forms a stable H-bond 
between the hydroxyl group of the hydroxamic acid and the oxazole nitrogen. 
 
 
 
Figure 10. A1,3 strain induces conformational rigidity. (Top) Energy minimization shows 
OxPreAcb adopts a planar geometry compared to pre-acinetobactin, causing reduced flexibility 
which may contribute to antibiotic properties. (Bottom) SAR shows that pre-acinetobactin, in the 
absence of a hydroxamate, can still bind iron and promote growth, indicating a flexibility in 
coordination geometry. OxPreAcb relies entirely on the hydroxamate for iron binding and 
growth inhibition, indicating that its structural rigidity is indeed playing a role in its bioactivity. 
A. B. C. 
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Figure 11. Oxidation of pre-acinetobactin oxazoline to the corresponding oxazole restricts 
rotation about the heterocycle-carbonyl bond through the introduction of A1,3 strain. (A.) 
Energy coordinate diagram for rotation around the oxazoline-carbonyl bond in pre-acinetobactin 
1. (B.) Energy coordinate diagram for rotation around the oxazole-carbonyl bond in oxidized 
pre-acinetobactin 3.  
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Scheme 3. Condensed synthetic scheme for OxPreAcb (3) analogs 12-19. Compound 12, 
containing no hydroxamate, required no final deprotection step. 
 
 
Figure 12: CAS assay determination of iron binding ability of OxPreAcb (3) and analogs (12-
19). 
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Compound MIC CAS 
3 1.56 + 
12 >200 - 
13 1.56 + 
14 0.78 + 
15 0.78 + 
16 0.78 + 
17 >200 - 
18 >200 - 
19 >200 - 
 
Table 3: MIC90 values of OxPreAcb (3) and analogs (12-19) directly correlate to the ability to 
bind iron. 
 
 
 
 
 
Figure 13. Hypothetical model for the mechanism of action of OxPreAcb growth inhibition of A. 
baumannii.  
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Figure 14. Structures of pre-acinetobactin (PreAcb), acinetobactin (Acb), OxPreAcb, 
pyochelin, yersiniabactin, and escherichelin. OxPreAcb and escherichelin both contain rigid 
aromatic heterocycles and inhibit the growth of pathogenic bacteria producing structurally 
similar siderophores with non-aromatic heterocycles. 
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Scheme 4. Full synthetic scheme for OxPreAcb (3) and analogs (12-19) 
 
 
Compound R1 
7, 8, 9 2,3-di-OH 
23, 29, 35 2-OH 
24, 30, 36 2,5-di-OH 
25, 31, 37 2,4-di-OH 
26, 32, 38 4-OH 
27, 33, 39 H 
28, 34, 40 2,3-di-OMe 
Compound R1 R2 R3 
11 2,3-di-OH  
 
OBn  OH (OxPreA, 3) 
12 2,3-di-OH H (12) 
41 2,3-di-OH 
 
OBn  OH (13) 
42 2-OH  
 
 
 
OBn  OH (14) 
43 2,5-di-OH OBn  OH (15) 
44 2,4-di-OH OBn  OH (16) 
45 4-OH OBn  OH (17) 
46 H OBn  OH (18) 
47 2,3-di-OMe OBn  OH (19) 
H2N
NH
N
2HCl
i. H2SO4, KBr
ii. NaNO2
X
NH
N
HCl
X = Br : Cl
3:1
BocN
OBn
H
NaH
DMF
Boc
N
OBn
NH
N
O
N
O
OH
TFA HN
OBn
NH
N
EDC, HOBt
NEt3, DMF
O
N
O
N R2
R3
52%, 3.5 hrs
78%, 3.5 hrs
O
N
O
OBnO
H
i. Thr-OBn, NEt3, K2CO3, 12h
ii. BrCCl3, DBU, 0
oC - rt, 12h
DMA
O
N
O
OBn Pd/C H2
MeOH 4, 10, or 22
99%, 1 hr
99%, 1 hr
4 5 6
7, 23-28 8, 29-34
8, 29-34 9, 35-40
10
72-91% crude yield
38-63%, 12 hrs
Br
BocN
OBn
H
NaH
DMF
90%
N
OBn
Boc
20 21
R1
R1
R1 R1
TFA
99%, 1 hr
HN
OBn
22
11, 12, 41-47
O
N
O
N R2
R3
11, 41-47
Pd/C H2
MeOH
99%, 1 hr
O
N
O
N R2
R3
3, 13-19
R1
R1 R1
166 
 
4.8 References 
 
1. Shapiro, J. A. & Wencewicz, T. A. Structure-function studies of acinetobactin analogs. 
Metallomics 9, 463–470 (2017). 
2. Balado, M. et al. Identification of the Ferric-Acinetobactin Outer Membrane Receptor in 
Aeromonas salmonicida subsp. salmonicida and Structure–Activity Relationships of 
Synthetic Acinetobactin Analogues. ACS Chem. Biol. 12, 479–493 (2017). 
3. Song, W. Y. et al. Key Structural Elements for Cellular Uptake of Acinetobactin, a Major 
Siderophore of Acinetobacter baumannii. Org. Lett. 19, 500–503 (2017). 
4. Liu, Z., Liu, F. & Aldrich, C. C. Stereocontrolled Synthesis of a Potential Transition-State 
Inhibitor of the Salicylate Synthase MbtI from Mycobacterium tuberculosis. J. Org. Chem. 
80, 6545–6552 (2015). 
5. Mislin, G. L., Burger, A. & Abdallah, M. A. Synthesis of new thiazole analogues of pyochelin, a 
siderophore of Pseudomonas aeruginosa and Burkholderia cepacia. A new conversion of 
thiazolines into thiazoles. Tetrahedron 60, 12139–12145 (2004). 
6. Mislin, G. L. et al. Binding properties of pyochelin and structurally related molecules to FptA 
of Pseudomonas aeruginosa. J. Mol. Biol. 357, 1437–1448 (2006). 
7. Miller, D. A. & Walsh, C. T. Yersiniabactin Synthetase:  Probing the Recognition of Carrier 
Protein Domains by the Catalytic Heterocyclization Domains, Cy1 and Cy2, in the Chain-
Initiating HMWP2 Subunit. Biochemistry 40, 5313–5321 (2001). 
8. Ohlemacher, S. I. et al. Enterobacteria secrete an inhibitor of Pseudomonas virulence during 
clinical bacteriuria. J. Clin. Invest. 127, 4018–4030 (2017). 
9. Shapiro, J. A. & Wencewicz, T. A. Acinetobactin Isomerization Enables Adaptive Iron 
Acquisition in Acinetobacter baumannii through pH-Triggered Siderophore Swapping. ACS 
Infect. Dis. 2, 157–168 (2016). 
10. Takeuchi, Y. et al. Synthesis of acinetobactin. Chem. Pharm. Bull. (Tokyo) 58, 1552–1553 
(2010). 
11. Graham, T. H. A Direct Synthesis of Oxazoles from Aldehydes. Org. Lett. 12, 3614–3617 
(2010). 
12. Motoya, T., Miyashita, M., Kawachi, A. & Yamada, K. Effects of ascorbic acid on interactions 
between ciprofloxacin and ferrous sulphate, sodium ferrous citrate or ferric 
pyrophosphate, in mice. J. Pharm. Pharmacol. 52, 397–401 (2000). 
13. Wuest, W. M., Sattely, E. S. & Walsh, C. T. Three Siderophores from One Bacterial Enzymatic 
Assembly Line. J. Am. Chem. Soc. 131, 5056–5057 (2009). 
14. Carvalho, D., R, C. C. C. & Fernandes, P. Siderophores as “Trojan Horses”: tackling multidrug 
resistance? Front. Microbiol. 5, (2014). 
15. Isolates Currently Available | Antimicrobial Resistance Isolate Bank | 
Antibiotic/Antimicrobial Resistance | CDC. (2017). Available at: 
https://www.cdc.gov/drugresistance/resistance-bank/currently-available.html. 
(Accessed: 14th November 2017) 
16. Mortensen, B. L. & Skaar, E. P. The contribution of nutrient metal acquisition and 
metabolism to Acinetobacter baumannii survival within the host. Front. Cell. Infect. 
Microbiol. 3, (2013). 
17. Huggins, D. J., Sherman, W. & Tidor, B. Rational Approaches to Improving Selectivity in Drug 
Design. J. Med. Chem. 55, 1424–1444 (2012). 
167 
 
18. Gaddy, J. A. et al. Role of Acinetobactin-Mediated Iron Acquisition Functions in the 
Interaction of Acinetobacter baumannii Strain ATCC 19606T with Human Lung Epithelial 
Cells, Galleria mellonella Caterpillars, and Mice. Infect. Immun. 80, 1015–1024 (2012). 
19. Stintzi, A. et. al. Microbial iron transport via a siderophore shuttle: A membrane ion 
transport paradigm. Proc. Natl. Acad. Sci. 97, 10691-10696 (2000). 
20. Chan, A. N. et. al. Role for dithiolopyrrolones in disrupting bacterial metal homeostasis. 
Proc. Natl. Acad. Sci. 114, 2717-2722 (2017)  
21. C. Hider, R. & Kong, X. Chemistry and biology of siderophores. Nat. Prod. Rep. 27, 637–657 
(2010). 
22. Dorsey, C. W. et al. The siderophore-mediated iron acquisition systems of Acinetobacter 
baumannii ATCC 19606 and Vibrio anguillarum 775 are structurally and functionally 
related. Microbiol. 150, 3657–3667 (2004). 
23. Louden, B. C., Haarmann, D. & Lynne, A. M. Use of Blue Agar CAS Assay for Siderophore 
Detection. J. Microbiol. Biol. Educ. 12, 51–53 (2011). 
 
 
 
 
168 
 
 
 
 
 
 
Chapter 5: Conclusions and Perspectives 
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5.1 Preface 
 
 This chapter was written by Justin A. Shapiro. 
5.2 Summary of Dissertation 
 
 Pathogenic Acinetobacter baumannii produces a cocktail of small-molecule iron (III) 
chelators (acinetobactin,1 fimsbactin,2 baumannoferrin3) to scavenge host iron supplies and 
establish infection. Acinetobactin is widely conserved for virulence and has been studied 
extensively.4 It is biosynthesized from 2,3-dihydroxybenzoic acid, threonine, and N-
hydroxyhistamine.5 While originally thought to contain an oxazoline core scaffold, it was later 
shown that the oxazoline is cleaved from the biosynthetic NRPS assembly line and undergoes a 
spontaneous non-enzymatic isomerization at pH = 8 to a stable isooxazolidinone.6 Thus, the 
oxazoline-containing molecule was renamed pre-acinetobactin and the isooxazolidinone-
containing molecule was dubbed acinetobactin. Pre-acinetobactin was therefore assumed to be a 
stepping-stone to the biologically relevant siderophore with no clinical significance of its own. 
Pseudomonine, a structurally related siderophore made from salicylate instead of 2,3-DHB from 
Pseudomonas aeruginosa, is produced by a homologous NRPS as an oxazoline and undergoes an 
analogous non-enzymatic isomerization.6 By contrast, anguibactin is produced from sulfur-
containing cysteine instead of oxygen-containing threonine and does not undergo an 
isomerization, locking it into a thiazoline form.6 Anguibactin is a virulence factor in the fish 
pathogen Vibrio anguillarum, indicating that the pre-isomerized form is a functional 
siderophore.7 This led us to believe that pre-acinetobactin may be more than just an intermediate 
but may have its own biological role.  
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We proceeded to synthesize pre-acinetobactin and perform kinetic isomerization studies 
to establish a pH-rate profile. Our work provided the first evidence of an Sn2 mechanism with 
attack of the hydroxamate onto the oxazoline, which had been proposed in the literature but 
unconfirmed. We showed that under acidic conditions the isomerization is slow and pre-
acinetobactin persists whereas under neutral or basic conditions the isomerization is rapid and 
acinetobactin predominates. We hypothesized a siderophore-swapping mechanism in which A. 
baumannii gets two siderophores for the biosynthetic cost of one to acquire iron under a broad 
range of conditions and expand the window for virulence. We showed that A. baumannii culture 
grown in acidic iron-deficient media excretes pre-acinetobactin into the supernatant and that it 
accumulates enough to be detected by LC-MS. We also showed that the two isomers form 
distinct stable high-affinity colored complexes with iron (III), and that each promotes growth of 
A. baumannii differently under varying pH conditions. Specifically, acinetobactin appears to lose 
its iron affinity, and thus its ability to promote growth, in acidic media. Furthermore, pre-
acinetobactin and acinetobactin appear to use the same uptake proteins for transportation into the 
cell. These results supported our initial hypothesis of a pH-triggered siderophore swapping 
mechanism.  
With newfound appreciation for the importance of this isomerization and the dual-
siderophore acinetobactin system, we questioned what chemical properties control isomerization 
rates, ability to bind iron (III), and ability to promote growth. By building a panel of 11 pre-
acinetobactin and 10 acinetobactin analogs, we were able to perform structure-activity analysis 
on the two siderophore scaffolds. We found that electron-donation at the ortho- or para- positions 
of the phenyl ring was the most significant factor in fast isomerization. This is likely due either 
to access to a quinone methide tautomer or stereoelectronic contributions (orbital overlap of the 
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electron rich 1-position of the phenyl ring with the π* orbital of the carbon-nitrogen double 
bond). Intramolecular hydrogen bonds between the hydroxamate and imidazole play a more 
subtle role. Chrome azural S assays showed that pre-acinetobactin chelates through an 
orthohydroxyphenylate oxazoline binding mode, whereas acinetobactin relies on the catechol. 
Interestingly, neither the imidazole or the hydroxamate are individually necessary for Fe(III) 
binding, indicating that in the absence of one moiety the other can compensate. Finally, we found 
a direct correlation between ability to tightly bind iron and ability to promote growth in iron-
deficient media. 
Our SAR on the natural scaffold set the stage for us to explore antibiotic analogs. We 
found that by rigidifying the pre-acinetobactin scaffold through the simple oxidation of oxazoline 
to oxazole, we could impart antibiotic activity under iron-deficient conditions. Our synthetic 
derivative, dubbed OxPreAcb, is stable against isomerization and is active against a variety of 
antibiotic resistant A. baumannii. Curious if similar properties dictated SAR in our antibiotic as 
in the natural siderophore, we synthesized a panel of 8 analogs and tested them in CAS and iron-
deficient MIC90 assays. In contrast to pre-acinetobactin, OxPreAcb does require the hydroxamate 
to bind iron. Computational analysis suggests that OxPreAcb binds iron through a planar 
tridentate phenolate-oxazoline-hydroxamate moiety. Similarly to pre-acinetobactin, OxPreAcb 
shows direct correlation between ability to bind iron and biological activity, although in this case 
the activity is inhibition as opposed to promotion. Rotation of the hydroxamate is predicted to be 
restricted compared to the natural scaffold, and the resulting rigidity may play a role in antibiotic 
activity. 
 This project has two key characteristics. First, we set out to apply a molecule-based 
organic chemistry perspective to a novel behavior in a biological system. Second, while a 
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practical application of our findings was the end goal, it was not clear what that application 
would be at the outset.  Shedding light on the natural system revealed a launching point from 
which we were able to find an application, disruption of siderophore cycling, which would 
otherwise have gone unexplored. This work highlights the importance of using a collaborative, 
multidisciplinary approach to create a base of fundamental knowledge upon which future work 
can build. 
5.3 Future Directions and Broader Context 
 
 Determining the mechanism of action of OxPreAcb will be critical for its ability to move 
forward as a potential drug candidate. As discussed in Chapter 4.5, possibilities for OxPreAcb 
inhibitory mechanism include blocking the uptake/utilization pathway for pre-
acinetobactin/acinetobactin, siderophore biosynthesis, or general metalloenzyme inhibition. The 
acinetobactin periplasmic binding protein (BauB) and the cytoplasmic FAD-dependent iron 
reductase (BauF) have both been isolated by our group. We have performed preliminary 
fluorescence titrations showing that acinetobactin and OxPreAcb quench the fluorescence of 
BauB with similar potency (Figure 1). While significant optimization is needed, this sets the 
stage for future work to validate that OxPreAcb interacts with the acinetobactin uptake pathway 
at high affinity. Additionally, collaborators at the Gulick lab are attempting to crystalize BauB 
with natural and synthetic substrates in order to determine important interactions in the binding 
pocket and prove the chelation geometry of the siderophores unequivocally. To add to these 
efforts, we have synthesized a pre-acinetobactin analog that lacks a hydroxamate and an 
imidazole in as-of-yet unpublished work. Preliminary studies indicate this molecule may bind in 
a 3:1 siderophore:iron ratio (Figure 2). Future work will focus on validating these results and 
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determining their implications for coordination geometry. Collaborators at the Sobrado lab are 
working on BauF and also looking for inhibitors of the histamine mono-oxygenase BasC. 
 A collaboration with Dr. Daryl Giblin is underway aimed at gaining insight into potential 
iron-binding geometries of pre-acinetobactin and acinetobactin through DFT calculations with 
basis sets Def2-SVP and Def2-TZVP. The only existing crystal structure for any member of the 
“acinetobactin family” is for anguibactin-Ga(III), showing a 2:2 siderophore:metal chelation 
geometry. Based on this structure, calculations were performed to generate analogous structures 
for pre- and post- acinetobactin (Figure 3). However, work from other groups as well as our own 
experimental evidence indicate that the siderophores bind in a 2:1 siderophore:iron ratio, 
suggesting that the anguibactin crystal structure is not the relevant structure found in nature. It is 
possible, although unlikely, that the subtle changes between anguibactin and acinetobactin result 
in very different chelation modes. It is also possible that Ga(III) behaves quite differently than 
iron when forming complexes, although gallium is widely used as an Fe(III) analog in these sorts 
of structures. A more plausible explanation, however, is that the reported anguibactin-Ga(III) 
crystal structure was an artifact of the crystallization conditions. Based on the fact that the 
reported anguibactin-Ga(III) crystal was highly unstable and degraded quickly, we believe this to 
be the case. New computational structures were generated based on a 2:1 chelation geometry 
(Figure 4). In conjunction with our experimental work, we will continue to collaborate with 
computational chemists to supplement our understanding of these ligands. 
As seen with antibiotics conjugated to a synthetic fimsbactin analog (Chapter 1.4), very 
large structures can be trafficked into the periplasm of A. baumannii through siderophore 
pathways. OxPreAcb clearly requires the phenolate-oxazoline-hydroxamate tridentate chelating 
moiety for iron binding and growth inhibition, but the imidazole appears to have potential for 
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derivatization. Furthermore, previous SAR has shown that a triazole in place of the imidazole 
retains biological activity in a fish pathogen; if this holds for A. baumannii, this could provide 
many opportunities for click-chemistry (Figure 5). Insight into how three-dimensional ligand 
geometry influences chelation could be gained by the synthesis of an OxPreAcb dimer. By 
conjugating with a second antibiotic, we could impart two modes of action, lowering the chance 
of resistance. An additional benefit to this approach is determining ultimate intracellular 
destination. If OxPreAcb-fluoroquinolone has antibiotic activity, we can infer that OxPreAcb 
accumulates in the cytoplasm. However, if OxPreAcb-β-lactam has activity, we can infer that 
OxPreAcb accumulates in the periplasm. Another strategy for identifying possible localization 
inside of the cell would be conjugation of a fluorophore and the use of fluorescence microscopy. 
Click chemistry could also be performed to identify possible molecular targets in a whole-cell 
protein pull-down assay. 
The reasons for A. baumannii to make multiple siderophores is still an open question. Bi- 
and tri- dentate siderophores are more kinetically labile than hexadentate siderophores.8 It has 
been speculated that lower-dentate chelators (pre-acinetobactin/acinetobactin) are synthesized in 
larger quantities to initially solubilize iron and then exchange the metal with the biosynthetically 
expensive higher-dentate chelators (fimsbactin and baumannoferrin).9 Alternatively, the 
siderophore cocktail may be meant to target different sources of iron. Genes in the 
baumannoferrin cluster have sequence homology with genes from acinetoferrin (Acinetobacter 
haemolyticus).3,10 Both siderophores have lipophilic side-chains which have been shown in 
acinetoferrin to enable a trans-membrane flip, perhaps allowing it to gain access to human 
intracellular iron stores. Baumannoferrin may be playing a similar role. Finally, the role of 
“siderophores” in non-iron metal acquisition (Mg, Zn, Cu, etc.) is becoming more appreciated in 
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the chemical literature.11 It is possible that pre-acinetobactin, acinetobactin, fimsbactin, and 
baumannoferrin have different metal-affinity profiles and are used to acquire different 
micronutrients during infection. The imidazole tail of pre-acinetobactin/acinetobactin is a 
somewhat unusual moiety amongst siderophore structures. Other siderophores with this moiety, 
staphylopine12 and pseudopaline,13 both play critical roles in bacterial zinc acquisition.14,15 The 
dual-siderophore acinetobactin system may be playing the role of an adaptable, multi-purpose 
metallophore, while the more traditional hexadentate chelators fimsbactin and baumannoferrin 
are dedicated iron-acquisition metabolites. A collaboration with Dr. Daryl Giblin is underway to 
determine computational structures of pre-acinetobactin and acinetobactin with different metals 
to gain insight into affinity. Future experimental work in our lab will focus on elucidating the 
true purpose of each member of the A. baumannii siderophore cocktail and how they work in 
tandem. 
As discussed in Chapter 1.4 in the subsection titled Sideromycins, there has been 
extensive work on siderophore-antibiotic conjugates and their potential for targeted drug 
delivery. All of these molecules rely on a traditional antibiotic warhead to impart the desired 
killing effect, creating the need for cleavable linkers that introduce issues of stability. 
Additionally, while siderophore conjugation can help to revive older drugs, they still ultimately 
rely on the same molecular targets, which may make them a stopgap in the long-term battle 
against resistance. Recently there has been an increased interest in molecules that contain the 
chelating motif and the antibiotic activity within the same core scaffold. Promysalin, a natural 
product from Pseudomonas putida, is a membrane disruptor and inhibitor of siderophore 
biosynthesis in other Pseudomonads.16,17 A diverted total synthesis of promysalin analogs has 
revealed a previously unexamined iron-binding moiety that is critical for antibiotic activity.18 
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Membrane disruption is often associated with toxicity. It is possible that promysalin utilizes 
siderophore pathways for targeted delivery, which may reduce toxicity to producing organisms 
or hosts. Another Pseudomonad natural product, the β-lactone antibiotic obiflourin, is 
synthesized from an NRPS assembly line and incorporates a 2,3-DHB monomer.19 It has yet to 
be explored exactly what role the catechol plays, but it has been hypothesized that it allows cell 
entry through siderophore proteins. The yersiniabactin/pyochelin intermediate, escherichelin, is 
secreted by beneficial commensal urinary E. coli and exhibits a protective antibiotic effect 
against Pseudomonas UTIs.20 This molecule has been shown to disrupt the siderophore uptake 
pathway of pyochelin.21 As in OxPreAcb, aromatization of the five-membered heterocycle 
results in a drastic change in activity from growth promotion to inhibition. Due to the ubiquity of 
oxazolines/thiazolines in siderophore structures (Figure 6), taken together these results could 
have wide ranging implications in the world of natural product drug development. Scaffolds that 
combine chelation and antibiotic activity could circumvent the need for new linker technology 
and may act by previously unexplored antivirulence mechanisms that are less susceptible to 
resistance. Our development of a rigidified antibiotic scaffold through minor modification of an 
existing structure is a crucial addition to this burgeoning field. 
 This research was ultimately motivated by a desire to understand the problem of 
pathogen virulence at a chemical level and use that knowledge to create rational, targeted 
solutions. While there is still a great deal of work ahead, there is also great opportunity, and I 
hope to keep contributing as best I can. 
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5.4 Materials and Methods 
 
Isolation of BauB-ss 
 E. coli BL21 strains with plasmid containing a modified bauB gene (coding for BauB-ss, 
or BauB minus a signal sequence) was kindly provided by Dr. Andrew Gulick. An overnight 
culture was grown in LB + 0.05 mg/mL ampicillin, and the next day a liter culture of LB + 0.05 
mg/mL ampicillin was inoculated and grown at 37 °C shaking at 225 RPM. Once OD600 reached 
0.8, the culture was allowed to cool to room temperature and spiked with 0.05 mg/mL ITPG to 
stimulate protein production. Culture was grown at 20 °C overnight. Culture was centrifuged at 
5000 RPM and cell pellets were resuspended in lysis buffer. Cells were lysed by homogenization 
and lysate was centrifuged at 45,000 RPM. Supernatent was run through nickel column to adhere 
protein, and protein was eluted off of the column with elution buffer. Elution was dialyzed 
overnight and concentrated in a spin column, frozen in liquid nitrogen as beads, and stored at -80 
°C. 
Siderophore Binding Assays for BauB-ss 
 From frozen protein stock a stock solution of 400 nM BauB-ss in TBS buffer was diluted. 
A fluorescence emission spectra was taken from 300-400 nanometers with an excitation 
wavelength of 280 nm. A stock solution of 400 nM protein and 16 μM substrate (acinetobactin 
or OxPreAcb) was prepared. Substrate was added in incrementally increasing amounts by 
removing volume from the cuvette and adding equal volume of substrate stock. Peak 
fluorescence (at 330 nm) was measured as a function of substrate concentration, and Kd values 
were calculated in GraphPad Prism. 
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Fluorescence Titrations of Pre-acinetobactin + Analogs with Fe(III) 
 Solutions of 500 μM pre-acinetobactin or analog was prepared in methanol and a 
fluorescence emission spectra was recorded between 350-550 nanometers with an excitation 
wavelength of 316 nm. Fe(acac)3 in methanol (10 mM) was added 1 μL at a time and a spetra 
was recorded with each addition. Peak fluorescence (at 380 nm) was measured as a function of 
Fe(III) equivalents and chelation stoichiometry was determined by ratio of ligand to iron once 
fluorescence had been completely quenched. 
Computational Studies 
 For starting geometry of the bimetallic complexes, we chose the crystal structure of the 
di-pre-anguibactin di-Ga(III) (S=0) complex22 and started with analogous structures for the 
neutral di-pre-acenitobactin di-Ga(III) complex, di-preacinetobactin di-Fe(III) and the 
corresponding neutral half complexes. Di-preacinetobactin Fe(III) and di-acinetobactin Fe(III) 
were also calculated. 
 Conformer spaces for complexes were explored by Monte Carlo/MMFF molecular 
mechanics/dynamics and first step of optimization was performed by using the PM3d semi-
empirical algorithm (Spartan Linux v10, WaveFunction, Inc.). Using either as input, we 
employed DFT (Density Functional Theory, Gaussian 09, Gaussian Inc.) for calculations by 
using the PBE0 hybrid functional (PBE1PBE in Gaussian parlance) with basis sets Def2-SVP 
and Def2-TZVP. Minima were optimized at the level PBE0/Def2-SVP and single-point energies 
were calculated at level PBE0/Def2-TZVP, with scaled thermal-energy corrections from scaling 
factors for B3LYP/6-31G(d,p). Solvent-based single-point energies were calculated at the same 
level by using the CPCM polarizable conductor calculation model for water and using the 
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Universal Force Field for atomic radii.  DFT was selected for computational efficiency and 
integrity.  Functional and basis sets were chosen for use with cupric and ferric complexes. 
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5.6 Figures 
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Figure 1. Fluorescence binding titrations of acinetobactin and oxidized pre-acinetobactin to the 
periplasmic binding protein BauB (100 nM in TBS buffer). Emission spectra recorded (300-400 
nm) with excitation wavelength = 280 nm. 
 
 
Figure 2. Fluorescence binding titrations of Fe(acac)3 into solutions (600 μM in methanol) of 
pre-acinetobactin or analogs lacking imidazole, hydroxamate, or both. Emission spectra recorded 
(350-450 nm) with excitation wavelength = 316 nm. 
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Figure 3. (Left) Published crystal structure of di-anguibactin di-Ga(III) complex.22 (Middle) 
Computational structure of di-preacinetobactin di-Ga(III) complex. (Right) Computational 
structure of di-preacinetobactin di-Fe(III) complex. 
 
 
 
Figure 4. Computational structures of di-preacinetobactin Fe(III) (left) and di-acinetobactin 
Fe(III) (right). 
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Figure 5. Potential applications of click chemistry in making OxPreAcb derivatives. 
 
 
 
Figure 6. Select structures of siderophores containing thiazoline or oxazoline heterocycles. 
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Appendix A: NMR Spectra for Chapter 2 
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2D NMR characterization data of pre-acinetobactin TFA salt in DMSO-d6. 
 
 
Atom 
13C 
(ppm) 
1H (ppm), 
multiplets in 
Hz 
gCOSY 
1H-1H  
3 bond 
TOCSY 
1H-1H  
4-5 bond 
  HMBC 
  1H-13C  
 2-3 bond 
ROESY 1H-
1H through 
space, 6 Å 
 
2 131.7       3, 5, 6, 7  
3 135.4 8.97 (s, 1H)  5 2, 5  
5 117.8 7.43 (s, 1H)  3 2, 3  
6 23.0 3.05 - 2.90 
(m, 2H) 
7 7 2, 5, 7 7 
7 47.0 4.00 - 3.72 (m, 
2H) 
6 6 2, 6 6 
9 170.9    4’, 5’  
2’ 167.3    4’, 6’’  
4’ 71.5 5.00 (d, J = 6.3 
Hz, 1H) 
5’  9, 2’, 6’ 6’ 
5’ 80.1 4.80 (td, J = 6.2, 
11.9 Hz, 1H) 
6’, 4’  9, 2’ 6’ 
6’ 21.7 1.42 (d, J = 6.3 
Hz, 3 H) 
5’ 4’, 5’ 4’, 5’ 4’, 5’ 
1’’ 150.0    4’’, 6’’  
2’’       
3’’ 147.0    4’’, 5’’  
4’’ 120.8 6.96 (dd, J = 
1.6, 7.8 Hz, 1H) 
5’’  1’’, 3’’, 6’’  
5’’ 120.0 6.74 - 6.70 (m, 1 
H) 
4’’, 6’’  3’’  
6’’ 119.2 7.04 (dd, J = 
1.6, 7.8 Hz, 1H) 
5’’  1’’, 4’’  
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1H-NMR spectrum (500 MHz) of pre-acinetobactin TFA salt in DMSO-d6. Signals are assigned 
on page 179. 
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13C-NMR spectrum (500 MHz) of pre-acinetobactin TFA salt in DMSO-d6. Signals are assigned 
on page 179. 
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gCOSY spectrum (500 MHz) of pre-acinetobactin TFA salt in DMSO-d6. Correlations are listed 
on table 179. 
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TOCSY spectrum (500 MHz) of pre-acinetobactin TFA salt in DMSO-d6. Correlations are listed 
on page 179. 
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gHSQC spectrum (500 MHz) of pre-acinetobactin TFA salt in DMSO-d6. Correlations are listed 
on page 179. 
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HMBC spectrum (500 MHz) of pre-acinetobactin TFA salt in DMSO-d6. Correlations are listed 
on page 179. 
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ROESY spectrum (500 MHz) of pre-acinetobactin TFA salt in DMSO-d6. Correlations are listed 
on page 179. 
 
 
 
 
 
 
 
194 
 
 
 
2D NMR characterization data of synthetic acinetobactin TFA salt in DMSO-d6. 
 
 
Atom 
13C 
(ppm) 
1H (ppm), 
multiplets in  
Hz 
gCOSY 
1H-1H  
3 bond 
TOCSY 
1H-1H  
4-5 bond 
  HMBC 
  1H-13C  
 2-3 bond 
ROESY 1H-
1H through 
space, 6 Å 
 
2 131.3    3, 5, 6, 7  
3 118.2 7.51 (s, 1H)  5 2, 5, 6  
5 135.4 8.98 (s, 1H)  3 2, 3  
6 23.3 3.04 - 2.86  
(m, 2H) 
7 7 2, 3, 7 7 
7 45.2 3.81 (t, J = 6.7 
Hz, 2H) 
6 6 2, 7, 9 6 
9 169.0    7, 4’  
2’ 171.0    3’, 6’  
3’  9.05 (d, J = 8.6 
Hz, 1H) 
4’ 4’, 5’, 6’ 2’ 4’, 5’, 6’’ 
4’ 58.4 4.61 (dd, J = 8.2, 
10.6 Hz,1 H) 
3’ 3’, 5’, 6’ 9, 2’, 6’ 
 
6’ 
5’ 79.0 4.46 - 4.34  
(m, 1H) 
6’ 3’, 4’, 6’ 6’ 6’ 
6’ 18.0 1.34 (d, J = 6.3 
Hz, 3H) 
5’ 3’, 4’, 5’ 4’, 5’ 4’, 5’ 
1’’ 147.6    5’’  
2’’ 150.5    4’’, 6’’  
3’’ 116.3    5’’  
4’’ 120.7 6.93 (d, J = 7.8 
Hz, 1H) 
5’’ 5’’, 6’’ 2’’, 6’’ 5’’ 
5’’ 119.7 6.75 - 6.63 (m, 1 
H) 
4’’, 6’’ 4’’, 6’’ 1’’, 3’’ 4’’, 6’’ 
6’’ 119.0 7.24 (d, J = 7.0 
Hz, 1H) 
5’’ 4’’, 5’’ 2’’, 4’’ 3’, 5’’ 
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1H-NMR spectrum (500 MHz) of synthetic acinetobactin TFA salt in DMSO-d6. Signals are 
assigned on page 187. 
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13C-NMR spectrum (500 MHz) of synthetic acinetobactin TFA salt in DMSO-d6. Signals are 
assigned on page 187. 
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gCOSY spectrum (500 MHz) of synthetic acinetobactin TFA salt in DMSO-d6. Correlations are 
listed on page 187. 
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TOCSY spectrum (500 MHz) of synthetic acinetobactin TFA salt in DMSO-d6. Correlations are 
listed on page 187. 
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gHSQC spectrum (500 MHz) of synthetic acinetobactin TFA salt in DMSO-d6. Correlations are 
listed on page 187. 
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HMBC spectrum (500 MHz) of synthetic acinetobactin TFA salt in DMSO-d6. Correlations are 
listed on page 187. 
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ROESY spectrum (500 MHz) of synthetic acinetobactin  TFA salt in DMSO-d6. Correlations are 
listed on page 187. 
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Appendix B: NMR Spectra for Chapter 3 
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NMR characterization data of compound 1b in DMSO-d6. HRMS (ESI+) m/z for [C17H21N5O4]
+ 
([M+H]+) calculated: 361.1506, found: 361.1498. 
 
 
  Compound 1b 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H–13C 2–3 
bond 
3 or 5 134.5 7.55 (br. s., 1 H)  
6 23.3 2.52 (m, 2 H) 7, 8 
7 26.0 1.88 – 1.84 (m, 2 H) 6, 8 
8 47.6 3.61 (t, J = 6.7 Hz, 2 H) 6, 7 
2’ 165.6  4’, 6” 
4’ 70.2 5.04 (d, J = 5.5 Hz, 1 H) 2’, 5’, 6’ 
5’ 78.6 4.89 (t, J = 6.3 Hz, 1 H) 4’, 6’ 
6’ 20.4 1.44 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
2” 148.3  4”, 6” 
4” 119.2 6.95 (dd, J = 1.6, 7.9 Hz, 1 
H) 
2”, 6” 
5” 118.5 6.73 (t, J = 7.9 Hz, 1 H)  
6” 117.6 7.05 (dd, J = 1.6, 7.9 Hz, 1 
H) 
2’, 2”, 4” 
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1H-NMR spectrum (600 MHz) of compound 1b in DMSO-d6. 
 
 
 
13C NMR spectrum (600 MHz) of compound 1b in DMSO-d6.  
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gHSQC spectrum (600 MHz) of compound 1b in DMSO-d6.  
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HMBC spectrum (600 MHz) of compound 1b in DMSO-d6.  
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NMR characterization data of compound 2b in DMSO-d6. HRMS (ESI+) m/z for [C17H21N5O4]
+ 
([M+H]+) calculated: 361.1506, found: 361.1499. 
 
 
  Compound 2b 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
3 or 5 134.4 7.59 – 7.54 (m, 1 H)  
6 23.5 2.60 – 2.55 (m, 2 H 7, 8 
7 26.1 1.89 – 1.85 (m, 2 H) 6, 8 
8 44.4 3.63 – 3.47 (m, 2 H) 6, 7 
10 166.9  8, 4’ 
2’ 169.8  4’, 6” 
3’  9.22 – 9.16 (m, 1 H) 2’ 
4’ 57.0 4.73 (s, 1 H) 10, 2’, 5’, 6’ 
5’ 77.7 4.46 – 4.40 (m, 1 H) 4’, 6’ 
6’ 16.6 1.38 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
2” 149.4  4”, 6” 
4” 119.1 6.95 (d, J = 7.9 Hz, 1 H) 2”, 6” 
5” 118.0 6.72 (t, J = 7.9 Hz, 1 H)  
6” 117.5 7.32 – 7.29 (m, 1 H) 2’, 2”, 4” 
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1H-NMR spectrum (600 MHz) of compound 2b in DMSO-d6.  
 
 
 
13C-NMR spectrum (600 MHz) of compound 2b in DMSO-d6. 
209 
 
 
 
gHSQC spectrum (600 MHz) of compound 2b in DMSO-d6.  
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HMBC spectrum (600 MHz) of compound 2b in DMSO-d6.  
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NMR characterization data of compound 1c in DMSO-d6. HRMS (ESI+) m/z for [C15H21N2O5]
+ 
([M+H]+) calculated: 309.1445, found: 309.1438. 
 
 
 Compound 1c 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
1 13.6 0.88 (t, J = 7.5 Hz, 3 H) 2, 3 
2 19.2 1.28 (dd, J = 7.9, 14.9 Hz, 2 
H) 
1, 3, 4 
3 28.1 1.58 – 1.52 (m, 2 H) 1, 2, 4 
4 47.2 3.55 (dt, J = 2.4, 7.1 Hz, 2 H) 2, 3 
2’ 165.6  4’, 6” 
4’ 70.2 5.02 (d, J = 5.5 Hz, 1 H) 2’, 5’, 6’ 
5’ 78.5 4.90 (t, J = 6.3 Hz, 1 H) 4’, 6’ 
6’ 20.3 1.44 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
2” 148.3  4”, 6” 
4” 119.2 6.96 (dd, J = 1.6, 7.9 Hz, 1 
H) 
2”, 6” 
5” 118.3 6.73 (t, J = 7.9 Hz, 1 H)  
6” 117.7 7.06 (dd, J = 1.6, 7.9 Hz, 1 
H) 
2’, 2”, 4” 
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1H-NMR spectrum (600 MHz) of compound 1c in DMSO-d6. 
 
 
 
 
13C-NMR spectrum (600 MHz) of compound 1c in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 1c in DMSO-d6.  
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HMBC spectrum (600 MHz) of compound 1c in DMSO-d6.  
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NMR characterization data of compound 2c in DMSO-d6. HR-MS (ESI+) m/z for 
[C15H21N2O5]
+ ([M+H]+) calculated: 309.1445, found: 309.1439. 
 
 
 Compound 2c 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
1 13.4 0.92 – 0.89 (m, 3 H) 2, 3 
2 19.2 1.35 – 1.32 (m, 2 H) 1, 3, 4 
3 28.2 1.58 – 1.53 (m, 2 H) 1, 2, 4 
4 44.3 3.58 – 3.45 (m, 2 H) 2, 3 
2’ 169.8  3’, 6” 
3’  9.34 – 9.27 (m, 1 H) 2’ 
4’ 57.0 4.73 (s, 1 H) 2’, 5’, 6’ 
5’ 118.2 4.45 – 4.39 (m, 1 H) 4’, 6’ 
6’ 16.5 1.38 – 1.36 (m, 3 H) 4’, 5’ 
2”   4”, 6” 
4” 119.2 6.96 (dd, J =1.6, 7.9 Hz, 1 H) 2”, 6” 
5” 118.2 6.75 – 6.71 (m, 1 H)  
6” 117.4 7.33 – 7.30 (m, 1 H) 2’, 2”, 4” 
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1H-NMR spectrum (600 MHz) of compound 2c in DMSO-d6.  
 
 
 
13C-NMR spectrum (600 MHz) of compound 2c in DMSO-d6.  
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gHSQC spectrum (600 MHz) of compound 2c in DMSO-d6.  
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HMBC spectrum (600 MHz) of compound 2c in DMSO-d6.  
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NMR characterization data of compound 1d in DMSO-d6. HRMS (ESI+) m/z for [C16H19N4O3]
+ 
([M+H]+) calculated: 315.1452, found: 315.1444. 
 
 
  Compound 1d 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
3 or 5 134.7 7.58 (br. s., 1 H)  
6 25.0 2.80 (t, J = 6.7 Hz, 2 H) 7 
7 47.5 3.90 – 3.65 (m, 2 H) 6 
9 169.6  4’ 
2’ 163.2  2” 
4’ 71.4 4.97 (d, J = 5.5 Hz, 1 H) 2’, 6’, 9 
5’ 78.7 4.89 – 4.77 (m, 1 H) 4’, 6’ 
6’ 20.6 1.40 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
2” 127.9 7.87 (d, J = 7.9 Hz, 2 H) 2’, 4” 
3” 128.6 7.50 – 7.46 (m, 2 H) 2” 
4” 131.59 7.58 – 7.54 (m, 1 H) 3” 
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1H-NMR spectrum (600 MHz) of compound 1d in DMSO-d6. 
 
 
 
 
13C-NMR spectrum (600 MHz) of compound 1d in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 1d in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 1d in DMSO-d6. 
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NMR characterization data of compound 2d in DMSO-d6. HRMS (ESI+) m/z for [C16H19N4O3]
+ 
([M+H]+) calculated: 315.1452, found: 315.1447. 
 
 
  Compound 2d 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
6 16.5 2.86 – 2.75 (m, 2 H) 7 
7  3.72 (d, J = 8.7 Hz, 2 H) 6 
9 168.3   
2’ 166.3  2” 
4’ 57.2 4.70 – 4.63 (m, 1 H) 5’, 6’, 9 
5’ 78.8 4.42 – 4.35 (m, 1 H) 4’, 6’ 
6’ 20.6 1.40 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
2” 127.4 7.88 (d, J = 7.1 Hz, 2 H) 2’, 4” 
3” 128.4 7.50 (t, J = 7.9 Hz, 2 H)  
4” 131.7 7.59 – 7.55 (m, 1 H) 2” 
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1H-NMR spectrum (600 MHz) of compound 2d in DMSO-d6. 
 
 
 
 
13C-NMR spectrum (600 MHz) of compound 2d in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 2d in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 2d in DMSO-d6. 
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NMR characterization data of compound 1e in DMSO-d6. HRMS (ESI+) m/z for [C16H19N4O4]
+ 
([M+H]+) calculated: 331.1401, found: 331.1390. 
 
 
  Compound 1e 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
3 or 5 134.7 7.59 (br. s., 1 H)  
6 24.5 2.84 – 2.79 (m, 2 H) 7 
7 47.6 3.77 (tt, J = 6.8,14.1 Hz, 2 
H) 
6 
9 165.2  4’ 
2’ 159.1  5”, 6” 
4’ 70.3 5.05 (d, J = 5.5 Hz, 1 H) 6’, 9 
5’ 78.7 4.90 – 4.87 (m, 1 H) 4’, 6’ 
6’ 20.6 1.45 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
2” 109.9  3”, 4” 
3” 116.5 6.99 (d, J = 7.9 Hz, 1 H) 2”, 4” 
4” 118.8 6.95 – 6.92 (m, 1 H) 2”, 3” 
5” 133.8 7.46 (t, J = 8.3 Hz, 2 H) 2’, 6” 
6” 127.8 7.61 (dd, J =1.6, 7.9 Hz, 1 H) 2’, 5” 
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1H-NMR spectrum (600 MHz) of compound 1e in DMSO-d6. 
 
 
 
13C-NMR spectrum (600 MHz) of compound 1e in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 1e in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 1e in DMSO-d6. 
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NMR characterization data of compound 2e in DMSO-d6. HR-MS (ESI+) m/z for 
[C16H19N4O4]
+ ([M+H]+) calculated: 331.1401, found: 331.1396. 
 
 
  Compound 2e 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
3 or 5 134.8 7.54 (s, 1 H)  
6 24.1 2.85 – 2.79 (m, 2 H) 7 
7 45.0 3.76 – 3.70 (m, 2 H) 6 
9 167.3  4’ 
2’ 168.6  3’, 6” 
3’  9.15 (d, J = 7.9 Hz, 1 H) 2’ 
4’ 57.0 4.74 – 4.68 (m, 1 H) 5’, 6’, 9 
5’ 77.8 4.47 – 4.40 (m, 1 H) 4’, 6’ 
6’ 16.6 1.39 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
1” 159.5  5”, 6” 
3” 118.7 6.93 – 6.91 (m, 1 H) 4” 
4” 117.4 6.94 (d, J = 7.9 Hz, 1 H) 3” 
5” 134.0 7.46 – 7.41 (m, 1 H) 1”, 6” 
6” 128.2 7.88 – 7.85 (m, 1 H) 1”, 5” 
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1H-NMR spectrum (600 MHz) of compound 2e in DMSO-d6. 
 
 
 
13C-NMR spectrum (600 MHz) of compound 2e in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 2e in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 2e in DMSO-d6. 
 
 
 
 
 
 
 
 
235 
 
 
 
NMR characterization data of compound 1f in DMSO-d6. HRMS (ESI+) m/z for [C16H19N4O4]
+ 
([M+H]+) calculated: 331.1401, found: 331.1390. 
 
 
  Compound 1f 
 
Atom 13C 
(ppm) 
1H (ppm), multiplets in 
Hz 
  HMBC 1H-13C 2-3 
bond 
2 136.1  6, 7 
3 or 5 134.6 7.58 (br. s., 1 H)  
6 24.8 2.80 (t, J = 7.1 Hz, 2 H) 2, 7 
7 47.5 3.84 – 3.68 (m, 2 H) 2, 6, 9 
9 169.6  4’, 7 
2’ 163.2  4’ 
4’ 71.3 4.93 (d, J = 6.3 Hz, 1 H) 2’, 6’, 9 
5’ 78.6 4.80 – 4.74 (m, 1 H) 4’, 6’ 
6’ 20.6 1.38 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
1” 157.1  2” 
2” 129.5 7.26 (s, 1 H) 1”, 3” 
3” 128.5  2” 
4” + 5” 114.4 and 
118.61 
7.30 – 7.27 (m, 2 H) 6” 
6” 118.63 6.95 – 6.91 (m, 1 H), 4” + 5” 
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1H-NMR spectrum (600 MHz) of compound 1f in DMSO-d6. 
 
 
 
13C-NMR spectrum (600 MHz) of compound 1f in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 1f in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 1f in DMSO-d6. 
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NMR characterization data of compound 2f in DMSO-d6. HRMS (ESI+) m/z for [C16H19N4O4]
+ 
([M+H]+) calculated: 331.1401, found: 331.1396. 
 
 
  Compound 2f 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
2 166.3  3, 5 
3 129.3 7.27 (s, 1 H) 2 
5  8.82 (d, J = 8.7 Hz, 2 H) 2 
6 25.0 2.86 – 2.75 (m, 2 H) 7 
7 44.8 3.76 – 3.66 (m, 2 H) 2, 6, 9 
9 167.8  4’, 7 
2’ 157.2  6” 
4’ 57.2 4.67 – 4.62 (m, 1 H) 5’, 6’, 9 
5’ 77.7 4.37 (dd, J = 6.3, 11.0 Hz, 1 
H) 
4’, 6’ 
6’ 16.5 1.36 (d, J = 5.5 Hz, 3 H) 4’, 5’ 
2” 134.8 7.53 (s, 1 H) 6” 
4” 117.7 7.26 (m, 1 H) 5”, 6” 
5” 118.5 6.95 – 6.93 (m, 1 H) 4”, 6” 
6” 114.3 7.29 (d, J = 3.1 Hz, 1 H) 2’, 2”, 4” 
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1H-NMR spectrum (600 MHz) of compound 2f in DMSO-d6. 
 
 
 
13C-NMR spectrum (600 MHz) of compound 2f in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 2f in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 2f in DMSO-d6.  
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NMR characterization data of compound 1g in DMSO-d6. HRMS (ESI+) m/z for [C16H19N4O4]
+ 
([M+H]+) calculated: 331.1401, found: 331.1390. 
 
 
  Compound 1g 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
3 or 5 134.7 7.57 (br. s., 1 H)  
6 25.0 2.84 – 2.73 (m, 2 H) 7, 2 
7 47.5 3.87 – 3.63 (m, 2 H) 6, 2 
9 169.6  4’, 5’ 
2’ 160.2  2”, 3” 
4’ 71.2 4.89 (d, J = 6.3 Hz, 1 H) 6’, 9 
5’ 78.2 4.74 (t, J = 5.9 Hz, 1 H) 4’, 6’, 9 
6’ 20.6 1.37 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
2” 129.7 7.69 (d, J = 8.7 Hz, 2 H) 2’ 
3” 115.2 6.81 (d, J = 8.7 Hz, 2 H) 2’, 4” 
4” 118.0  3” 
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1H-NMR spectrum (600 MHz) of compound 1g in DMSO-d6. 
 
 
 
 
13C-NMR spectrum (600 MHz) of compound 1g in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 1g in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 1g in DMSO-d6. 
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NMR characterization data of compound 2g in DMSO-d6. HRMS (ESI+) m/z for [C16H19N4O4]
+ 
([M+H]+) calculated: 331.1401, found: 331.1396. 
 
 
  Compound 2g 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
3 134.9 7.53 (s, 1 H)  
5  8.66 (d, J = 8.7 Hz, 1 H)  
6 25.1 2.87 – 2.74 (m, 2 H) 7 
7 44.9 3.77 – 3.65 (m, 2 H) 2, 6, 9 
9 167.8  7, 4’ 
2’ 160.5  2”, 3” 
4’ 57.1 4.66 – 4.62 (m, 1 H) 5’, 6’, 9 
5’ 77.8 4.38 – 4.32 (m, 1 H) 4’, 6’ 
6’ 16.5 1.35 (d, J = 6.3 Hz, 2 H) 4’, 5’ 
2” 129.2 7.75 (d, J = 8.7 Hz, 2 H) 2’ 
3” 114.8 6.82 (d, J = 8.7 Hz, 2 H) 2’, 4” 
4” 124.0  3” 
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1H-NMR spectrum (600 MHz) of compound 2g in DMSO-d6. 
 
 
 
13C-NMR spectrum (600 MHz) of compound 2g in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 2g in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 2g in DMSO-d6. 
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NMR characterization data of compound 1h in DMSO-d6. HRMS (ESI+) m/z for [C16H19N4O5]
+ 
([M+H]+) calculated: 347.1350, found: 347.1338. 
 
 
  Compound 1h 
 
Atom 13C (ppm) 1H (ppm), multiplets in 
Hz 
  HMBC 1H-13C 2-3 
bond 
3 or 5 134.6 7.58 (s, 1 H)  
6 24.1 2.84 – 2.78 (m, 2 H) 7 
7 47.6 3.82 – 3.73 (m, 2 H) 6, 9 
9 168.7  7, 4’ 
2’ 165.1  4’ 
4’ 70.3 5.03 (d, J = 5.5 Hz, 1 H) 6’, 9 
5’ 78.4 4.85 (t, J = 5.9 Hz, 1 H) 6’ 
6’ 20.4 1.44 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
3” 112.5 6.97 (d, J = 3.1 Hz, 1 H) 4”, 5” 
4” 121.6 6.88 (d, J = 3.1 Hz, 1 H) 3”, 5” 
5” 152.1  3”, 4”, 6” 
6” 117.1 6.83 – 6.81 (m, 1 H) 5” 
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1H-NMR spectrum (600 MHz) of compound 1h in DMSO-d6. 
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13C-NMR spectrum (600 MHz) of compound 1h in DMSO-d6. 
 
 
gHSQC spectrum (600 MHz) of compound 1h in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 1h in DMSO-d6.  
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NMR characterization data of compound 2h in DMSO-d6. HRMS (ESI+) m/z for [C16H19N4O5]
+ 
([M+H]+) calculated: 347.1350, found: 347.1345. 
 
 
  Compound 2h 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
3 or 5 134.7 7.53 (s, 1 H)  
6 24.8 2.85 – 2.77 (m, 2 H) 7 
7 44.6 3.75 – 3.68 (m, 2 H) 6 
2’ 168.2  3’, 3” 
3’  9.03 (d, J = 7.1 Hz, 1 H) 2’ 
4’ 57.0 4.70 – 4.66 (m, 1 H) 5’, 6’ 
5’ 77.9 4.42 (dd, J = 6.3, 11.0 Hz, 1 
H) 
4’, 6’ 
6’ 16.6 1.38 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
3” 113.7 7.25 (d, J = 2.4 Hz, 1 H) 4”, 5” 
4” 121.6 6.87 (d, J = 3.1 Hz, 1 H) 3”, 5” 
5” 151.6  3”, 4”, 6” 
6” 117.6 6.78 (s, 1 H) 5” 
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1H-NMR spectrum (600 MHz) of compound 2h in DMSO-d6. 
 
 
 
13C-NMR spectrum (600 MHz) of compound 2h in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 2h in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 2h in DMSO-d6. 
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NMR characterization data of compound 1i in DMSO-d6. HRMS (ESI+) m/z for [C16H19N4O5]
+ 
([M+H]+) calculated: 347.1350, found: 347.1142. 
 
 
  Compound 1i 
 
Atom 13C (ppm) 1H (ppm), multiplets in 
Hz 
  HMBC 1H-13C 2-3 
bond 
3 or 5  7.66 – 7.53 (m, 1 H)  
6 25.0 2.87 – 2.71 (m, 2 H)  
7 47.2 3.85 – 3.65 (m, 2 H)  
2’ 163.3  2” 
4’ 71.3 4.92 – 4.88 (m, 1 H) 6’ 
5’ 78.4 4.79 – 4.68 (m, 1 H) 6’ 
6’ 20.6 1.36 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
2” 106.4 6.73 (d, J = 1.6 Hz, 2 H) 2’, 3”, 4” 
3” 158.2  2”, 4” 
4” 105.5 6.38 – 6.30 (m, 1 H) 2”, 3” 
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1H-NMR spectrum (600 MHz) of compound 1i in DMSO-d6. 
 
 
 
13C-NMR spectrum (600 MHz) of compound 1i in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 1i in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 1i in DMSO-d6. 
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NMR characterization data of compound 2i in DMSO-d6. HRMS (ESI+) m/z for [C16H19N4O5]
+ 
([M+H]+) calculated: 347.1350, found: 347.1345. 
 
 
  Compound 2i 
 
Atom 13C (ppm) 1H (ppm), multiplets in 
Hz 
  HMBC 1H-13C 2-3 
bond 
3 134.7 7.76 – 7.69 (m, 1 H) 5 
5  6.98 – 6.93 (m, 1 H) 3 
6 23.9 2.85 – 2.78 (m, 2 H) 7 
7 44.9 3.74 – 3.69 (m, 2 H) 6, 9 
9 167.9  7, 4’ 
2’ 166.5  3’, 2” 
3’  8.74 – 8.64 (m, 1 H) 2’, 4’ 
4’ 57.2 4.63 – 4.55 (m, 1 H) 9, 3’, 5’, 6’ 
5’ 77.6 4.40 – 4.29 (m, 1 H) 4’ 
6’ 16.5 1.34 (d, J = 5.5 Hz, 3 H) 4’, 5’ 
2” 105.55 6.70 (d, J = 2.4 Hz, 2 H) 2’, 3”, 4” 
3” 158.0  2”, 4” 
4” 105.50 6.38 (s, 1 H) 2”, 3” 
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1H-NMR spectrum (600 MHz) of compound 2i in DMSO-d6. 
 
 
 
13C-NMR spectrum (600 MHz) of compound 2i in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 2i in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 2i in DMSO-d6. 
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NMR characterization data of compound 1j in DMSO-d6. HRMS (ESI+) m/z for [C18H23N4O5]
+ 
([M+H]+) calculated: 375.1663, found: 375.1650. 
 
 
  Compound 1j 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
3 or 5 134.6 7.57 (br. s., 1 H)  
6 24.5 2.84 – 2.76 (m, 2 H) 7 
7 47.6 3.78 – 3.74 (m, 2 H) 6 
4’ 71.4 4.92 (d, J = 5.5 Hz, 1 H) 5’, 6’ 
5’ 78.3 4.76 (m, 1 H) 4’, 6’ 
6’ 20.6 1.38 (d, J = 5.5 Hz, 3 H) 4’, 5’ 
2” 152.9  6”, 7” 
3” 147.8  4”, 8” 
4” 115.3 7.21 – 7.19 (m, 1 H), 3”, 5” 
5” 121.7 7.18 (br. s., 1 H) 4” 
6” 123.9 7.13 (d, J = 7.9 Hz, 1 H) 2” 
7” 55.8 3.82 (s, 3 H) 2” 
8” 60.8 3.72 (s, 3 H) 3” 
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1H-NMR spectrum (600 MHz) of compound 1j in DMSO-d6. 
 
 
 
13C-NMR spectrum (600 MHz) of compound 1j in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 1j in DMSO-d6. 
 
 
 
 
 
 
 
 
 
270 
 
 
 
 
 
HMBC spectrum (600 MHz) of compound 1j in DMSO-d6. 
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NMR characterization data of compound 2j in DMSO-d6. HRMS (ESI+) m/z for [C18H23N4O5]
+ 
([M+H]+) calculated: 375.1663, found: 375.1658. 
 
 
  Compound 2j 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
3 or 5 134.7 7.52 (s, 1 H)  
6 25.1 2.80 (d, J = 6.3 Hz, 2 H) 7 
7 45.1 3.73 – 3.69 (m, 2 H) 6 
4’ 56.8 4.66 (dd, J = 8.7, 11.0 Hz, 1 
H) 
5’, 6’ 
5’ 78.1 4.38 (dd, J = 6.3, 11.0 Hz, 1 
H) 
4’, 6’ 
6’ 16.6 1.39 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
2” 152.5  6”, 7” 
3” 146.4  8” 
4” 115.2 7.19 (d, J = 2.4 Hz, 1 H) 5” 
5” 120.6 7.17 – 7.16 (m, 1 H) 4” 
6” 123.7 7.16 – 7.14 (m, 1 H) 2” 
7” 55.9 3.84 (s, 3 H) 2” 
8” 61.0 3.79 – 3.76 (s, 3 H) 3” 
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1H-NMR spectrum (600 MHz) of compound 2j in DMSO-d6. 
 
 
 
13C-NMR spectrum (600 MHz) of compound 2j in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 2j in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 2j in DMSO-d6. 
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NMR characterization data of compound 1k in DMSO-d6. HRMS (ESI+) m/z for [C18H23N4O5]
+ 
([M+H]+) calculated: 331.1401, found: 331.1388. 
 
 
  Compound 1k 
 
Atom 13C (ppm) 1H (ppm), multiplets in Hz   HMBC 1H-13C 2-3 
bond 
3 134.6 7.51 (s, 1 H) 5 
5 116.3 6.79 (s, 1 H) 3 
6 26.6 2.67 (t, J = 7.1 Hz, 2 H) 3, 5, 7 
7 38.55 3.40 – 3.26 (m, 2 H) 3, 6, 9 
8  8.42 (s, 1 H)  
9 169.3  7, 4’ 
2’ 165.5  2” 
4’ 73.6 4.44 (d, J = 7.1 Hz, 1 H) 2’, 6’, 9 
5’ 78.7 4.82 (m, 1 H) 9, 4’, 6’ 
6’ 20.6 1.40 (d, J = 6.3 Hz, 3 H) 4’, 5’ 
2” 148.2  4”, 6” 
4” 119.3 6.97 (dd, J = 1.6, 7.9 Hz, 1 
H) 
2”, 6” 
5” 118.5 6.75 – 6.70 (m, 1 H)  
6” 117.7 7.06 (d, J = 7.9 Hz, 1 H) 2’, 2”, 4” 
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1H-NMR spectrum (600 MHz) of compound 1K in DMSO-d6. 
 
 
 
13C-NMR spectrum (600 MHz) of compound 1k in DMSO-d6. 
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gHSQC spectrum (600 MHz) of compound 1k in DMSO-d6. 
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HMBC spectrum (600 MHz) of compound 1k in DMSO-d6. 
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Appendix C: NMR and MS Data  
for Chapter 4 
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Benzyl 2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-carboxylate (8) 
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2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-carboxylic acid (9) 
 
 
282 
 
N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-
carboxamide (11) 
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N-(2-(1H-imidazol-4-yl)ethyl)-2-(2,3-dihydroxyphenyl)-N-hydroxy-5-methyloxazole-4-
carboxamide (3) 
Oxidized Pre-Acinetobactin (3) 
2D-NMR characterization data of oxidized pre-acinetobactin (3) in DMSO-d6. 
Atom 13C 
(ppm) 
1H (ppm), 
Multiplets in Hz 
COSY 
1H-1H  
3 bond 
HMBC 
  1H-13C  
 2-3 bond 
HSQC 
2      
3  6.86 (s, 1H) - - - 
5 134.8 7.54 (s, 1H) - - 5 
6 24.9 2.88 (t, 2H) 7 7 6 
7 48.1 3.93 (s(br), 2H) 6 - - 
9   - - - 
2’ 157.8  - - - 
4’ 128.0  - - - 
5’ 151.5  - - - 
6’ 11.5 2.50 (s, 3H) - 5’ 6’ 
1’’ 110.7  - - - 
2’’ 145.3  - 4’’,6’’ - 
3’’ 146.2  - 5’’ - 
4’’ 118.2 6.92-6.95 (m, 1H) 5’’ 2’’,5’’ 4’’ 
5’’ 119.6 6.80 (t, 1H) 6’’ 3’’,4’’ 5’’ 
6’’ 116.1 7.23 (dd, 1H) 5’’ 2’,2’’,4’’ 6’’ 
 
 
286 
 
 
 
287 
 
 
 
288 
 
 
 
HRMS – OxPreA (3) 
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OxPreAcb (TFA salt) 
OxPreAcb (3) was re-purified by preparatory HPLC upon reviewer request. Prep HPLC 
was performed with a mobile phase of 0.1% trifluoroacetic acid in (A) water and (B) acetonitrile 
(gradient of 0% B to 95% B in 17 min, 95% B to 100% B in 2 min, hold 100% B for 8 min).  See 
1H NMR and LC-MS below. This batch of OxPreA was higher purity and reproduced the iron-
dependent growth inhibitory effects on A. baumannii (Chapter 4, Figure 3). 
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Absorbance spectra of OxPreAcb at 260 nm 
from LC-MS analysis. 
Extracted for OxPreAcb (m/z 345 for [M+H]+)  
from LC-MS analysis. 
Time (min) 
Time (min) 
Io
n
 c
o
u
n
t 
A
b
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ce
 
291 
 
 
benzyl 2-(2-hydroxyphenyl)-5-methyloxazole-4-carboxylate (29) 
 
 
292 
 
 
benzyl 2-(2,5-dihydroxyphenyl)-5-methyloxazole-4-carboxylate (30) 
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benzyl 2-(2,4-dihydroxyphenyl)-5-methyloxazole-4-carboxylate (31) 
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benzyl 2-(4-hydroxyphenyl)-5-methyloxazole-4-carboxylate (32) 
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benzyl 5-methyl-2-phenyloxazole-4-carboxylate (33) 
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benzyl 2-(2,3-dimethoxyphenyl)-5-methyloxazole-4-carboxylate (34)
 
 
297 
 
 
N-(benzyloxy)-N-butyl-2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-carboxamide (41) 
 
 
 
298 
 
 
N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(2-hydroxyphenyl)-5-methyloxazole-4-carboxamide 
(42) 
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N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(2,5-dihydroxyphenyl)-5-methyloxazole-4-carboxamide (43) 
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N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(2,4-dihydroxyphenyl)-5-methyloxazole-4-carboxamide (44) 
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N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(4-hydroxyphenyl)-5-methyloxazole-4-carboxamide (45) 
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N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-5-methyl-2-phenyloxazole-4-carboxamide (46) 
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N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(2,3-dimethoxyphenyl)-5-methyloxazole-4-
carboxamide (47) 
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N-(2-(1H-imidazol-4-yl)ethyl)-2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-carboxamide–
(12) 
HRMS cald for C16H17N4O4 (M + H)+ 329.1244; found 329.1245 
 
Atom 13C 
(ppm) 
1H (ppm), 
Multiplets in Hz 
COSY 
1H-1H  
3 bond 
HMBC 
  1H-13C  
 2-3 bond 
HSQC 
2      
3  6.85 (s, 1H)    
5 134.8 7.57 (d, 1H)   5 
6 27.9 2.76 (t, 2H) 7 7 6 
7 37.6 3.47 (q, 2H) 6   
9      
2’ 157.6     
4’ 128.8     
5’ 151.4     
6’ 11.3 2.66 (s, 3H)  5’ 6’ 
1’’ 110.7     
2’’ 145.1   4’’, 6’’  
3’’ 146.3   5’’  
4’’ 118.3 6.65 (dd, 1H) 5’’ 2’’, 5’’ 4’’ 
5’’ 119.5 6.80 (t, 1H) 6’’ 3’’, 4’’ 5’’ 
6’’ 116.3 7.23 (dd, 1H) 5’’ 2’, 2’’, 4’’ 6’’ 
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307 
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LC_MS and HRMS for 12 
 
 
  
Absorbance Spectra of 12Spectra 
of 19 
Extracted ion of 12 ([M+1]) = 329Spectra 
of 19 
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N-butyl-2-(2,3-dihydroxyphenyl)-N-hydroxy-5-methyloxazole-4-carboxamide – (13) 
HRMS cald for C15H19N2O5 (M + H)+ 307.1288; found 307.1286 
 
Atom 13C 
(ppm) 
1H (ppm), 
Multiplets in Hz 
COSY 
1H-1H  
3 bond 
HMBC 
  1H-13C  
 2-3 bond 
HSQC 
1 
2 
     
3 34.1 2.98 (m, 2H) 4 4 3 
4 27.5 1.65 (m, 2H) 3, 5 3, 5 4 
5 21.2 1.48 (m, 2H) 4, 6 4, 6 5 
6 1.32 1.32 (m, 3H) 5 5 6 
2’ 157.8     
4’ 128.0     
5’ 151.5     
6’ 11.5 2.54 (s, 3H)  5’ 6’ 
1’’ 110.8     
2’’ 145.2   4’’, 6’’  
3’’ 146.1   5’’  
4’’ 118.3 6.94 (dd, 1H) 5’’ 2’’, 5’’ 4’’ 
5’’ 126.4 6.80 (t, 1H) 6’’ 3’’, 4’’ 5’’ 
6’’ 115.5 7.23 (dd, 1H) 5’’ 2’, 2’’, 4’’ 6’’ 
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LC_MS and HRMS for 13 
 
 
Absorbance Spectra of 14Spectra 
of 19 
Extracted ion of 14 ([M+1]) = 307Spectra 
of 19 
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N-(2-(1H-imidazol-4-yl)ethyl)-N-hydroxy-2-(2-hydroxyphenyl)-5-methyloxazole-4-
carboxamide – (14) 
HRMS cald for C16H17N4O4 (M + H)+ 329.1244; found 329.1241 
 
Atom 13C 
(ppm) 
1H (ppm), 
Multiplets in Hz 
COSY 
1H-1H  
3 bond 
HMBC 
  1H-13C  
 2-3 bond 
HSQC 
2      
3  6.85 (s, 1H)    
5 134.7 7.54 (s, 1H)   5 
6 24.5 2.88 (t, 2H) 7  6 
7  3.93 (s(br), 2H) 6   
9      
2’ 157.3     
4’ 128.7     
5’ 151.6     
6’ 11.5 2.50 (s, 3H) 
*under DMSO peak 
 4’, 5’ 6’ 
1’’ 110.6     
2’’ 156.1     
3’’ 117.0 7.05 (d, 2H) 4’’ 1’’, 5’’, 2’’ 3’’ 
4’’ 132.5 7.42 (t, 1H) 3’’ 6’’, 2’’ 4’’ 
5’’ 119.8 7.01 (t, 1H) 4’’, 6’’ 1’’, 3’’, 6’’ 3’’ 
6’’ 126.4 7.79 (d, 1H) 3’’ 2’’, 4’’, 2’ 6’’ 
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LC_MS and HRMS for 14 
 
  
Absorbance Spectra of 14Spectra 
of 19 
Extracted ion of 14 ([M+1]) = 329Spectra 
of 19 
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N-(2-(1H-imidazol-4-yl)ethyl)-2-(2,5-dihydroxyphenyl)-N-hydroxy-5-methyloxazole-4-
carboxamide – (15) 
HRMS cald for C16H17N4O5 (M + H)+ 345.1193; found 345.1190 
 
Atom 13C 
(ppm) 
1H (ppm), 
Multiplets in Hz 
COSY 
1H-1H  
3 bond 
HMBC 
  1H-13C  
 2-3 bond 
HSQC 
2      
3  6.86 (m, 3H)    
5 134.7 7.53 (s, 1H)   5 
6 21.2 2.87 (t, 2H) 7 7 6 
7 45.7 3.91 (s (br), 2H) 6   
9      
2’ 158.2     
4’ 128.0     
5’ 149.1     
6’ 11.5 2.50 (s, 3H) 
Under DMSO peak 
 5’ 6’ 
1’’ 110.2     
2’’ 126.4     
3’’ 126.6 6.86 (m, 3H)  4’’ 2’’, 4’’ 3’’ 
4’’ 120.3 6.86 (m, 3H) 3’’ 3’’ 4’’ 
5’’ 150.0     
6’’ 117.9 7.14 (d, 1H)   6’’ 
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LC_MS and HRMS for 15 
 
  
Extracted ion of 15 ([M+1]) = 345Spectra 
of 19 
Absorbance Spectra of 15Spectra 
of 19 
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N-(2-(1H-imidazol-4-yl)ethyl)-2-(2,4-dihydroxyphenyl)-N-hydroxy-5-methyloxazole-4-
carboxamide – (16) 
HRMS cald for C16H17N4O5 (M + H)+ 345.1193; found 345.1190 
 
Atom 13C 
(ppm) 
1H (ppm), 
Multiplets in Hz 
COSY 
1H-1H  
3 bond 
HMBC 
  1H-13C  
 2-3 bond 
HSQC 
2      
3  6.85 (s, 1H)    
5 134.7 7.53 (s, 1H)   4 
6 28.0 2.09 (t, 2H) 7 7 6 
7 45.2 3.91 (s(br), 2H) 6   
9      
2’ 158.0     
4’ 128.2     
5’ 150.4     
6’ 11.4 2.47 (s, 3H)  5’ 6’ 
1’’ 102.4     
2’’ 158.0   3’’  
3’’ 102.8 6.40 (d, 1H)  2’’, 4’’ 3’’ 
4’’ 161.6     
5’’ 108.3 6.43 (dd, 1H) 6’’ 6’’, 4’’ 5’’ 
6’’ 127.5 7.59 (d, 1H) 5’’  6’’ 
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LC_MS and HRMS for 16 
 
  
Absorbance Spectra of 16Spectra 
of 19 
Extracted ion of 16 ([M+1]) = 345of 
19 
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N-(2-(1H-imidazol-4-yl)ethyl)-N-hydroxy-2-(4-hydroxyphenyl)-5-methyloxazole-4-
carboxamide – (17) 
HRMS cald for C16H17N4O4 (M + H)+ 329.1244; found 329.1242 
 
Atom 13C 
(ppm) 
1H (ppm), 
Multiplets in Hz 
COSY 
1H-1H  
3 bond 
HMBC 
  1H-13C  
 2-3 bond 
HSQC 
2      
3  6.88 (m, 3H)    
5 134.7 7.50 (s, 1H)   5 
6 28.0 2.88 (t, 2H) 7 7 6 
7 45.2 4.02 (s (br), 2H) 6   
9      
2’ 158.0     
4’ 127.2     
5’ 158.1     
6’ 11.4 2.43 (s, 3H)  5’ 6’ 
1’’      
2’’ 117.5 7.77 (d, 2H) 3’’ 3’’ 2’’ 
3’’ 115.9 6.88 (m, 3H) 2’’ 2’’ 3’’ 
4’’ 160.0     
5’’ 115.9 6.88 (m, 3H) 6’’ 6’’ 5’’ 
6’’ 117.5 7.77 (d, 2H) 5’’ 5’’ 6’’ 
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LC_MS and HRMS for 17 
 
 
  
Absorbance Spectra of 16Spectra 
of 19 
Extracted ion of 16 ([M+1]) = 329 of 
19 
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N-(2-(1H-imidazol-4-yl)ethyl)-N-hydroxy-5-methyl-2-phenyloxazole-4-carboxamide – (18) 
HRMS cald for C16H17N4O3 (M + H)+ 313.1295; found 313.1295 
 
Atom 13C 
(ppm) 
1H (ppm), 
Multiplets in Hz 
COSY 
1H-1H  
3 bond 
HMBC 
  1H-13C  
 2-3 bond 
HSQC 
2      
3  6.80 (s (br), 1H)    
5 134.7 7.54 (m, 4H)     
6  2.89 (t, 2H) 7  6 
7  4.02 (s (br), 2H) 6  7 
9      
2’ 157.7     
4’ 127.8     
5’ 156.6     
6’ 11.52 2.45 (s, 3H)   5’ 6’ 
1’’ 130.7     
2’’ 129.2 7.54 (m, 4H) 3’’ 3’’, 4’’ 2’’ 
3’’ 125.8 7.95 (m, 2H) 2’’, 4’’ 2’’, 4’’, 5’’ 3’’ 
4’’ 129.3 7.54 (m, 4H) 3’’, 5’’ 2’’, 3’’, 5’’, 
6’’ 
4’’ 
5’’ 125.8 7.95 (m, 2H) 4’’, 6’’ 3’’, 4’’, 6’’ 5’’ 
6’’ 129.2 7.54 (m, 4H) 5’’ 4’’, 5’’ 6’’ 
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LC_MS and HRMS for 18 
 
 
 
 
  
Absorbance Spectra of 18Spectra 
of 19 
Extracted ion of 18 ([M+1]) = 313 of 
19 
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N-(2-(1H-imidazol-4-yl)ethyl)-2-(2,3-dimethoxyphenyl)-N-hydroxy-5-methyloxazole-4-
carboxamide- (19) 
HRMS cald for C18H21N4O5 (M + H)+ 373.1506; found 373.1502 
 
Atom 13C 
(ppm) 
1H (ppm), 
Multiplets in Hz 
COSY 
1H-1H  
3 bond 
HMBC 
  1H-13C  
 2-3 bond 
HSQC 
2      
3  6.85 (s (br), 1H)    
5 134.6 7.48 (s (br), 1H)   5 
6 28.0 2.87 (m, 2H) 7   
7  4.08 (s (br), 2H) 6   
9      
2’ 158.0     
4’      
5’      
6’ 11.4 2.47 (s, 3H)  5’ 6’ 
1’’ 121.1     
2’’ 153.4     
3’’ 147.0     
4’’  7.20 (m, 2H) 5’’ 5’’, 6’’ 4’’ 
5’’ 120.8 7.40 (dd, 1H) 6’’ 4’’, 6’’ 5’’ 
  6’’ 124.6 7.20 (m, 2H) 5’’ 4’’, 5’’ 6’’ 
7’’ 60.8 3.78 (s, 3H)  3’’ 7’’ 
8’’ 55.8 3.86 (2, 3H)  2’’ 8’’ 
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Absorbance Spectra of 19Spectra 
of 19 
Extracted ion of 19 ([M+1]) = 373 of 
19 
